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Cancer diagnosis and therapy are perhaps the most promising areas for 
nanotechnology in medicine, and are expected to soon have applications in the market. An 
ideal therapeutic agent should perform like a magic bullet to simultaneously target cancer 
cells and avoid healthy cells, therefore, increase the treatment efficiency and reduce side 
effects. The current research is mainly devoted to minimizing the negative impacts that 
anti-cancer drugs put on normal cells, and eventually propose a “smart drugs” as the 
ultimate goal. The goal of this dissertation was to develop a technological foundation for 
synthesis and evaluation of polymer-based cancer therapeutic. This was performed using a 
microfluidic platform for optimization, and characterization of resulted particles for 
controlled drug release within the tumor environment. This technique was first optimized 
to show the feasibility of making drug-nanoparticles (NPs) out of different synthetic and 
natural polymers with it. The biophysical properties of these particles were also 
investigated at nano-biointerface. The process was then adjusted to develop pH- responsive 
core-shell NPs enabling oral administration of hydrophobic cancer therapeutics. Precise 
coating over the NPs with a sacrificial pH-responsive layer prevented drug release in severe 
pH conditions of the gastrointestinal tract, while allowing the drug to be released in tumor 
proximity. This technique was also adjusted to fabricate complex NPs via controlled self-
assembly of several components in a single step. Resulted particles can be used for 
theranostics applications or provide ultra-high drug loading capacity. Tuning the surface 
properties was also possible via this system and it was used to control immune-NPs and 
cancer cell-NPs interactions. To prolong blood circulation and enhance cell internalization, 
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feasibility of making one-dimensional nanocarriers by template-based self-assembly 
approach was also confirmed. These nanocarriers can serve as suitable candidates for 
combinatorial cancer therapy as they can load and deliver substantial amounts of drugs 
while allowing for hyperthermia effect thanks to their carbon nanotube core. Mechanical 
properties of nanocarriers can also influence a broad range of NPs’ biological behaviors. 
Here, inspired by viruses, systematic investigation of the mechanobiological properties of 
NPs are done to determine the optimized range for in vitro and in vivo targeting. NPs with 
switchable mechanical properties are proposed capable of switching from soft to stiff state 
in the site of action and provide enhanced therapeutic efficiencies. Overall, we hope that 
this research provides broad information on how NP design can affect and control the 
efficacy of cancer nanomedicine. These findings point to the high potential of microfluidic 
platforms as engineering toolboxes that enable design of complex multifunctional 







CHAPTER 1. OUTLINES 
Nanomedicine has a wide range of possible applications, including disease 
prevention, diagnosis, monitoring, management, and treatment. Cancer diagnosis and 
therapy are perhaps the most promising areas for nanotechnology in medicine, and are 
expected to soon have applications in the market (1-3). Although there are many diverse 
problems in treating cancer, a magic bullet that can simultaneously target cancer cells and 
avoid healthy cells, therefore, increase the treatment efficiency and reduce side effects (4, 
5), has long been the dream of cancer researchers (6). The current research is mainly 
devoted to minimize the negative impacts that anti-cancer drugs put on normal cells, and 
eventually propose a “smart drugs” as the ultimate goal (4). One of the most promising 
techniques is using engineered vehicles for drug transportation and targeting (7, 8). In an 
effort to reach this goal, targeted  drug delivery systems (DDS) based on the polymeric 
nanoparticles are selected due to the unique opportunities that they offer as drug carriers 
(3, 7), although using the correct polymer is of great importance (7, 9, 10). 
Nanoscale dimensions are known to have properties distinct from their bulk which 
creates additional opportunities for tuning material properties in this scale, and makes 
nanoparticles (NPs) great candidates to serve our means. Synthesizing polymeric NPs can 
be done using either top-down or bottom-up approaches. As bottom-up process involves 
the self-assembly of particles via intermolecular  forces, it comes with this great 
opportunity to tailor the particle structure and properties (11). However, controlling a wide 
range of mechanical and chemical properties in this powerful technique can be really 
challenging (12). 
 2 
Traditionally, drug loaded nanoparticles are formed with bulk self-assembly in the 
presence of the drug, which is then trapped in the formed particles (7, 13).  
Rapid mixing, precise tunability, and reproducability independent of user talents are 
properties difficult to obtain through those traditional methods (14-17). Recently 
microfluidic approaches have made these properties more obtainable by introducing 
parameters such as flow ratio, mixing time, and microchip design (18, 19).  
Fortunately, now we can create small and monodisperse nanoparticles (14, 20-22), 
by creating a narrowly defined mixing regime via hydrodynamic flow focusing (23, 24). 
This well-controlled mixing regime can be precisely adjusted with the microfluidic 
platform (primarily through flow ratio and velocity) and is crucial in creating monodisperse 
nanoparticles with tunable properties, including size, surface charge, compactness as well 
as drug encapsulation efficiency and release rate. As a demonstration of this, we detailed 
formation of various kinds of nanoparticles loaded with the anti-cancer drug Paclitaxel 
(PTX). 
This project details an exciting innovation in nanoparticle formation for drug 
delivery: the ability to finely tune various physical and chemical properties of nanoparticles 
with microfluidic assembly and a study on how these nanoparticles can interact with cancer 
cells both in vitro and in vivo.  
Furthermore, our system can be tuned to be water-based, and drive nanoparticle 
assembly with local changes in pH. This can avoid the use of organic solvent used by 
others, thus eliminate the biocompatibility issues raised by solvent residues. 
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Generally, NPs that are able to enter cells and release their therapeutic contents in 
close proximity to intracellular machineries can be of great value in the field of 
nanomedicine. Size and surface charge of these nanoparticulate systems strongly tune their 
nanobio-interactions. We demonstrated the ability to control the nanoparticle size and 
surface charge in a way that maximized cellular endocytosis in Chapter 2. In this chapter, 
the role of protein corona surrounding the NPs upon entering the blood plasma and before 
interacting with cells are also investigated. Moreover, considering NP’s diffusion and 
sedimentation properties, we conducted our experiments for the cells in both upright and 
inverted configurations to show how disparities can vary depending on the concentration 
of NPs in the interaction zone.  
The common chemotheraputic systems are normally administered by blood injection 
that may present significant dose of toxic drugs systemically. Our microfluidic approach 
can be adjusted to develop NPs for oral administration of cancer therapeutics. To this end, 
we developed a dual microfluidic platform for synthesis and coating of nanocarriers with 
highly pH-tunable core-shell structure as described in Chapter 3. Precise coating over NPs 
with a sacrificial pH-responsive layer prevents PTX release in severe pH conditions of the 
gastrointestinal tract, while allowing the drug to be released in tumor proximity. The 
release profile and cytotoxicity of the nanoparticles against various cell line were studied 
using sequential incubation in different pH conditions.  
Furthermore, the proposed microfluidic-assisted synthesis of NPs can be adjusted to 
make more complex nanoparticles like “nano-in-nano” particles. In Chapter 4, we report a 
one-step approach for synthesis of finely tuned targeted hybrid NPs. A microfluidic 
platform was used to precisely control the nanoprecipitation of bisphosphonate-
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functionalized copolymer, while co-encapsulating superparamagnetic iron oxide 
nanoparticles (SPIONs) and the anticancer drug at the same time. Designed NPs were 
tested to evaluate their affinity for hydroxyapatite (bone-like structure). In vivo 
experiments were also performed to check pharmacokinetic and biodistribution of these 
NPs such as tumor localization and suppression of a bone metastatic tumor. 
Increasing the loading capacity of drug carrier and the efficiency of its targeting can 
significantly decrease the administered dosage of the drug. While traditional amphiphilic 
(co-)polymers cannot encapsulate substantial amounts of hydrophobic drugs, dendritic 
polymers like dendritic polyethylene (dPE) can be suitable candidates. In Chapter 5, we 
offered a microfluidic platform for synthesis of complex nanocapsules via controlled self-
assembly of several components in a single step. The resultant nanocarriers can encapsulate 
large amounts of hydrophobic drugs while creating low complement activation as well as 
sustained release profile with high tunability. 
Recently, scientists realized the importance of nanocarrier’s shape on its blood 
circulation and cell internalization which adds more complexity to the designing elements 
of an ideal drug carrier (12). Such challenges become more prominent for hydrophobic 
anti-cancer drugs, which calls for multistep reactions for synthesis of engineered 
copolymers. On the other hand, combinatorial cancer therapies offer a great potential to 
increase the treatment efficiency and decrease the side effects. In Chapter 6, we tried to 
address this point by proposing a one-step microfluidic-assisted approach for controlled 
self-assembly of carbon nanotubes (CNT)-based hybrid nanostructures for combinatorial 
cancer therapy. The dendritic polyethylene nanoparticles (dPE), developed in Chapter 5, is 
used as a PTX loading materials. While CNTs fulfill the hyperthermia therapy, decorated 
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dPE nanoparticulate layer provides efficient loading of hydrophobic anticancer drugs. 
These nanostructures show high cellular uptakes, and sustainable release profiles with high 
tunability. Our proposed technique paves the way to design and fabricate complicated 
nanokits as fine-tuned drug delivery systems for targeted cancer therapy. 
Mechanical properties of nanocarriers is an underrepresented factor that can affect a 
broad range of biological interactions of nanoparticles. However, there is no systematic 
study to investigate the mechanobiological properties of NPs while keeping all the other 
physical variants such as size and surface properties, constant. In Chapter 7, we tried to 
propose microfluidic-based engineering strategies for enhancing the efficacy of cancer 
nanotherapeutics by controlling their physicomechanical properties. At first, we aimed to 
optimize the required mechanical properties for effective in vitro and in vivo targeting of 
cancer cells in static and dynamic cultures. To achieve this goal and have a more realistic 
idea of the interactions around the tumor tissue, we developed a 3D tumor-on-chip 
(3DToC) device. Thanks to this platform we could provide dynamic and 3D cultures for 
tumor cells and were able to do real-time evaluations of the NPs-matrix interactions. 
Having these data collected, we then tried to optimize the required mechanical properties 
and accordingly design nanotherapeutics with prolonged blood circulation, enhanced 
tumor penetration tendency and apoptosis promoting capability. Eventually, to provide the 
needed trade-off for optimal mechanical properties, virus-mimicking nanoparticles capable 
of switching from soft-to-stiff state were proposed. Therefore, these particles could 
circulate the blood in their soft state while switching to their stiff mode upon arrival to 
target tissues so that they could express their highest penetration efficiency.  
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CHAPTER 2. UNDERSTANDING BIOPHYSICAL BEHAVIOURS 
OF MICROFLUIDIC-SYNTHESIZED NANOPARTICLES AT 
NANO-BIOINTERFACE1 
Serious challenges in case of using unencapsulated oral drugs for cancer treatment 
are high potential for sequestration in the first few cell layers they come in contact with 
and binding to the interstitial ECM components. By encapsulating the drugs in 
nanoparticles (NPs) capable of entering the target cancer cells, drugs can be made safer 
until reaching their intracellular site of action and more effective once it reaches the site. 
Upon entering the bioenvironment, NPs establish a number of interactions with their 
surroundings based on their physicochemical properties. Here we demonstrate how the 
size-surface charge interplay of chitosan nanoparticles (NPs) affects the protein corona 
formation and endocytosis pathway in the HeLa cells at non-toxic concentrations. 
Generally, large NPs (102 and 161 nm) with low surface charge (+6.7 and +3.6 mV) 
exhibited weaker tendency for endocytosis in comparison with smaller ones (63 and 83 nm 
with 10 and 9.3 mV surface charge, respectively). This is mainly because the interactions 
of these NPs with the plasma membrane were too weak to release enough free energy 
required for cellular internalization. Furthermore, we tested the upright and inverted cell 
culture configurations to better understand the impact of the sedimentation and diffusion 
velocities of NPs on the resulting cellular uptake pattern in both serum free and serum 
containing culture medias. Considering the different particokinetics, the amount of 
                                                 
1 This work has been published by S. Soleimani, M.M. Hasani-Sadrabadi, F.S. Majedi, E. Dashtimoghadam, 
M. Tondar, K. I. Jacob, (2016) Colloids and Surfaces B: Biointerfaces 145, 802-811. Reproduced with 
permission from Elsevier. 
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internalized NPs in upright and inverted positions differed in all cases by a factor of 
approximately three (for 161 nm particles), or less for smaller ones. Ultimately, our results 
offer a paradigm for analyzing the biobehavior of NPs under the precise control of their 
physicochemical characteristics. 
2.1 Introduction 
The effectiveness of nanomedicine in developing therapeutic systems with nanoscale 
components (e.g. nanoparticles – NPs) that can reach the pathologic sites depends on our 
ability to tailor such systems with a unique set of properties, including composition, 
structure, size, radius of curvature, shape and charge (25). Yet, very little is known about 
how these parameters influence the final biodistribution and pharmacokinetics of NPs 
(26).When the biological target for treatment is localized in the subcellular organelles, the 
plasma membrane plays a significant role because it acts as a bulwark that is only 
selectively permeable to small, uncharged molecules. To be effective, NPs must cross the 
plasma membrane to reach the action site of the drug, which requires careful design of NPs 
with specific properties that enables them to enter cells and reach their intracellular targets 
(27).  
Despite the striking advances in nanoscience, relatively little is known about the 
interactions that occur during the cellular uptake. One of the most studied uptake 
mechanisms is endocytosis, an energy-dependent uptake process in which the cell 
membrane protrusions spread over  NPs, forming vesicles known as endosomes that carry 
the engulfed NPs into the cellular interior (28). Different endocytic pathways in non-
phagocytic cells (e.g. caveolae/clathrin mediated, caveolae/clathrin independent and 
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pinocytosis)  have distinct components and mechanisms (29). Additionally, it has been 
reported that some NPs may slip directly through the plasma membrane of eukaryotic cells, 
which is similar to the processes exhibited by bacteria crossing the plasma membrane (30). 
Clearly, cell type is an important parameter determining the internalization 
mechanism, but, the physicochemical properties of NPs are also key players of cellular 
uptake (26, 31). Particle size is an important parameter considering the space available in 
these endocytic compartments (32),  but the interplay of different physicochemical 
characteristics may also play a decisive role. 
Accumulation of NPs in pathologic sites can be adjusted both actively and passively 
(33). The passive homing mechanism of NPs in cancer is based on the enhanced 
permeability and retention effect (EPR) that allows a NP to penetrate into a tumor tissue 
due to the vascular hyperpermeability (380-780 nm in diameter pores) as well as the chance 
of taking long residence time within the cancerous hive due to the decreased, sluggish 
lymphatic drainage in the interstitial space (34). To take advantage of this phenomenon, 
the size of NPs needs to be optimized. Large NPs cannot pass through vascular 
fenestrations, or even if they could, they would not get far beyond the vessels to distribute 
throughout the whole tumor environment (35). In contrast, small NPs have the ability to 
penetrate deep into tumors. But, these particles can only remain there transiently(36, 37). 
To establish a balance between an efficient distribution of NPs and a sufficiently long 
residence time, an optimum size is required for NPs (33). 
In addition to the size, surface charge is another significant factor responsible for 
charge-charge interactions, which results in the formation of NP aggregations. 
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Sedimentation of NPs above cells, a factor that is often ignored, makes the final results less 
reliable and causes deviation from the in vivo conditions (38).   
NPs with high surface energy will strongly interact with biomolecules in the 
bioenvironment; as a result NPs become surrounded by biomolecules, a masquerade called 
protein corona. This ‘corona’ lowers the metastable state energy of NPs. Thus, it seems 
logical that these NPs approach the cell surface as particles with a bio-corona (39-41). 
Hence, the coverage of NPs with a natural physiological coating layer can affect the cellular 
internalization patterns and NPs’ final effects on cells’ viability (42, 43).  
Finally, in order to explore the effect of particle size on the NPs’ bio-behavior, NPs 
with different sizes were selected for this study. To efficiently investigate the effect of size, 
the fundamental objective is to employ a fabrication procedure with high control over the 
NPs’ size and monodispersity since even minute size changes may alter many non-specific 
interactions that occur at the cell–particle interface. To precisely fabricate the NPs, we 
employed a microfluidic technique taking advantage of a solvent free cross-junction device 
that can generate a narrow mixing regime via a hydrodynamically focused flow to form 
chemically and physically tuned monodisperse chitosan NPs (17, 20, 44, 45). This system 
lets us have a better understanding of the effects that key particle variables (size, chemical 
composition and surface charge) have on the cell entering mechanisms. 
2.2 Materials and Methods: 
2.2.1 Particle preparation: 
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The chitosan nanoparticles were fabricated according to a previously published 
protocol (44). To summarize it briefly, a solution of acetic acid (50 mL, 1% w/v; Sigma-
Aldrich) containing one-gram chitosan (CS; Mn= 280 kg/mol, degree of deacetylation 83%, 
Fluka) was stirred for 12 h. The resulting solution was filtered with a 0.45-μm Nylon 
syringe filter. The solution pH was maintained at 5.5 by the drop-wise addition of sodium 
hydroxide (Sigma-Aldrich). 300 mg palmitic acid N-hydroxysuccinimide ester (Sigma–
Aldrich) in absolute ethanol (Sigma-Aldrich) solution was added drop-wise to the chitosan 
solution at 98°C under reflux. The ethanol was allowed to dissolve and distribute 
homogeneously throughout the solution by stirring for 48 h. The solution temperature was 
then decreased to reach to the room temperature. Then, adding acetone under the pH of 9.0 
precipitated chitosan in the solution. The resultant polymer precipitate was filtered twice, 
washed with an excess of acetone, and vacuum-dried at room temperature. The product 
was analyzed by 1 H NMR (Bruker 400 MHz) and the palmitoyl groups placement on 
chitosan chains was determined using the ninhydrin assay (46). The high molecular weight 
chitosan supplement (HMCS) was dissolved in aqueous acetic acid. Then, 0.5 mL acetic 
acid/acetate buffer (4 M, pH= 5.5) was added into 0.5 mL of the prepared solution. The 
test tubes were filled with 1 mL of ninhydrin reagent (Sigma–Aldrich) and placed in a 
boiling water bath for 20 min. The solutions were then cooled and their absorbance was 
read at 570 nm and compared with the unmodified chitosan solution, the control sample, 
and the acetic acid/acetate buffer, the blank sample (47). 
The microfluidic device for the fabrication of nanoparticles consists of two inlets for 
water at a basic pH (pH 9.0) and one main inlet for the entrance of HMCS solution at an 
acidic pH (pH 4.5). The resulting outlet nanoparticle stream was collected in disposable 
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cuvettes (Eppendorf) and used for further analysis. A critical parameter in determining 









                                             (Eq. 2-1) 
where W is the main channel width (150 μm), D is the diffusion constant (10-9 m2/s) 
and R is the ratio of the polymeric stream and basic water flow rates (R = 0.03–0.2). 
For comparison with the microfluidic fabrication, bulk synthesized samples were 
also prepared as follows: the polymeric solutions were prepared by a constant stirred- 
dissolving of 2.5 mg/mL HMCS in 1% w/v acetic acid, and the nanoprecipitated HMCS 
molecules resulted at a pH of 7.4 by the drop-wise addition of 1M NaOH. 
The fluorescently-labeled HMCS were synthesized based on the reaction between 
the fluorescein isothiocyanate (FITC) and the chitosan (48). The prepared FITC in 
methanol (2 mg/mL) was added gradually to the solution of 1% w/v acetic acid containing 
the HMCS. After 5 h of reaction in dark at room temperature, the FITC-labeled chitosan 
was precipitated in 0.2 M NaOH and separated from the unreacted FITC via a Sephadex 
G-50 column with 1/15 M phosphate buffer/0.2 M NaCl as an elution solvent. The fractions 
containing the labeled polymers were collected and dialyzed against deionized water using 
a 3 kDa molecular weight cut-off dialysis cartridge (Thermo Scientific, Rockford, IL). The 
process was continued for almost 4 days until no fluorescence was detected in the 
supernatant. The resulting sample was ultimately freeze-dried. 
2.2.2 Particle size and surface charge analysis 
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Dynamic light scattering (DLS) and zeta potential measurements were performed 
using a Zetasizer (Zetasizer 3000HS, Malvern Instruments Ltd., Worcestershire, UK) in 
the backscattering mode at 173°C for the particles dispersed both in water and FBS at a 
concentration of 0.3 mg/ml. Three measurements were performed for each sample. 
2.2.3 Turbidimetry 
The measurement of transmittance of the nanoparticle suspensions was performed 
via the spectrophotometry method (Shimadzu UVmini-1240 UV-Vis spectrophotometer) 








) (Eq. 2-2) 
where L, I, and I0 are the thickness of the cell, the intensity of the light transmitted 
through the sample, and through the solvent, respectively. Measurements were done at the 
wavelength of 635 nm for at least three times.  
2.2.4 Refractive index 
A PTR 46 refractometer (Index Instruments, UK) was used to measure the refractive 
index of 1% v/v aqueous acetic acid solution which was obtained as n0 =1.332. The values 
of the refractive index increment (dn/dc) of the polymer solutions were determined through 
the asymmetric flow field-flow fractionation (AFFFF) method using AF2000 FOCUS 
system (Postnova Analytics, Landsberg, Germany). The dn/dc was measured at the 
wavelength of 635 nm. 
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2.2.5 In vitro cytotoxicity 
The cytotoxicity tests were performed using an MTT colorimetric assay (49). The 
cytotoxicity of the nanoparticles was determined after 72 h incubation with the HeLa cells 
seeded in 100μl of the medium. The cells were left for 24 h to adhere to the plate. The 
HeLa cells were incubated with the NPs with concentrations varying from 10 to 1000 μg/ml 
at 37°C in a humidified 5% CO2 atmosphere. After the incubation period, the negative 
control samples were prepared by adding the lysis solution to a few wells containing the 
cells only. The MTT assay solution was added to each well and remained for 3h to allow 
the MTT to diffuse through the medium and react with the cells. The optical density at 570 
nm was measured using a Bio-Rad model 3550 microplate reader (Bio-Rad Laboratories).  
Since the NPs had highly metastable surfaces, they might agglomerate and change 
their physical characteristics. As a result, the concentration of NPs on the cell surface was 
different from the initial bulk concentration.  Considering the fact that toxicity, endocytosis 
and a collection of other factors are directly related to NPs’ concentration, we preferred to 
minimize the effect of agglomeration by performing an inverted culture configuration. To 
do so, the cells were seeded on a coverslip and suspended in the medium (The cells faced 
the bottom of the wells). The rest of the experiment was the same as the upright position. 
2.2.6 Uptake experiments 
The HeLa cell line was used to investigate the uptake of the FITC-labeled HMCS 
NPs. The particles were incubated with the cells over a time period ranging from 0 to 5h 
(37°C, 5% CO2). After incubating the cells with the particles, the cells were washed and 
trypsinized to detach from the plates. The resulting cells were centrifuged and suspended 
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in a 0.4% trypan blue solution in the Dulbecco’s Phosphate Buffers Saline (DPBS) solution 
to quench the extracellular FITC fluorescence. The cells were centrifuged again and the 
dye solution was withdrawn. Then, the cell pellets were resuspended in DPBS. All of the 
samples were kept on ice until FACS analysis. Ultimately, the samples were analyzed by 
flow cytometry (CyAn ADP, Beckman Coulter, Inc) for the green and red fluorescence. 
The process was repeated for the cells positioned in an inverted configuration as described 
earlier. 
2.2.7 Endocytosis blockage studies 
The HeLa cells were seeded in a T-25 flask and treated with 0.1% NaN3 (Sigma-
Aldrich) and 80 μM Dynasore (Sigma-Aldrich) in a serum-free MEM for 1 h before 
incubation of the nanoparticles at 37°C/5% CO2. For the action of chlorpromazine, the cells 
were pre-incubated in a serum-free MEM containing 10 μg/ml chlorpromazine 
(ChemBridge) for 15 min at 37°C and 5% CO2. The medium was then replaced with a 
fresh media containing the inhibitors and particles. These cells were further incubated for 
30 min at 37°C and 5% CO2. The cells were washed with D-PBS and trypsinized and 
processed for the flow cytometry test. Moreover, to examine the contribution of 
macropinocytosis in the uptake cascade, the cells were incubated with a macropinocytosis 
inhibitor, 5-(N-ethyl-N-isopropyl) amirolide (EIPA), at the concentration of 100 μM for 
30 min. Then, the cells were incubated with a fresh medium containing the nanoparticles. 
Then, the cells were washed after 1 h (50). The resulting cells were analyzed via FACS. 
To further explore the mechanism through which these nanoparticles entered the cells, we 
performed an internalization experiment at 4°C to block the active endocytosis cascade. 
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2.2.8 Incubation of Nanoparticles with the plasma: 
Another experiment was also conducted with the particle–protein complexes. The 
particle suspensions were incubated with the fetal bovine serum (FBS). According to 
previous reports, 1h incubation time scale is enough to form a relatively stable protein 
corona on NPs’ surface. After that, we selected 1 h for the formation of protein corona 
around nanoparticles. Then, the samples were centrifuged to pellet the particle–protein 
complexes and the pellets were resuspended in PBS, which were ready to be exposed to 
the cells. Note that in the medium that contained serum, the serum-to-particle surface ratio 
should be fixed to ensure the comparability between results (51). 
2.2.9 Hemolysis of erythrocytes:  
The sheep blood was collected in heparinized-tubes. The blood plasma was separated 
by centrifugation at 4500g for 5 min (Eppendorf Centrifuge 5804R, Eppendorf, Hamburg, 
Germany). The resultant pellet was washed three times with a cold 1.5×10-3 M phosphate-
buffered saline (pH 7.4) (PBS) by centrifugation at 4500g for 5 min followed by 
resuspention in the same buffer. Afterwards, the nanoparticles were prepared in PBS buffer 
with concentrations of 50, 100, 200 and 500 μg/ml, mixed 1:1 with erythrocytes and 
incubated in a waterbath at 37°C for 60 min. After the centrifugation at 2400g for 5 min 
(Eppendorf mini spin, Eppendorf), the hemoglobin release was determined by the 
spectrophotometric analysis of the supernatant at 544 nm. The Dextran nanoparticles were 
used as negative control and the treated erythrocytes with PEI served as the positive control 





× 100%  
(Eq. 2-3) 
2.3 Result and discussion 
2.3.1 Nanoparticle fabrication 
Due to the fact that NPs’ size has remarkable impact on the nanobio interactions, it 
is crucial to choose a fabrication method that is successful in terms of monodispersity, 
stability, compactness and ordered composition over bulk and surface (52). To set up a 
system that can effectively control these properties, we need to account for inter and intra-
molecular interactions as well as their strengths (53).  
One of the easiest ways to control the electrostatic interactions is changing the pH 
spectrum, which affects the ionic strength of solutions and their impacts on NPs’ assembly. 
We have previously designed a microfluidic system that arrests the NPs’ growth when the 
electrostatic repulsion and hydrophobic attraction forces are balanced as a function of pH 
(44). In addition, convective forces and flow ratio play critical roles in giving the NPs’ an 
ordered pattern both in bulk and the surface (23, 44). 
Using the unique molecular mechanisms underlying this microfluidic system, the 
NPs were made from the assembly of cationic chitosan chains modified with the 
hydrophobic groups of N-palmitoyl with the degree of substitution of 18.2  0.3 mol% 
(measured by the Ninhydrin assay). Four series of cationic NPs were fabricated: 
microfluidic fabricated nanoparticles (μF NPs) of 63, 83, and 102 nm as well as the bulk 
synthesized spheres of 161 nm.  
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The hydrodynamic diameter of synthesized nanoparticles at various flow ratios has 
been shown in Figure 2-1a. As can be seen, the time of mixing affect the size of the 
nanoparticles and size of the nanoparticles increases with increasing flow ratio. It should 
be noticed that over the whole flow ratio range the microfluidic generated nanoparticles 
were found to be smaller with narrower size distribution compared to the bulk synthesized 
nanoparticles. In fact, turbulence and convective mixing in the bulk method cause 
residence time distributions and consequently broader particle size distribution. 
As can be seen in Figure 2-1a, Zeta potential of particles is decreasing with the size 
enlargement. Such an observation can be interpreted in terms of hydrophobic interactions 
among aliphatic moieties on chitosan chains. In other words, at low flow ratio and shorter 
mixing time, hydrophobically modified chains tend to form smaller and more compact 
nanoparticles formed owing to dominant intermolecular hydrophobic interactions rather 
than intramolecular interactions. In view of this, the lower flow ratio, the more 
unsubstituted amine groups are exposed on the surface and consequently the zeta potential 
increases (Figure 2-1a). As shown in Figure 2-1b, in the FBS media, more protein 
adsorption on the surface of particles with higher positive zeta potential results in particles 
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with higher negative zeta potential. Such an effect is more pronounced for the synthesized 
nanoparticles at lower flow ratios. 
Figure 2-1 The effect of flow ratio on hydrodynamic diameter (Based on the DLS results) and 
zeta potential of the synthesized NPs in (a) the serum free and (b) 10% FBS containing culture 
media. The theoretical mixing time is also shown (a) as filled square in blue. (c) The calculated 
NPs’ molecular weight (MNP) and local polymer concentration (CNP) inside the NPs as a 
function of size. (d) The aggregation number (Nagg) of the polymer chains in the corresponding 
NPs and concentration of NPs (NNP) as a function of size. The lines are guide for the eyes. 
The local polymer concentration inside the nanoparticles, cNP, was calculated based 










[1 − 𝑐𝑜𝑠(𝑤𝑐𝑁𝑃)]}) (Eq. 2-4) 
where ct, τ, and Rh are the total polymer concentration, the turbidity of the 




⁡wherein λ is the wavelength of the turbidity measurements, n0 is the refractive 
index of the solvent, and dn/dc is the refractive index increment of the polymer solution.  
Generally, the hydrodynamic size of polymeric nanoparticles depends on the 
aggregation number of chains and their swelling state. 
The results for cNP calculated based on nanoparticles’ size and their suspension 
turbidity has been shown in Figure 2-1c. As seen, the compactness of nanoparticles is 
increased with decreasing flow ratio. At shorter mixing time, higher probability of 
hydrophobic segments to form intermolecular association leads to formation of more 
compact nanoparticles. The estimation of compactness revealed that the bulk nanoparticles 
show lower value compared with the microfluidic nanoparticles synthesized even at the 
highest flow ratio of 0.2.  
Having calculated the cNP, the molecular weight of nanoparticles, MNP, can be 





3𝑐𝑁𝑃𝑁𝐴 (Eq. 2-5) 
Accordingly, the number of polymer chains aggregated to form nanoparticles, Nagg, 





 (Eq. 2-6) 
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The results for aggregation number for nanoparticles synthesized at various flow 
ratios as well as bulk nanoparticles have been shown in Figure 2-1d. As can be seen, the 
number of aggregated chains rises with increasing time of mixing. Such observation 
suggests that at lower flow ratios and on the account of rapid mixing regime, chains have 
limited time to aggregate, which results in a lower number of kinetically assembled chains 
forming nanoparticles. The obtained results for compactness and aggregation number 
converge to indicate that at low flow ratio smaller and more compact nanoparticles 
composed of less number of aggregated chains are formed. In view of this, for bulk 
nanoparticles it could be inferred that the higher hydrodynamic size and lower compactness 
is due to the arrangement of hydrophobically modified chitosan chains to form 
intramolecular hydrophobic associations at longer time of mixing.  
Although number of nanoparticles in suspension is always of great interest from a 
practical point of view, but due to measurement complexities is rarely reported. Based on 
the calculated values for compactness of the nanoparticles, the number density of the 




3 (Eq. 2-7) 
As shown in Figure 2-1d, the number density of nanoparticles decreases with 
increasing flow ratio, which well consistent with the aggregation number results. 
2.3.2 Cellular viability 
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The high molecular weight cationic polyelectrolytes, such as chitosan, may induce 
an in vitro cytotoxicity owing to the possible plasma membrane disruption as a result of 
the ionic interactions between positively charged surfaces of NPs with the negatively 
charged membrane phospholipids (55). It is notable that regardless of charge density, size 
and shape, cationic particles are able to form holes in lipid bilayers, a phenomenon that can 
disrupt the balance between cells’ interior and exterior ions and damage other important 
elements that are required for the maintenance of the membrane’s integrity and the normal 
function of cells (56). The cytotoxicity of each NP group with concentrations varying from 
10 to 1000 μg.ml-1 was determined by the MTT cell viability assay. No obvious toxicity 
was detected, suggesting that these NPs were safe at the mentioned concentrations (Figure 
2-2). 
 
Figure 2-2 Since particles can sink down on the cell surface in an upright configuration, their 
nanotoxicity nature might change. (a,c) The cells in the upright configuration, which are 
assumed to experience higher NPs’ concentrations. (b,d) The cells in an inverted cell 
configuration in which NPs’ sedimentation occurs at the bottom of the well and results in the 
concentration reduction of NPs on the cell surface. The disparity between the viability rates 
for these two positions becomes larger when the sedimentation dominates the diffusion.  
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One of the kinetic features of NPs is their sedimentation behavior. It means that 
NPs gradually sink down on cells at the bottom of wells, creating concentration gradients 
in contact with cells. This growing concentration of NPs within the interaction zone 
increases the aggregation probability (38). Aggregation alters NPs’ size, shape and density, 
leading to NPs’ behavior transformations. Here an important question is that whether these 
aggregates affect cells differently in comparison with single particles.(57).  
To understand how these aggregates, affect the cell viability, the MTT assay was 
performed for the invert cell configuration in which the nanoparticle aggregations settle 
down the bottom of the wells, not at the cell surface. The results show that even though the 
effects are small, they cannot be neglected, suggesting that the different nanotoxicity levels 
are due to the different sedimentation and diffusion rates of NPs (Figure 2-2). 
2.3.3 Nanoparticles’ endocytosis into cells 
When NPs meet cells, they walk randomly to search for a suitable interaction site. 
Doing so, they face three different options depending on the nature of the local membrane 
and the NPs’ ability to start a contact with that membrane: i) they can simply make contact 
and then move away in a manner that NPs land on the membrane, traverse through the 
membrane and detach in order to come back to their free diffusing state, ii) they can also 
touch membrane, adhere to that and stay there, iii) they would strongly attach to the 
membrane and enter cells (26).  
Cell membrane re-conformation, parallel with NPs’ curvature, costs a certain 
amount of energy. If some NPs were capable of forming stable bonds at the nanobio 
interface, which reduces the plasma membrane’s Gibbs free energy, they can make the 
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membrane more prone to grow its contact zone with the NPs’ surface, which further 
balances the resistive and driving forces (Figure 2-3) (58). If we assume that all of the 
driving forces act together to overcome the kinetic barrier, the inability of plasma 
membrane to reconfigure in a reasonable time scale, the surface chemistry and radius of 
curvature become the most important factors to consider when designing NPs. The surface 
chemistry is the first factor dictating the interaction of NPs with a wide variety of proteins, 
carbohydrates and lipids on the cell surface. The cellular uptake of NPs was measured in 
HeLa cells after 2 h of NP-cell incubation using CLSM (Figure 2-3, a-d) and FACS (Figure 
2-3, g-h). The kinetics of NPs’ uptake was also assessed using FACS (Figure 2-3, f). Note 
that trypan blue worked well for the quench of the FITC fluorescence of the NPs trapped 








Figure 2-3 The confocal laser scanning microscopy (CLSM) images showing the cellular 
uptake of the FITC-labeled NPs, µF-63nm (a), µF-83nm (b), µF-102nm (c), and Bulk-161nm 
(d), after 2 h incubation with the HeLa cells. The cell nucleuses were stained with DAPI (blue). 
The green dots represent the internalized NPs and the red colors represent the cell 
membrane. The scale bar is 15 μm. (e) The schematic representation of NPs encountering a 
cell. Nanobio interactions are a set of specific and nonspecific interactions resulting in Gibbs 
free energy release. If this energy is large enough to resist the opposing forces (e.g. membrane 
reorganization process or thermal fluctuations), endocytosis will take place. f) The uptake 
kinetics of NPs incubated with the upright positioned cells in a serum-free medium. Initially, 
the NPs start to enter the hungry cells with a high endocytic capability. As the time passes by, 
the cells reach a saturation point, resulting in a steady state uptake pattern. (g-h) The cellular 
uptake of NPs incubated in a serum-free (black column) and in a 10% FBS containing culture 
(grey column) media in the upright (g) and inverted (h) configurations. The corona-coated 
NPs have a higher tendency for colony formation than the bare NPs. Obviously, the high 
tendency for settling down will supplement significantly less number of particles in contact 
with the cells in the inverted position, resulting in the salient uptake disparities in these two 
cell configurations.  
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The HeLa cells internalized all of the four groups of NPs, but their internalization 
kinetics was different. Indeed, less internalization took place for the larger NPs. As shown 
in Figure 2-3f, all of the NP groups had an increasing internalization rate at their initial 
stage of incubation. But as time passes by, they reach a plateau pattern, indicating that they 
reached a thermodynamically equilibrated state at which cells were almost saturated with 
the endocytosed particles. Since the probability of NPs’ exocytosis was not surveyed, this 
plateau pattern can also be related to the balance between the endocytosed and exocytosed 
NPs. 
In case of nonspecific interactions, NPs’ surface charge has a decisive effect on 
guaranteeing the success or failure of the cellular internalization. For example, for larger 
NPs with a less surface charge density, weak unspecific interactions with the plasma 
membrane released less free energy than the amount that was required for the cell 
membrane reorientation, resulting in reduced cellular uptake. 
For in vitro assessments, it is assumed that the Brownian motion creates a well-
dispersed system in which the concentration is the same for the whole system. But, this 
assumption is implausible since the inevitable sedimentation phenomenon- settling down 
of the NPs at the bottom of the well- increases the NPs’ concentration on the interaction 
zone. Depending on the sedimentation to diffusion ratio, this concentration gradient of NPs 
varies (38). For the traditional culture systems with upright configuration, NPs reach cell 
surface via both diffusion and gravitational sinking or sedimentation. But, when the cells 
are positioned in an inverted configuration, NPs’ transportation takes place only via 
diffusion. It is obvious that in the upright configuration, the synergic effect of both 
sedimentation and diffusion results in a higher NPs’ concentration in the interaction zone. 
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However, this concentration decreases when the effect of sedimentation is eliminated in an 
inverted configuration. 
Since the cellular uptake of NPs depends directly on the interactions happening at 
the cell-particle contact zone (59), and considering that the number of particles in contact 
with the cell surface differs in the upright and inverted configurations, the NPs’ 
internalization was also evaluated in the inverted position. Clearly, decreasing the number 
of NPs in contact with the cells resulted in the reduced internalization. This reduction was 
directly related to the diffusive and sedimentation behavior of NPs (Table 2-1). 
NPs with high diffusivity can quickly move toward the cell surface before settling 
down. For these NPs, the difference in the cell uptake for the upright and inverted 
configurations was less than the uptake difference seen for NPs with a higher tendency for 
sedimentation rather than diffusion. 
In static cell culture conditions, three processes control particles’ motion: i) 
diffusion, ii) sedimentation and iii) advection (60). However, advection, which happens as 
a result of fluid motion, is not very important since culture media’s disturbances and 






Table 2-1 The nanoparticles’ sedimentation and diffusion behavior in the water and 10% FBS- 
containing culture medium. 


























7.16 5.98 21.15 5.96 7.19 30.56 
µF-
83nm 
5.44 7.86 15.64 4.45 6.92 23.43 
µF-
102nm 
4.41 9.71 7.30 3.35 12.77 12.64 
Bulk-
161nm 
2.79 15.33 2.58 2.11 20.26 4.50 
1 Diffusion coefficient: D=kBT/6πηr; KB: Boltzmann constant; T: absolute temperature; 
η: solution viscosity, r: hydrodynamic radius; 
 2 Drag coefficient: f=kBT/D;  
3 Sedimentation coefficient: S=m(ρNP-ρ0)/fρNP; m: mass of NPs; ρNP: NPs density; ρ0: 
Density of the culture medium; *ρNP=φNP(ρP-ρ0)+ρ0; ρP: Density of the pure polymer; φNP: Volume 
fraction of polymer inside the particle 
As shown in Figure 2-3f, the smaller NPs with higher potential for diffusion show 
a remarkably lower uptake difference in upright and invert configurations compared to the 
larger NPs. Note that for short heights of culture medium, NPs were in close proximity to 
cells whereas for longer heights only a limited number of NPs could reach cells. Thus, the 
culture medium volume was another important variable that had to be taken into account 
(61). 
When NPs are exposed to biological fluids, they experience surface alterations, one 
of the most significant demonstrations of which is the formation of biomolecular corona. 
However, even in serum-free culture media, many proteins are adsorbed on the surface of 
NPs as a result of NPs’ interaction with the cellular secreted metabolites such as cytokines. 
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To find out how these corona-coated particles affect the cellular uptake pattern, NPs were 
incubated with the cells in a 10% FBS containing culture medium for two hours. During 
this incubation, the NPs’ surface charge dropped and approached that of the proteins and 
their hydrodynamic diameter became larger. Protein corona components present on the 
surface of NPs are of biological origin and some of them are able to start specific 
interactions with their complementary compartments expressed on the cell membrane. This 
protein masquerade, regardless of its ability to induce specific interactions, increases the 
size of NPs while reducing the adhesion power of NPs by eradicating the pristine 
metastable surface of NPs. Consequently, size enlargement beside lowered adhesion 
affinity of NPs for binding to cell membrane decreases the amount of cellular 
internalization (Figure 2-3f) (59). Since the surface charge of the particles incubated in the 
10% FBS culture medium was not high enough to prevent their aggregation, it negatively 
influenced the system’s stability. These aggregations had lower ability to enter cells.  
The main factors affecting the aggregation of proteins are: i) hydrophobic 
complementarity, ii) electrostatic complementarity, and iii) shape complementarity (62). 
Generally speaking, the electrostatic complementarity is controlled by long-range ordered 
forces that bring complementary partners together to form specific chemical or physical 
bonds and associations (63, 64). In addition to electrostatic complementarity, hydrophobic 
mismatching and hydrophobic complementarity bonds have several roles in the processes 
of protein aggregation as well. Hydrophobic mismatching bonds are formed by the 
interactions between hydrophobic chains of proteins and lipids (65). They are structural, 
geometrical and curvature couplings with correct and incorrect binding modes.  However, 
because of the high rate of the clustering process, misbinding is not hampered Even the 
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false complements can be stabilized over time since they will become trapped within the 
high-rate growing protein aggregations (62).  As discussed above, protein-coated NPs have 
a variety of binding chances to form aggregations with high sedimentation coefficients 
(Table 2-1 and Figure 2-4a). Hence, it is expected that in comparison with the bare NPs, 
the corona-coated particles have higher uptake differences in the upward and inverted 
configurations (Figure 2-3, g-h).  
 
Figure 2-4 The diffusion1 (a) and sedimentation2 (b) velocities of the microfluidic and bulk 
synthesized nanoparticles in the protein free and 10% FBS media. 1Diffusion velocity: 
VD=2D/x; x: certain distance of travel (culture medium height); 2sedimentation velocity: 
Vs=2gr2CNP(ρP-ρ0)/9ηρP; g: gravitational acceleration, CNP: NPs compactness. 
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To investigate the preferential internalization mechanisms of these NPs, the HeLa 
cells were treated with several pharmacological inhibitory agents, (66, 67) which blocked 
different endocytic pathways (Figure 2-5).  
 
Figure 2-5 The uptake pattern of the NPs incubated with the cells treated with the 
pharmaceutical inhibitory agents. 
To explore whether the endocytosis occurred actively (ATP driven) or passively 
(no cell machinery involvement during the internalization), the cells were pre-incubated 
with NaN3/2-deoxyglucose (NaN3/DOG) at 37°C to block the ATP synthesis by inhibiting 
the mitochondrial respiration (31). As a result, a noticeable decrease in the uptake was seen 
for all of the NP sizes emphasizing on the bold role of energy dependency. But some of the 
NPs were still localized in the cells even in the absence of ATP. This finding can be 
attributed to the presence of ATP and glucose in the serum-free medium. There is also the 
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likelihood of NPs’ passive internalization. As NPs are absorbed on lipid bilayers, they 
locally reconstruct the plasma membrane, which enables NPs to diffuse or slip over lipid 
bilayers. NPs may prefer the microdomains of lipid bilayer called lipid rafts, where the 
liquid-ordered and liquid-disordered states of phospholipids coexist. These domains have 
more diffusion potential in comparison with other sites of the plasma membrane (68). All 
in all, NPs have shown different affinities for diffusion corresponding to their site of 
landing because different sites of the membrane show different viscosities with different 
diffusive states (69, 70).  
To further study the NPs’ diffusion via the plasma membrane, the internalization 
experiments were repeated again at 4°C where the active uptake is totally stopped (31). 
The uptake of NPs under this circumstance suggests that a small fraction of these NPs are 
able to directly slip through the cell membrane via diffusion. However, potential changes 
in the membrane fluidity and structure as a result of incubation at 4°C is unavoidable, 
which reduces the ability of the plasma membrane to bend. Since the passive internalization 
of the larger NPs requires higher degrees of local reconstruction in comparison with the 
smaller ones, the decreased flexibility of the cell membrane as a result of the 4°C incubation 
leads to a salient decrease of the larger NPs’ uptake (6.2 ±1.5% for 161 nm and 9.0 ±2.7% 
for 102 nm particles) in comparison with the smaller particles (16.8 ±3.5 for 83 nm and 
17.3 ±2.7 for 63 nm particles). 
The ingestion of particles and fluids via endocytosis and micropinocytosis requires 
the formation of large endocytic vesicular compartments within cells by coordinated 
movements of the membranes and the actin cytoskeleton (29). Blocking the metabolic 
generation of protons during the actin polymerization can effectively impede the F-actin 
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polymerization. Na+/H+ exchangers exchange these protons with externally located Na+ 
ions. Blocking this exchanging process results in an environmental acidification caused by 
H+ accumulation, which stops further polymerization of the actin filaments. Amiloride and 
its family members, such as EIPA, are candidate inhibitory agents working on the basis of 
environment acidification by acting as general inhibitors of all the internalization pathways 
that are dependent upon the F-actin rearrangement. But this group of inhibitors can also 
cause cell-matrix dissociation, which is a serious side effect (66). 
Micropinocytosis, the most occurring mechanism among the internalization 
pathways, attenuates as a result of actin polymerization blockage (67). Micropinocytosis is 
responsible for the internalization of large particles. But, if NPs’ size becomes larger than 
the punctuate anchoring sites of the cytoskeleton, micropinocytosis will vanish because 
spreading of the cell lamellipodia around such particles will create local stresses, making 
the internalization process less functional (71). As a result of the actin polymerization 
blockage, the 161-nm particles experienced the largest decrease in internalization amount, 
19.6 ±7.3% (Figure 2-5). The art of the cytoskeleton to bend the cell membrane in order to 
reorient it to particles’ curvature, is one of the key steps in the endocytosis, which can be 
blocked by the F-actin polymerization obstruction. A certain amount of energy is required 
to make the cell membrane bend. For larger NPs, a greater amount of energy is required in 
order to reorganize the plasma membrane. As it was expected, the EIPA treatment reduced 
the NPs’ internalization to 32.3 ±4.2, 27.4 ±5.2 and 30.2 ±5.7 for the 63, 83 and 102-nm 
particles, respectively (Figure 2-5). 
One of the most studied mechanisms of endocytosis is clathrin-mediated pathway 
during which clathrin and other accessory proteins are clustered at the site of the coated pit 
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followed by the membrane bending around NPs. This bent region is connected to the flat 
region of the plasma membrane via a small neck that ultimately undergoes fission from the 
plasma membrane. This process is catalyzed by the ring-shaped assembly of the GTPase 
dynamin at the neck of the budding vesicle. The ruptured point is quickly healed 
completely (29). But, the clathrin endocytosis is not the only mechanism that benefits from 
the GTPase activity of dynamin. There is also another endocytic pathway based on the 
action of the wedge-shaped scaffolding proteins present on the plasma membrane. These 
proteins are called caveolins. They require the formation of dynamin helical structures to 
separate assembled vesicles, caveosomes, from the cell membrane (69). 
To investigate the share of dynamin action in the uptake of NPs, the cells were 
treated with dynasore, which inhibits the GTPase activity of dynamin. In other words, 
dynasore can be considered as a chemical that inhibits the completion of both caveolae and 
clathrin- dependent endocytic pathways. Inhibiting the dynamin lets the cell membrane 
spread over the NPs with no splitting of the formed vesicles. As a result of the dynasore 
treatment, the NPs’ internalization decreased to 47.3 ±3.4, 36.5 ±2.5, 17.3 ±4.5 and 12.9 
±5.3 for 63, 83, 102, and 161-nm particles, respectively. Moreover, we incubated the cells 
with a specific inhibitory agent of clathrin pathway to compare the results with those of the 
dynasore treatment to find out how the NPs’ properties led them to prefer clathrin or 
caveolae mechanisms. As previously mentioned, the clathrin-mediated mechanism is one 
of the prominent pathways of uptake in which triskelion clathrin proteins act as key players 
of the scenario. The proportion of this mechanism in the uptake process is of great 
importance due to the presence of the dominant-negative proteins that specifically interfere 
with the clathrin-mediated endocytosis(72). This phenomenon is of particular interest since 
 34 
our NPs are positively charged and it is expected that non-specific attraction forces can act 
as strong amplifiers of the cellular uptake. 
To investigate the share of the clathrin pathway, the cells were pre-incubated with 
chlorpromazine, a cationic amphipathic molecule with a strong affinity for lipids (73). The 
resultant attraction force between chlorpromazine and lipids alters lipid fluidity within the 
plasma membrane. The physical state transformations of lipid constituent of the cell 
membrane can weaken the cell membrane ability to form invaginations. This inability leads 
to the clathrin-adaptin protein2 complex dissociation. 
Although chlorpromazine acts specifically to block the clathrin-mediated pathway, 
the possible interactions of chlorpromazine with the cytoskeleton cargos or intracellular 
lipids may lead to undesired side effects, such as increasing the membrane’s permeability. 
To avoid such negative outcomes, choosing the optimum concentration of chlorpromazine 
is of great importance. 
55.3 ±3.4% of 63-nm particles were internalized after the pre-incubation of the cells 
with chlorpromazine. When the cells were treated with dynasore, 47.3 ±3.4 percent of these 
NPs were internalized. This result means that the 63-nm particles have a higher tendency 
to be internalized via the clathrin pathway in comparison with the caveolae pathway. This 
phenomenon can be due to the 63-nm NPs’ higher cationic nature. Variable specific and 
non-specific adhesion strengths critically control the cellular uptake. This binding energy 
drives the process of membrane spreading over NPs, but the plasma membrane’s bending 
rigidity and thermal fluctuations act against the deformation. If the encouraging forces are 
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large enough to overcome the opposing forces with respect to the free energy balance, the 
adhesion areas between cells and NPs grow and lead to a successful uptake (58). 
For the 161 and 102-nm particles (107.3 ±10.2 and 90.1 ±6.2 respectively), a 
significant difference (Nearly 94 and 73% in the order that already mentioned) in the 
internalization amount in the dynasore and chlorpromazine treated cells was observed, 
showing the dominant maneuver of the caveolae-mediated internalization pathway.  
It should be noted that a substantial number of accessory proteins take part in 
different routes of the endocytosis. The molecular compartments of some of these 
endocytic mechanisms may overlap. Accordingly, the inhibitory effects of the chemicals 
employed are not restricted to a defined internalization pathway. 
2.3.4 EPR: The advanced state of NPs’ extravasation art 
Enhanced Permeation and Retention (EPR) effect is a crucial pharmacokinetic 
attribution of nanomedicine. Due to the derivation of tumor blood vessels from normal 
vessels present in healthy tissues, the normal neighboring vessels could affect some of the 
tumor blood vessels’ properties, such as their cut off size, which varies with tumor type, 
growth location, and progression stage. For a single tumor, vessels’ pore size distribution 
is highly heterogeneous, which should be carefully taken into consideration for designing 
nanomedicine tools. This pore size distribution also varies with orders of magnitude among 
different types of solid tumors from a few nanometers in the brain and pancreatic tumors 
to a few micrometers in some kinds of breast cancer (74).  
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There are several complications in the crosstalk between NPs and cells in tumor 
microenvironments. In addition to vessels’ pores, the interstitial environment of tumors, 
mainly composed of the collagen and hyaluronan, have rough barriers with pore diameters 
ranging from a few to hundreds of nanometers. These barriers can cause steric hindrances 
on the way of NPs to central parts of the tumors (75, 76). Thus, it is logical to consider 
NPs’ size and diffusive behavior as a determinant factor in their interstitial trafficking.  
For each nanoparticle size, there is an ideal pore size for which transvascular flux 
reaches its maximum level (77). As the size difference between NPs and vascular pores 
gets smaller, steric, hydrodynamic and electrostatic forces act more synergetic to either 
facilitate or hinder NPs’ extravasation. In addition, the pressure gradient across vessels’ 
walls acts as an encouraging parameter under these conditions. But, when the pores become 
larger in comparison with NPs, the dominant forces, which were described earlier, vanish. 
Likewise, the pressure gradient also disappears, leaving diffusion as the only mechanism 
of entrance (77).  
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Figure 2-6 The NPs pass through the membranes with different pore sizes. 
Thus, we can conclude that there must be an optimal ratio of nanoparticle size to 
vessel pore size where both diffusion and convection act synergetic for a successful 
extravasation process. For a definite nanoparticle size, there is an amount of surface charge 
density above which electrostatic forces are strong enough to dominate opposing forces, 
leading to an increased extravasation. But, if the vascular pore size becomes significantly 
smaller, steric and hydrodynamic forces become powerful barriers against which high 
surface charge cannot resist (77). It is noteworthy that there are two upper and lower 
extremes, above and below which, electrostatic forces do not have a key role in NPs’ 
extravasation. These two extremes happen when the pore size is significantly smaller or 
larger than NPs’ sizes. In order to simply study the extravasation behavior of our NPs, we 
used the 4-20% porous polycarbonate membranes with different pore sizes. As shown in 
Figure 2-6, when the membrane pore size is nearly equal to the size of NPs, the steric 
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hindrance results in a lower extravasation of the smaller NPs. when the pore size becomes 
larger than the NPs’ size, the behavior of NPs becomes independent of the pore size in 
which all of the NPs show the same extravasation pattern.  
2.3.5 Nanoparticles touching Red Blood Cells (RBCs) 
The blood components are the first elements that NPs encounter when they are 
injected into the blood. To find out how wildly NPs act after they contact the blood 
elements, we studied erythrocytes’ hemolysis when they were incubated with the NPs. We 
chose PEI as positive control since free PEI results in the necrotic cell death due to its 
ability to damage erythrocytes’ membrane integrity at the very first stage of contact. 
Dextran was selected as negative control due to its reputation for blood compatibility. 
The toxicity magnitude of NPs depends on their concentration and their time of 
incubation with cells. Fischer et al. demonstrated the cationic charge density as a key 
parameter directly affecting the magnitude of cell damage (43). Accordingly, higher 
surface charges resulted in higher degrees of hemolysis. In addition, concentration 
increment also led to more intense cellular damages. The 63-nm particles had the highest 
potential for the erythrocytes damage, but their offensive effects, even at high 
concentrations (e.g. 500 μm), was less than 11.5%, indicating that these NPs are safe for 
injection (Figure 2-7). 
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Figure 2-7 The NPs incubated with the RBCs. The higher concentrations and higher charge 
densities of NPs increased the damages to the RBCs. 
2.4 Conclusions 
Generally, NPs that are able to enter cells and release their therapeutic contents in 
close proximity to intracellular machineries have a bright future in the field of 
nanomedicine. Size and surface charge of these nanoparticulate systems strongly tune their 
nanobio interactions. In the current study, we evaluated the role of NPs’ size-surface charge 
interplay in dictating their cellular internalization. Furthermore, the role of biomolecular 
corona surrounding the NPs upon entering the biological fluids was also investigated. To 
date, almost all of the cellular studies on NPs have been carried out with cells positioned 
in the upright configuration, which may add errors to final results, depending on the NPs 
diffusion to sedimentation ratio. We conducted our experiments for the cells in both the 
upright and inverted configurations to show how disparities can vary depending on the 
concentration of NPs in the interaction zone. Altogether, these results are expected to 
 40 
provide a paradigm for explicating the nanobio interactions happening when NPs face cells 
















CHAPTER 3. MICROFLUIDIC MANIPULATION OF 
CORE/SHELL NANOPARTICLES FOR ORAL DELIVERY OF 
CHEMOTHERAPEUTICS: A NEW TREATMENT APPROACH 
FOR COLORECTAL CANCER 2 
Conventional chemotherapy systems are normally administered by injection that may 
introduce significant concentrations of toxic drugs systemically. To address that we 
demonstrate an efficient tumor targeting nanoparticulate drug delivery system, designed as 
oral administration for cancer therapy. For the first time, a dual microfluidic platform has 
been employed to synthesize nanocarriers with highly pH-tunable core-shell structure. 
These nanocarriers consist of a fine-tuned self-assembled polymeric core precisely coated 
with a sacrificial pH-responsive layer fabricated via a microfluidic device with two discrete 
mixing steps. The sacrificial shell protects the core layer with drugs, which encapsulated 
in the core layer, and prevents their release in severe pH conditions of the gastrointestinal 
tract, while allowing for drug release in the proximity of a tumor. Quantum and molecular 
dynamic simulations were performed to investigate molecular interactions governing 
behavior of the core-shell system. The release profile and cytotoxicity of the nanoparticles 
(loaded with paclitaxel, PTX) against Caco-2 cell line were studied using sequential 
incubation in different pH conditions. The obtained results revealed a PTX release profile 
highly dependent on environmental pH. This microfluidic approach is a new way for 
efficient chemotherapeutic delivery systems to deliver more potent therapeutics to the 
                                                 
2 This work has been published by M.M. Hasani‐Sadrabadi, S. Taranejoo, E. Dashtimoghadam, G. 
Bahlakeh, F.S. Majedi, J.J. Van Dersarl, M. Janmaleki, F. Sharifi, A. Bertsch, K. Hourigan, L. Tayebi, P. 
Renaud, K. I. Jacob (2016) Advanced Materials 28 (21), 4134-4141. Reproduced by permission of Wiley- 
VCH. 
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target site. Such advancements in oral administration routes promise ‘chemotherapy at 
home’ for future cancer care. 
3.1 Introduction 
 Colon cancer is one of the most prevalent cancers today that is affecting people at 
an increasing rate. Currently, the lifetime risk of developing colon cancer runs at 5-6%.(78, 
79) Considering the growing rate of colorectal cancer, considerable scientific effort has 
been applied to find effective therapeutic approaches.(80-82) During the conventional 
route of chemotherapy, influencing of non-tumor cells and hence involving normal 
tissues/organs are unavoidable. Due to these side effects, the contribution of cytotoxic 
chemotherapy in cancer survival is limited. Nanoparticulate drug delivery systems make 
the chemotherapeutic approaches more selective with less off-target toxicity. A central 
challenge in nanomedicine is fine design of nanoparticles for their desired physicochemical 
properties in a reproducible manner. A significant part of this research has been focused 
on developing smart targeting drug delivery systems, to both minimize side effects and 
increase drug efficacy.(83-86) Oral drug delivery is an important administration pathway 
as it improves patient compliance and is self-administrable, which allows for more regular 
dosing schedules at a lower cost. Oral chemotherapeutics can also lead to lower toxicity 
and improved efficacy.(87-90) Due to the pH variations in the gastrointestinal tract during 
oral drug administration,(91-93) employing pH sensitive polymers as carriers can result in 
more specific chemotherapeutic delivery for cancer therapy.(91-99) Polymers and 
copolymers such as methacrylic acid (MAA) and methylacrylate (MA) or ethylacrylate 
(EA) are typical pH responsive polymeric materials employed in the preparation of 
extended release oral administered drugs for cancer therapy.(98, 100, 101) These 
copolymers are insoluble at low pH but dissolve at high pH, triggering the encapsulated 
drugs or inner core to be released.(101) Despite recent advances in chemotherapeutic 
delivery systems for colon cancer, most researches have focused on conventional bulk 
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mixing, which results in polydisperse nanoparticles (NPs).(99, 102, 103) However, 
attaining more precise drug release profiles requires a reproducible approach to fabricate 
finely-tuned nanocarriers with a narrow size distribution and predetermined properties.  We 
have recently introduced a microfluidic technique to synthesize monodisperse chitosan 
based NPs for cancer therapy applications.(99, 103) Compared to bulk mixing producer, 
microfluidic systems can synthesize the nanoparticles in a well-controlled, reproducible 
and high-throughput manner. Moreover, microfluidic systems, by mixing dissimilar 
materials (with distinct functional groups) at varying ratios, provide a solution for the 
challenge of finding right formulation for delivering therapeutic agents to specific sites in 
the body. 
Chitosan derivatives are widely used in drug delivery applications due to their outstanding 
biological characteristics.(104) Here we employ a hydrophobically modified chitosan 
derivative, N-palmitoyl chitosan, to improve the loading of hydrophobic anticancer 
drugs.(20) Moreover, N-palmitoyl chitosan chains allow for NPs to be shaped via self-
assembly, avoiding problems related to the removal of chemical crosslinking agents.(23, 
99, 105) Microfluidic platforms, benefiting from a controlled mixing regime, provide 
adjustable drug encapsulation efficiency and release rate from self-assembled 
hydrophobically modified chitosan (HMCS).(52, 99, 103) In this study, we used 
microfluidic techniques to design well-controlled monodisperse HMCS NPs coated by a 
pH-responsive layer (Eudragit FS 30D) with an adjustable thickness. The NPs behavior 
was assessed as they were exposed to variant pH conditions that simulate the digestive tract 
environment. Quantum mechanics (QM) and classical molecular dynamics (MD) 
simulations were also performed to investigate the molecular interactions governing the 




Chitosan with a deacetylation degree of 84% was purchased from Pronova Biopolymers. 
Size-exclusion chromatography measurements revealed a weight-average molecular 
weight (Mw) of 400 kg.mol
-1 and a polydispersity index (Mw/Mn) of ~2.7. The hydrophobic 
modification of chitosan was accomplished through the reaction of amino groups on the 
biopolymer chains with a palmitic acid N-hydroxysuccinimide ester (Sigma–Aldrich) in 
absolute ethanol. The substitution of C15 aliphatic groups on the chitosan backbone was 
confirmed by 1H NMR spectroscopy (Bruker 400 MHz). The details of the modification 
procedure and characterization methods have been described elsewhere.(99) Eudragit (FS 
30D), a pH sensitive derivative of PMMA, was purchased from Evonik Industries.  
Ninhydrin assay was employed to determine the substitution degree of the hydrophobically 
modified chitosan (HMCS) samples.(99) In brief, a solution was prepared through adding 
0.5 mL of 4 M acetic acid/acetate buffer (pH= 5.5) into the same volume of an aqueous 
acetic acid solution of HMCS. Adding 1 mL of ninhydrin reagent (Sigma-Aldrich), the test 
tubes were incubated in a boiling water bath for 20 min, followed by cooling the solutions 
at ambient temperature. Absorbance intensity was assessed at 570 nm using Shimadzu UV 
mini-1240 UV-vis spectrophotometer while employing unmodified chitosan solution and 
the acetic acid/acetate buffer solution as the control and blank samples, respectively. 
According to this assay method, value of 18.2 ± 0.3 mol% was obtained as the degrees of 
hydrophobic substitution for HMCS.   
3.2.2 Microfluidic device fabrication 
Microfluidic chips were fabricated at the EPFL Center for Micronanotechnology 
(CMi)with PDMS (Sylgard 184, Dow Corning, Switzerland) via soft lithography method. 
Silicon wafers spin-coated with SU-8 photocurable epoxy to a thickness of 60 μm on the 
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normal 4 inch silicon wafer and then baked. Conventional photolithography is used to 
fabricate master that contains patterned relief structures on the surface in the clean room. 
The surface of molds was modified using trimethylethoxy silane (Sigma) as self-assembled 
monolayer to prevent PDMS sticking. PDMS resin and its curing agent (10:1), poured over 
the patterned master mold, degassed in desiccators, and baked in the oven. After curing, 
PDMS was removed from the wafer and the holes were punched. The PDMS was then 
bonded to a glass slide after oxygen plasma activation (100 mW, 1 min; Diener electronic 
GmbH). Each of microfluidic devices consists of three inlets and one outlet. Fluorescent 
flows were used to determine the range of stable flow rates. 
3.2.3 Synthesis of HMCS nanoparticles 
The PDMS microfluidic device (μR1) had two inlets for basic water (pH of 9) as 
precipitation agent, one for the aqueous solution of HMCS with the pH of 5.5, and one 
outlet. The water stream was split into two, in order to achieve two lateral water streams at 
the same flow rate. The mixing channel was 150 μm wide, 60 μm high and 1 cm long. 
For bulk synthesis of nanoparticles, polymeric solutions were prepared by dissolving 
HMCS (2.5 mg.mL-1) in acetic acid solution (1% w/v) under constant stirring. The 
precipitation of HMCS molecules and formation of the nanoparticles were performed by 
dropwise addition of 1M NaOH to adjust the pH to 7.4. For drug loaded nanoparticles, 
Paclitaxel (Sigma-Aldrich) was dissolved in acidic water (pH 4.5) and mixed with the 
polymeric solution. The preparation of nanoparticles was performed as described above. 
3.2.4 Coating HMCS nanoparticles with Eudragit  
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The Tesla micromixer (μR2) consists of two inlets for Eudragit FS 30D (0.2 wt%) in 
ethanol/ deionized water solution as coating polymer, one for the aqueous solution of 
HMCS nanoparticles at 1 mg.mL-1, all at the constant pH of 6.5, and one outlet.  
3.2.5 Characterization of nanoparticles 
The size and size distribution of the prepared NPs at pH 7.4 were investigated using 
dynamic light scattering (Zetasizer 3000HS, Malvern Instruments Ltd., Worcestershire, 
UK). To characterize the shape and size of the prepared NPs, transmission electron 
microscopy (TEM; CM200-FEG-Philips) was employed. First, dilute suspensions of the 
NPs samples were deposited onto the Cu grid with a carbon film, and the instrument was 
operating at 100 kV accelerating voltage. ImageJ software was employed to analyze the 
obtained images. 
To study the effect of pH and immersion time on the structure and size of the NPs, 2 mg 
of NPs were immersed in 1 ml of PBS media when applying sequential change in buffer 
pH (4, 7.4, and 5.5) in consecutive time intervals (0-5, 5-12, and 12-30 h, respectively). At 
predetermined time intervals, samples were collected and measured using dynamic light 
scattering as stated before. 
The core-shell nanoparticles were washed and then suspended in the simulated gastric fluid 
(SGF). SGF was prepared by dissolving 2 g sodium chloride and 3.2 g purified pepsin in 7 
ml of hydrochloric acid and diluted with water to 1000 ml. The pH of the test solution was 
1.2 (106). The size of nanoparticles was measured as a function of time using DLS. By 
changing the media after washing of nanoparticles, the hydrodynamic diameter of 
nanoparticles were measured in the simulated intestinal fluid (SIF). SIF was prepared by 
dissolving 68.05 g potassium dihydrogen phosphate (KH2PO4) and 8.96 g sodium 
hydroxide in 10 L water. The pH of this solution was 6.8 (106). The size of nanogels was 
determined in their equilibrium swelling state by DLS method. 
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3.2.6 Cell uptake, CLSM and Fluorescence activated cell sorting (FACS) studies  
The cellular uptake of FITC-labeled nanoparticles (f-NP) was measured using 
Fluorescence activated flow cytometry (FACS) on a CyAnTM ADP Analyzer (Beckman 
Coulter, Inc). For the FACS analysis, human epithelial colorectal adenocarcinoma (Caco-
2) cells (106 cells) were dispersed into Eppendorf tubes. The NPs pre-processed in different 
pH separately before being added to the cells for the internalization experiments. Then, f-
HMCS NPs were added at concentration of 100 μg.mL-1, except for the unstained negative 
control, and the cells were incubated for 2 h in normal medium in a standard tissue culture 
incubator (37°C in a 5% CO2). The cells were then washed using ice-cold PBS containing 
10% FBS, and transferred into FACS tubes. All samples were kept on ice until FACS 
analysis.(99) The same experiments also performed on human cervical carcinoma 
epithelial (HeLa) and MCF-7 (Michigan Cancer Foundation-7) breast cancer cell lines. 
For microscopy, 105 cells per well were seeded on round glass cover-slips in 12-well plates. 
Once reaching 80% confluency, the growth media was aspirated and 400μL of f-NPs in 
PBS was added to each well, at concentrations of 0.2 μM. Cells were then incubated for 2 
h at 37°C and 5% CO2 at different pH levels. Then, samples were washed five times with 
PBS and fixed them with 3% paraformaldehyde solution, cell nuclei were stained with 
DAPI (0.2 μM). Fluorescent microscopy measurements were performed using a ZEISS 
LSM700 UP2 (Jena, Germany) confocal laser scanning microscope (CLSM).  
3.2.7 Cell proliferation assay 
Effect of different NP concentrations on the cell proliferation was evaluated by MTT assay. 
In brief, Caco-2 and MEF cells were cultured on standard 96-well plate at a density of 104 
cells per well. After incubating for 24 h, the culture medium was replaced by fresh medium 
containing specific concentrations of uncoated and coated NPs (50-800 mg/ml) and 
 48 
incubated for 72 h. Then, tetrazolium salt (M2128, Sigma) was added for an additional 4 
h. Thereafter, formazan crystals were dissolved in Dimethyl sulfoxide (Sigma) while 
shaking for 20 min. Absorbance at 570 nm was measured by utilizing a standard microplate 
reader. 
3.2.8 Drug encapsulation and in vitro release 
In vitro drug release from PTX-loaded NPs was studied using a dialysis cassette (3500 
MWCO, Thermo Scientific) immersed in PBS. Briefly, 1 ml of PTX-loaded NPs 
suspension in phosphate buffered saline (1 mg.ml-1) PH 7.4 was introduced into the dialysis 
cassette, then gently shaken and incubated at a temperature of 37°C.  A Sequential pH 
change (4, 7.4, and 5.5) in PBS medium was applied. The pH of PBS medium was kept 
constant at 4 in the first 72 h, then was increased to 7.4 for simulating human intestinal 
fluid in the next 72 h interval, and finally reached to 5.5 and remained without any further 
change for the third similar time interval. Samples were periodically removed and studied 
using high-performance liquid chromatography (HPLC). 2 ml mixture of sample and 
acetonitrile in a same portion was assessed. Separation procedure was done at a constant 
flow rate of 1 ml.min-1, followed by PTX detection at a wavelength of 230 nm.  In this 
study, a reverse phase C18 column and a mixture of acetonitrile:water (60:40 v/v) were 
employed as the stationary and mobile phases, respectively.  
To eliminate the sampling effect during release tests, drug concentration was corrected 
according to following equation (99): 
Cn
l = Cn[VT/(VT-VS)](Cn-1
l/Cn-1)                                                             (Eq. 3-1) 
where Cn
l is the corrected concentration of the nth sample, Cn is the measured concentration 
of PTX in the nth sample, Cn-1 the measured concentration of the (n-1)
th sample, VT is the 
volume of receiver fluid, and VS represents volume of the drawn sample (1 mL). 
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3.2.9 Statistical analysis 
For statistical analysis SigmaPlot software (version 11.0) was used. Data are presented as 
mean values ± SD. Comparison of two groups was performed by unpaired or paired t-test, 
while comparison of more than two groups was performed using ANOVA. Differences 
were considered significant at p <0.05. 
3.2.10 Fluidic Modeling 
In this simulation, two dimensional modeling of a Tesla micromixer with ten individual 
mixer units is carried out using COMSOL Multiphysics 4.2. Continuity and Navier-Stokes 
equations along with Convection-Diffusion equation are solved using finite element 
method for this geometry. Equations of continuity and momentum for steady state and an 
incompressible fluid as follows: 
 (Eq. 3-2) 
 
(Eq. 3-3) 
where is fluid flow velocity, ρ is fluid density, μ is fluid dynamic viscosity and p is 
pressure. In this study, all fluid properties are assumed to be equal to those of water, i.e. 
density of 1000 kg/ m3, and a viscosity of 0.001 Pa- s. 
The micromixer has three inlets and one outlet. The inlet boundary condition is defined as: 











where U0 is the free stream velocity which is assumed to be 9.26 10
-4 and 0.003704 m/s for 
main and both sheath flows, respectively. Outlet boundary condition is set to be at the 
atmospheric pressure. It is assumed that no slip boundary condition is applied on the 
remaining walls. The mass transport equation is  
 
(Eq. 3-5) 
where is the flux vector defined as: 
 (Eq. 3-6) 
In the above equation, D denotes diffusivity and C is concentration. Also, the inlet 
boundary condition for concentration is approximated by a concentration of one in both 
sheath flow and the diluents with a concentration of zero in the main flow inlet.  
Tesla mixer uses Coanda effect in order to bend fluid stream lines and increase mixing 
effects. As flow enters the micromixer, part of it deflects toward the side narrow channel 
due to Coanda effect. The remaining part of fluid flows through the curved- section until 
these two sub-flows join and integrate again. Then this recombined flow again experiences 
another Coanda effect and this separation and mixing continues until the flow reaches the 
outlet.  
3.2.11 Computational details 
In order to fundamental understanding of Eudragit coated chitosan constituting core-shell 
nanoparticles at molecular level, first principle quantum mechanics (QM) and molecular 
dynamics (MD) simulations were carried out to explore their molecular interactions 













3.2.12 First principle simulations 
First principle QM simulation methods were applied for three molecular systems including 
Eudragit, chitosan, and Eudragit-chitosan cluster. QM simulations were specifically 
utilized to assess the intermolecular interaction energy between Eudragit and chitosan, 
which determine their affinity to each other. The interaction energy (ΔEbinding) between 
Eudragit and chitosan was computed by using the following equation: 
ΔEbinding = (EEudragit-chitoasn – (EEudragit +EChitosan)                                                     (Eq. 3-7) 
where, EEudragit-chitoasn is the electronic energy of molecular system consisting of Eudragit 
and chitosan polymers, and EEudragit and EChitoasn represent electronic energy of molecules 
Eudragit and chitosan, respectively.  
Molecular structures for Eudragit and chitosan polymers are shown in Figure 3-1. It is 
known from Eudragit chemical structure that the ratio of ester groups to carboxyl groups 
(i.e., the x plus y to z ratio) is 10:1. Due to the highly expensive computational time of QM 
calculations, only one monomeric unit of Eudragit and chitosan was chosen for QM 
evaluations involving Eudragit, chitosan and Eudragit-chitosan cluster model. In particular, 
because of such time-consuming QM computations, it was difficult for the case of Eudragit 
monomer to preserve the mentioned 10:1 ester groups to carboxyl groups ratio at 
electronic-structure calculation scale. Consequently, for Eudragit structure, QM 
examinations were executed on Eudragit monomer containing only single unit of methyl 
acrylate, methyl methacrylate and methacrylic acid.  
For QM modeling studies, geometries of all structures including Eudragit, chitosan, as well 
as the Eudragit-chitosan cluster model were initially optimized by means of Hartree-Fock 
(HF) theory employing 6-31G** basis set.(107) Then, the optimized structures so obtained 
were further optimized by density functional theory (DFT) (108, 109) using B3LYP hybrid 
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functional (110, 111), first with 6-31G** basis set and then with larger basis set of 6-
311G**.(112) These successive QM calculations were performed to attain fully optimized 
structures. The electronic energies corresponding to final optimized structures were used 
to determine interaction (binding) energy between Eudragit and chitosan. All QM 
computations were carried out by means of Gaussian 09 software package.(113)   
 
Figure 3-1 Chemical structures of (a) Eudragit, and (b) chitosan polymers. 
3.2.13 MD simulations 
In order to examine the structural characteristics of Eudragit and chitosan in Eudragit-
chitosan layered system, for which Eudragit layer interacts with chitosan layer, MD 
simulations were conducted on a three-dimensional (3D) cell consisting of Eudragit and 
chitosan chains. First, polymeric chains of chitosan and Eudragit both with polymerization 
degree of 50 (i.e., the values of n and m in Figure 3-1) were constructed. The constructed 
polymers were subjected to energy minimization for 5000 steps using Smart minimizer 
algorithm available in Materials Studio software.(114) Then, with using minimum energy 
Eudragit and chitosan polymers, corresponding 3D simulation cells were created. 
Subsequently, the Eudragit and chitosan simulation cells were utilized in order to create 
another 3D simulation cell representing a simulation cell consisting of Eudragit and 
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least 10 Å above the chitosan layer. The 10 Å initial interlayer distance was chosen to 
eliminate dependency of the final structure form MD simulation upon its initial structure. 
Moreover, to reduce the interactions between Eudragit and chitosan layers to only one side, 
and thereby removing periodic boundary conditions (PBC) in z direction, vacuum distances 
were placed below chitosan layer and above Eudragit layer, as shown in Figure 3-2.  
The constructed layered cell was first optimized by means of Smart minimizer algorithm 
for 5000 steps, and then subjected to NVT MD simulations of 750 ps at temperature of 300 
K. MD simulations were carried out by use of COMPASS force field (115, 116), an ab 
initio based force field that have been successfully applied in earlier MD studies of 
polymeric materials. Non-bonded electrostatic and van der Waals (vdW) interactions were 
truncated at cutoff distance of 9.5 Å, and long-range electrostatic interactions were 
calculated using Ewald summation method. Newton equation of motion was integrated via 
velocity Verlet procedure by using 1 fs as time step.(117) Andersen thermostat was 
employed to control temperature at desired level. All MD simulations were done using 
Materials Studio software.(114)  
 
Figure 3-2 Eudragit-chitosan layered 3D cell used for MD simulation. All atoms of Eudragit 
and chitosan polymers are in Line, and Ball & Stick style, respectively. The color code is: 
carbon in gray, oxygen in red, nitrogen in blue, and hydrogen in white. 
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3.3 Results and Discussion 
Schematic representations of the microfluidic platforms are shown in Figure 3-3a. The 
nanoparticle cores are created in the first microreactor, where hydrodynamically focused 
flow precisely controls the mixing time of the two solutions (HMCS and water), creating 
monodispersed nanoparticles with precisely controlled properties. These particles are then 
coated in a Tesla micromixer, where they are sealed with a Eudragit (pH-sensitive PMMA 
derivative) shell. The micromixer inputs (flow ratios) determine the reactor conditions, and 
thus the nanocapsule properties. The effect these inputs have on the nanocapsule Zeta 
potential, Eudragit shell thickness, and overall NP size and morphology is shown in Figure 
3-3c. The design of the Tesla micromixer was finalized using COMSOL Multiphysics 
software to investigate the flow/concentration profiles. Using two-dimensional modeling 
of ten individual mixer units the continuity and constitutive Navier-Stokes equations along 
with convection-diffusion equation were solved using finite element method for various 
geometries. The inlet boundary condition is approximated by the sheath flow and core flow 
concentrations and flow rates. Tesla mixers use the Coanda effect to bend fluid stream lines 
and increase the mixing effects. As flow enters the micromixer, part of it deflects toward 
the side narrow channel due to the Coanda effect, while the remaining fluid flows through 
the curved- section until these two sub-flows merge. This recombined flow then 
experiences the Coanda effect again, and this separation and mixing continues until the 
flow reaches the outlet. The concentration distribution for this Tesla micromixer is shown 
in Figure 3-3 (b-i). For this flow condition, full mixing is obtained after passing two cell-
pairs. The velocity stream lines are shown in Figure 3-3 (b-iii).  
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 Figure 3-3 (a) A schematic representation of the dual microfluidic platform used to synthesis 
tunable core-shell nanoparticles: a cross-junction microfluidic device used to control 
formation of chitosan based NPs from polymer core flow, which hydrodynamically focused 
with sheath flows of water at basic pH (μR1), and a Tesla micromixer to make Eudragit FS 
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30D coated onto NPs (μR2). (b) COMSOL simulation results on concentration distributions 
(b-i), velocity distributions (b-ii), and velocity streamlines (b-iii) for the Tesla micromixer. (c) 
3D plots of NPs’ experimental characteristics, which were adjusted via the parameters of μR1 
and μR2. (c-i) NPs’ diameter without paclitaxel (PTX), (c-ii) shell thickness, (c-iii) Zeta 
potential, (b-iv) diameter with PTX. The white arrows represent the positions of NP samples 
selected for further experiments. (d-e) Transmission electron microscopy (TEM) images of 
uncoated (i) and masked (ii) HMCS NPs; (d-i) μR1:0.03, no coating, (d-ii) μR1:0.03, μR2: 
0.10, (e-i) μR1:0.10, no coating, (e-ii) μR1:0.10, μR2: 0.10, (f-i) R1: Bulk, no coating, (f-ii) R1: 
Bulk, μR2: 0.10. 
Increasing the flow ratio (volumetric ratio of sheath flow to main flow from 0.03-0. in the 
microreactors caused a strong increase in total NP diameter for both neat and PTX-loaded 
particles (Figure 3-3c-i and 1c-iv). Figure 3-3 (c-ii) shows the shell thickness for the coated 
NPs increases with increasing flow ratio. For instance, by increasing the flow ratio in the 
Tesla micromixer (μR2) from 0.07 to 0.3 while keeping the flow ratio constant for the first 
micromixer (0.03)), the average shell thickness increased from 8 nm to more than 22 nm. 
A more complex trend in Zeta potential variation was observed. As shown in Figure 3-3 
(c-iii), the highest Zeta potential value (+10 mv) occurred for the NPs synthesized at the 
lowest flow ratio in reactor 2 (0.07). This is consistent with the shell thickness results. The 
Eudragit supportive layer and HMCS core have negative and positive charges, respectively. 
Hence, decreasing the shell thickness, as a direct consequence of decreasing the flow ratio 
in micromixer 2, resulted in NPs with a higher net positive charge, and an increased Zeta 
potential.  
Employing the microfluidic process is a significant improvement over the traditional bulk 
mixing procedures, and results in NPs with smaller diameter for both uncoated and masked 
NPs at all flow ratios. A broad distribution of residence times in the turbulent regime and 
variations of local pH at bulk mixing condition are considered the main reasons for such 
non-uniformity in bulk NPs.(103, 105) The first microreactor establishes a well-controlled 
hydrodynamically focused mixing region with short and narrowly distributed residence 
times, defined by the input flow rates and ratios, which generates smaller NPs with uniform 
diameter and microstructure.(99, 103, 105) In the first micromixer (cross-junction), the pH 
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increases through diffusion of the basic water into the aqueous polymer stream, which leads 
to HMCS amine group deprotonation and aggregation of the macromolecules.  A narrow 
distribution of residence times provided by on-chip diffusion mixing gives the opportunity 
for the polymer chains to benefit from similar reaction times.(99) Solution pH controls the 
balance between electrostatic repulsion and hydrophobic attraction forces, so the time scale 
associated with the pH rearrangement determines the self-assembly timescale, which is 
short in the microfluidic device and thus generates  small and uniform NPs (Figure 3-3 (d-
i)).(99) 
In microreactor 2, bulk mixing and laminar flow are the predominant routes of mass 
transfer, where reactions mainly occur in the microscale rather than the molecular scale. 
This resulted in more non-uniformity in shell thickness and morphology of the masked 
NPs. The very slow kinetic diffusion of Eudragit chains prevents the ‘t’ microreactor 
design used to create the NP cores from being used to coat the NPs.(118) This limitation 
leads to the design of the Tesla mircoreactor with alteration in shape, residence time and 
thus the predominant route of mass transfer. Still, the NPs coated with Eudragit in the 
microreactor were more uniformly coated than those coated via bulk mixing. 
In order to better understand the molecular interactions in the Eudragit-chitosan core-shell 
NPs, molecular dynamics (MD) simulations were conducted on a three-dimensional (3D) 
cell consisting of Eudragit and chitosan chains by use of COMPASS force field. 
Equilibration of the simulated structures was first checked by monitoring time evolution of 
the potential energy as well as temperature of the cell (Figure 3-4).] As shown, the total 
potential energy and temperature fluctuate slightly around an average value, which 




Figure 3-4 Total potential energy and temperature variation against simulation time during 
last 100 ps NVT MD simulation. 
The final structure from the last 100 ps NVT (moles (N), volume (V) and temperature (T) 
are conserved) MD simulation of layered Eudragit-chitosan cell is shown in Figure 3-5 (a). 
To make a better comparison, the initial layered structures used for MD simulation are also 
shown. It is obvious that in comparison with the initial 3D cell the distance between 
Eudragit and chitosan layers in the equilibrated cell became closer. Such an observation is 
attributed to the strong affinity of Eudragit and chitosan chains, as confirmed quantitatively 
by the binding energy value, and the strong intermolecular hydrogen bonding interactions 
between Eudragit and chitosan. Figure 3-5 (a) shows both the initial and final structures 
with periodic boundary conditions, which clearly demonstrates the tendency of Eudragit 
and chitosan chains to interface tightly. 















































Figure 3-5 (a) Eudragit-chitosan layered structure (a-i) initial structure and (a-ii) after 600 
ps NVT MD simulations. Polymer chains are shown inside the simulation cell with periodic 
boundary conditions; All atoms of Eudragit and chitosan polymers are in Line, and Ball & 
Stick style, respectively. (b) B3LYP/6-311G** optimized model structure of (b-i) Eudragit, 
(b-ii) chitosan and (b-iii) Eudragit-chitosan cluster. Hydrogen bonding interactions are 
shown as dashed line; All atoms are in Ball and Stick model. (c) Hydrogen bond length in 
B3LYP/6-311G** optimized model structure of (c-i) chitosan, and (c-ii) Eudragit-chitosan 
cluster. Hydrogen bonding interactions are shown as dashed lines. All atoms are in Line style. 
The color code for all items is: carbon in gray, oxygen in red, nitrogen in blue, and hydrogen 
in white. (d) Total electronic energy (Hartrees) and ZPE (Hartrees) (kCal.mol-1) for 
B3LYP/6-311G** optimized Eudragit, chitosan and Eudragit-chitosan cluster structures. 
First principle quantum mechanics (QM) simulations were applied for the three molecular 
systems including Eudragit, chitosan, and Eudragit-chitosan clusters. QM simulations were 
specifically utilized to assess the intermolecular interaction energy between Eudragit and 
chitosan, which allows us to determine their affinity to each other. Figure 3-5 (b) shows 
the final energy-minimized model structures for Eudragit, chitosan as well as Eudragit-
chitosan, resulted from B3LYP/6-311G** level of theory. We find that the optimized 
monomer structure of Eudragit is not able to form any intramolecular hydrogen bonds, 
while chitosan can form intramolecular hydrogen bonds between amine (–NH2) and 
hydroxyl (–OH) groups. In the simulation, hydrogen bonds are assumed when two 
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hydrogen donor and hydrogen acceptor atoms satisfy the following geometrical conditions: 
(1) the distance between a hydrogen donor atom and hydrogen acceptor atom is less than 
2.5 Å, and (2) the hydrogen donor-hydrogen-hydrogen acceptor angle is greater than 90°. 
For the single chitosan structure, the nitrogen atom in the amine groups act as both 
hydrogen donor and hydrogen acceptors, while the oxygen atom in one of hydroxyl groups 
directly attached to the chitosan backbone act as a hydrogen donor in hydrogen bond 
formation, and the oxygen atoms in the other hydroxyl group directly bonded to the 
polymer backbone appears as hydrogen acceptor atoms.  
In the case of Eudragit-chitosan cluster model, two intermolecular hydrogen bonding 
interactions are formed between Eudragit and chitosan units, in which oxygen atoms in the 
Eudragit carboxylic group act as hydrogen bond donor and acceptor atoms, and hydroxyl 
group attached to the backbone via methyl group and hydroxyl group directly attached to 
the backbone act as hydrogen donor and acceptor atoms, respectively. These types of 
interactions show that Eudragit polymers are able to interact via their methacrylic acid 
groups with chitosan. The intramolecular hydrogen bonds formed in chitosan only 
structures and in of Eudragit-chitosan clusters are the same. 
In order to gain further insights into the interaction between Eudragit and chitosan, length 
of the hydrogen bonding interactions was examined (Figure 3-5 (c)). The depicted 
hydrogen bond lengths clearly indicate that intramolecular hydrogen bond length in 
chitosan and also in chitosan interacting with Eudragit is almost the same, which signifies 
that interaction of chitosan with Eudragit does not influence the strength of intramolecular 
hydrogen bonding interactions within chitosan. However, as the intermolecular hydrogen 
bond length in Figure 3-5 (c-ii) exhibits, the length of the Eudragit-chitosan hydrogen 
bonds is shorter than that of intramolecular hydrogen bonds within chitosan, which 
demonstrates the strong binding affinity between Eudragit and chitosan chains. The 
findings of the QM and MD simulation results are consistent with each other. 
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Total electronic energy and zero-point energy (ZPE) corrected total electronic energy of 
the final B3LYP/6-311G** optimized Eudragit, chitosan, and Eudragit-chitosan structures 
are shown in Figure 3-5 (d). From these total energy levels the interaction energy (ΔE) 
values for the Eudragit-chitosan cluster model were calculated to be -11.23 kCal.mol-1 
(ΔEelectronic) and -9.60 kCal.mol
-1 (ΔEZPE). We observed that the interaction energies are 
negative, which is indicative of the fact that Eudragit and chitosan chains tend to be located 
in the vicinity of each other and interact together. The Eudragit-chitosan affinity is 
associated with their intermolecular interactions, especially the hydrogen bonding 
displayed in Figure 3-5 (b).  
Figure 3-6 shows the hydrodynamic diameter of synthesized core-shell NPs over time at in 
various pH conditions. The pH alterations were intended to somewhat mimic the digestive 
tract. In the gastrointestinal tract, the intraluminal pH increases from highly acidic medium 
(pH 1-2 which increases to 4 during digestion) in the stomach to about pH 7.4 in the 
terminal ileum of the small intestine. This change is followed by a pH drops to 5.7 in the 
caecum (Colon).(119) It is worth noting that no significant differences were found in the 
gastrointestinal pH levels between normal subjects and people suffering from colorectal 
carcinoma.(120) 
Generally, the size of NPs depends on the number of polymer chains as well as their 
swelling state. It has been shown that swelling state is highly affected by the compactness 
of self-assembled NPs, which can be controlled by changing the flow ratio on microfluidic 
platforms.(105) The probability of hydrophobic side chains  competing with intramolecular 
interactions is highly influenced by the mixing time, where it has been shown that longer 
mixing time results in less compact NPs.(105) As is shown in Figure 3-6, NPs synthesized 
at lower flow ratios in µR1 (t-shape microreactor) show higher stability, which is due to 
their more compact structure. In comparison with microfluidic NPs, less compact bulk 
synthesized NPs show less resistance to chemical and physiological alterations, leading to 
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more swelling when exposed to pH alteration. Increasing the pH to 7.4 is associated with 
an initial NP swelling, and is followed by a significant decrease in the size of the NPs. 
Early stage increase in diameter of the NPs can be interpreted as the swelling of the 
Eudragit layer in the solubilizing pH medium. Subsequently, gradual dissolution of the 
Eudragit layer in the neutral medium leads to a drop in the size of the NPs. It should be 
noticed that the observed differences in the size of the NPs are related to their different 
compactness. After removal of the Eudragit layer, the next change in pH from 7.4 to 5.5 
results in a significant increase in the size of NPs. Swelling of the NPs in this stage is due 
to the electrostatic repulsion of the highly protonated HCMS chains, which ends in 
dissolution of the swollen NPs (Figure 3-6).  Bulk synthesized NPs coated at FR of 0.1 
were found to show the most significant and rapid size alterations The overall diameter 
changes of the NPs were less significant over the first pH transition (pH 4 to 7.4) compared 
to the second transition (pH 7.4 to 5.5). This effect was more pronounced for the 
microfluidic NPs, which disclose the ability of microfluidic synthesis method to produce 
dense and compact NPs.(105) Over the second pH transition, the removal of the shell layer 




Figure 3-6 pH/time dependency of hydrodynamic diameter for different types of Eudragit 
coated NPs. 
The dynamic size of microfluidic core-shell nanoparticles formed at μR1:0.03, μR2: 0.10 
in the simulated gastric (SGF) and intestinal fluids (SIF) also investigated and shown in 
Figure 3-7.  
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Figure 3-7 The dynamic size of microfluidic core-shell nanoparticles formed at μR1:0.03, 
μR2: 0.10 in the simulated gastric (SGF) and intestinal fluids (SIF). 
Stability of core-shell nanoparticles (μR1:0.03, μR2: 0.10) after incubation for 120 h in the 
gastric simulated (pH=4) and intestinal simulated (pH=7.4) conditions are examined 




Figure 3-8 Stability of core-shell nanoparticles (μR1:0.03, μR2: 0.10) after incubation for 120 
h in the gastric simulated (pH=4) and intestinal simulated (pH=7.4) conditions. The shell 
(Eudragit) dissolved after incubation at neutral pH (pH=7.4) in about 30 min and 
subsequently we have bare chitosan NPs.  
Here, we also tried to show the applicability of this approach for other charged polymers. 
As shown in Figure 3-9, we coated chitosan-based bulk- and microfluidic-synthesized NPs 
by Alginate (as a representative charged natural polymer) in addition to Eudragit (as a 
representative charged synthetic polymer). We also made PEI/DNA nanoplexes and coated 
them with Alginate and Eudragit using the same microfluidic platform.  
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Figure 3-9 The proof-of-concept results of applicability of proposed coating technique for 
other charged macromolecules. Here we tested our approach in four different systems (a). 
Eudragit (b) and Alginate (c) coating of chitosan-based nanoparticles using both of 
microfluidic and bulk coating methods. Chitosan nanoparticles were synthesized using both 
of bulk mixing and microfluidic assisted synthesizing methods. The Eudragit (d) and Alginate 
(f) coating of positively charged PEI/DNA-based nanocomplex also examined. The flow ratio 
of 0.10 is used for all of microfluidic assisted coating experiments 
Figure 3-10a shows the in vitro release profiles of different synthesized paclitaxel (PTX) 
loaded NPs over the sequential changes in pH (4, 7.4, and 5.5) at 37 °C. The relatively 
rapid initial drug release from uncoated NPs (both microfluidic and bulk synthesized 
particles), more than 30% in the first 24 h, has been typically reported for PTX-loaded 
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chitosan-based NPs at low pH medium.(121, 122) In the self-assembled NPs, drug 
molecules may have been partially loaded in the outer layers of particles, specifically in 
the case of bulk synthesized NPs, resulting in their accelerated release. Core-shell NPs 
which were prepared on the dual microfluidic platforms, have more developed release 
profiles, limited burst release at low pH, followed by more sustained release profiles at the 




Figure 3-10 Cumulative in vitro release of PTX from uncoated (empty symbols) as well as 
coated (filled symbols) chitosan-based NPs after sequential change in pH (4, 7.4, and 5.5) at 
37 °C (Mean ± SD, n = 3 independent experiments). (b) Cell viability of Caco-2 cells after 72 
h exposure to free PTX as well as PTX loaded NPs as a function of pH at 37°C. (c) IC50 values 
for different types of uncoated/coated NPs after sequential incubation at different pH. Lower 
IC50 value indicate more potent therapeutic agent. * indicate IC50 < 0.001. Results presented 
as mean value ± SD, n = 3 independent experiments. 
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As previously stated, using microfluidics provides the possibility to synthesis more 
compact and smaller NPs in comparison with bulk synthesized particles. Hence, the slower 
release rate of the microfluidic prepared NPs is due to their relatively more compact 
microstructure.(105) Coating the NPs with Eudragit, as shown in Figure 3-10a, strongly 
affected the release profile. The pH-sensitive Eudragit outer layer, which is insoluble in 
low pH environment, hinders PTX diffusion to the surface of the NPs in early stage of 
release and reduces burst release in the acidic medium. In the case of uncoated NPs, the 
major part of the encapsulated PTX is released in the first stage (acidic pH), an effect which 
is more pronounced for the bulk synthesized NPs. Obviously, the release rate of the 
microfluidic NPs accelerated after increasing pH from 4 to 7.4, which is in contrast of the 
decreased release rate of the uncoated NPs after a similar pH Transition. This trend is 
attributed to the dissolution and higher swelling ratio of Eudragit layer at neutral pH in 
comparison with acidic pH. Such pH-responsive release behavior has been reported by 
some researchers.(123, 124)  
Practically, coating the NPs with pH-sensitive layer gives them the ability to bypass the 
acidity of gastric fluid without releasing considerable amounts of the loaded drug.(124) 
After dissolution of the supportive layer at higher pH, modified chitosan core forms a gel 
like insoluble structure, hence the rate of drug release is controlled.(125) Interestingly, a 
further acceleration of release rate was observed for the microfluidic NPs after decreasing 
pH from 7.4 to 5.5. Over the last release stage, protonation of amino groups on chitosan 
chains causes swelling of NPs, which ultimately results in an increased rate of PTX 
release.(126) 
The effect of unloaded NPs at different concentrations (50-800 μg.ml-1) on the viability of 
two kinds of cells (Caco-2 and MEF) after 72 h using the MTT assay is presented in Figure 
3-11. These results are the average of a series of three different experiments. All types of 
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NPs have shown cell viability levels of more than 90% after 72 h, indicating low toxicity 
of the coated and uncoated chitosan nanocarriers. 
 
Figure 3-11 Cell viability of Caco-2 (a, b) and MEF (c, d) cells after 72 h exposed to the (a, c) 
uncoated and, (b, d) coated unloaded chitosan NPs at different concentration and 37°C, 
(Mean ± SD, n = 3 independent experiments). 
Cell viability and IC50 results for different types of the synthesized NPs are presented in 
Figure 3-10. Figure 3-10b displays the viability of Caco-2 cells after 72 h exposure to 
different concentrations of the PTX loaded NPs as a function of pH at 37°C. Increasing 
PTX concentration caused a sharp drop in cell viability.(127, 128) It is also found that pH 
of the medium plays a leading role in the toxicity of PTX loaded NPs. Sequential incubation 
at different pH caused a significant decrease in the Caco-2 cell viability. As stated above, 
sequential incubations at pH 7.4 and 5.5 leads to dissolution of the outer layer and swelling 
of inner core respectively, which resulted in increased release of the drug. There is also a 
clear relationship between the amount of released PTX and the IC50 value. Amoozgar et 
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al. reported incubation of the cells at pH 6.2 with PTX loaded NPs, coated with a layer of 
chitosan, caused a significant dose-dependent reduction of the value of cell viability. This 
trend was comparable of moderate decrease in viability of the cells incubated with the 
PTX-loaded NPs at pH 7.4.(129) Such pH-dependent cytotoxicity has been reported 
elsewhere even for neat chitosan-based NPs. Loh et al. reported Caco-2 cellular uptake of 
chitosan NPs in pH 6.0 results in lower cell viability than at pH 7.4.(130)  
Figure 3-10c illustrates the IC50 trend, which shows the effective PTX concentration 
required for a 50% decrease in cell viability. Results show that for all the PTX-loaded NPs 
IC50 decreased when applying the pH sequence. This finding implies3enhanced efficiency 
of the PTX loaded NPs in the sequential incubation at different pH values (4, 7.4, and 5.5). 
Interestingly, the viability of cells incubated with unloaded NPs varies little with NP 
properties (flow ratio), again emphasizing the pH-dependency of IC50 on the drug delivery 




Figure 3-12 (i) Schematic representation of facilitated cellular uptake of NPs after unmasking 
upon incubation at different pH. (ii) Confocal laser scanning microscopy (CLSM) images 
showing cellular uptake of FITC-labeled HMCS NPs after 2h incubation with Caco-2 cells 
after changing the medium pH. Cell nucleus stained with DAPI (blue fluorescence), the green 
dots represent internalized NPs. Scale bar is 15 μm. (iii) Fluorescence activated cell sorting 
(FACS) results of facilitated cellular uptake after unmasking of NPs at different pH. 
As shown in Figure 3-12, changing the pH from 4 to 7.4 and then 5.5, results in unmasking 
of HMCS NPs and facilitated cellular uptake of NPs. It seems masked NPs with anionic 
surfaces have less interaction with the negatively charged cell membrane, which leads to 
lower transfection efficiency. It was previously reported that surface charge affects cellular 
uptake of chitosan-based NPs.(131)   
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Changing the pH to 7.4 is combined with the dissolution of Eudragit layer and a higher 
degree of cellular accessibility for unmasked HCMS NPs. Although removing the Eudragit 
shell generates more cellular transfection, a greater amount of cellular uptake is observed 
with protonation of amino groups of chitosan as a result of changing the pH from 7.4 to 
5.5.(126, 132, 133) Due to this charge, as shown in Figure 3-3 (c-iv), chitosan NPs are 
often endocytosed by the cells.(99, 134) The cell uptake trend is quantitatively reported in 
Figure 3-12 (iii). The ratio of the florescence intensity for cells with and without NP uptake 
shows the NPs uptake efficiency, and increased with altering the pH to 7.4 and then 5.5. 
The cellular uptake is positively correlated with the surface charge in the NPs. Normally 
transfection efficiency of chitosan is higher for culture medium with lower pH value due 
to a higher degree of chitosan protonation.(121, 131) 
Cellular uptake nanoparticles as a function of applied pH is evaluated in other cancerous 
cell lines (MCF-7 and HeLa cells) and the results are presented in Figure 3-13 and the same 
trends are seen in the other cell lines as well. To investigate the effects of presence of serum 
proteins on NPs-cells interactions, cellular uptake of prepared coated and uncoated NPs is 
measured in serum-based culture (10% FBS containing medium) in three different cell 
lines (Figure 3-13) as a function of pH and after 2 h of incubation. 
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Figure 3-13 Cellular uptake of FITC-labeled nanoparticles as a function of applied pH in 
Caco2 (a), HeLa (b), and MCF-7 (c) cell lines. The effects of pH-sensitive coating as well as 
presence of serum-based media (10% FBS containing culture) investigated by measuring 
fluorescent intensity of cultured cells after 2 h of incubation with nanoparticles at 37°C using 
flow cytometry. The pH value of media changed subsequently from 4 (gastric mimic pH) to 
7.4 (intestinal mimic pH), and from 7.4 to 5.5 (tumor local pH). Values indicate mean ± 





Nanoparticle systems, due to their unique features as drug carriers, have attracted a great 
deal of interest in colon cancer chemotherapy.  For the first time, we employed a dual 
microfluidic procedure to attain highly tunable core-shell drug carriers with customized 
and reproducible characteristics adjusted for targeted colon cancer therapy. Self-assembled 
hydrophobically modified chitosan nanoparticles (NPs) were produced in a cross-junction 
microfluidic device and finely coated with a pH- sensitive copolymer (Eudragit) through a 
Tesla micromixer. Quantum mechanics (QM) and classical molecular dynamics (MD) 
simulations indicate a good level of molecular interactions between the layered 
nanostructures. NPs fabricated and coated via microfluidics showed increased cellular 
uptake during pH changes compared to those prepared with bulk mixing. MTT assays and 
in-vitro results showed coating the NPs with a pH-sensitive Eudragit layer gives the NPs 
the ability to bypass the acidic gastric fluid without releasing the majority of the loaded 
anticancer drug. Considering the pH-sensitive characteristics of the microfluidic NPs, such 
a highly tunable drug delivery system enabling physiological-stimuli release is a potential 







CHAPTER 4. ON-CHIP SYNTHESIS OF FINE-TUNED BONE-
SEEKING HYBRID NANOPARTICLES3 
 Reproducibility of physicochemical properties of multifunctional nanoparticles has 
been always their major challenge for various for therapeutic and diagnostic applications. 
Commonly nanoparticles are produced as rather heterogeneous mixtures with a subsequent 
range of functional properties.  Here we report an one-step approach for synthesis of finely 
tuned targeting hybrid nanoparticles (HNPs). A microfluidic platform was used to precisely 
control the nano-precipitation of bisphosphonate-conjugated poly(D,L-lactide-co-
glycolide) chains, while co-encapsulating superparamagnetic iron oxide nanoparticles 
(SPIONs) and the anticancer drug. The size of the nanoparticles was found to increase with 
rising mixing times, whereas smaller and more compact HNPs, were obtained at the rapid 
mixing regimen. Furthermore, drug encapsulation studies revealed significantly higher 
loading (73-80%) efficiencies for the microfluidic technique compared to the conventional 
bulk synthesis techniques (50%), and a sustained release profile was achieved with the 
microfluidic synthesized HNPs. The HNPs were shown to have a strong affinity for 
hydroxyapatite, as demonstrated in vitro bone binding assay, which was further supported 
by molecular dynamics simulations. In vivo proof of concept results verified the prolonged 
circulation of targeted microfluidic HNPs. Biodistribution as well as non-invasive 
bioimaging experiments showed higher tumor localization and suppression of targeted 
HNPs to the bone metastatic tumor compared with controls. The hybrid bone-targeting 
nanoparticles fabricated with fine, reproducible precision can be considered as promising 
nanoplatforms for various theragnostic applications. 
                                                 
3 This work has been published in part by M.M. Hasani-Sadrabadi, E. Dashtimoghadam, G. Bahlakeh, F.S. 
Majedi, H. Keshvari, J.J. Van Dersarl, A. Bertsch, A. Panahifar, P. Renaud, L. Tayebi, M. Mahmoudi, K. I. 
Jacob (2015) Nanomedicine 10 (23), 3431-3449. 
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4.1 Introduction 
Finding the optimal treatment for bone cancers, osteoporosis, osteoarthritis, and other bone 
diseases has long been a matter of great interest for health care providers (135, 136). 
Particular emphasis has been centered on the development of personalized treatments for 
bone cancers, in order to both improve the efficacy of drugs and reduce the side effects 
associated with chemotherapy. Many bone tumors are linked to some form of excessive 
local bone resorption (i.e., osteolytic tumors) or formation (i.e., sclerotic tumors), 
distinguishable by their unique appearance on radiography and uptake of radioactive tracer 
on bone scintigraphy (137, 138).  Osteosarcoma is the most common primary bone 
malignancy and an aggressive osteoblastic form of bone cancer, which is characterized by 
its rapid osteoblastic activity, followed by sclerosis of the affected regions (139). The 
99mTc-MDP (99mTc-methylene diphosphonate) scan from patients with osteosarcoma is 
accompanied by significant homogeneous accumulation of the radioactive bisphosphonate 
(BP) tracer in the primary tumor as well as in the metastatic sites (140).  These distinctive 
patterns in bone cancers could be used to design a bone-seeking platform carrying anti-
cancer drugs for more efficient drug delivery (141-143). Nanoparticles (NPs) have unique 
properties that make them good candidates for this purpose. This type of approach, centered 
around smart and active targeting, may result in a considerable decrease in side effects of 
chemotherapy drugs, and more efficient destruction of tumor cells (144, 145). 
Inorganic NPs can be tracked in vivo with many imaging modalities, as their high electron 
density structures and/or their magnetic properties make them good contrast agents (83, 
146-148).  Among the different types of magnetic particles, superparamagnetic iron oxide 
NPs (SPIONs) are recognized as one of the most promising materials for biomedical 
applications such as image guided drug delivery and cancer treatment (149-151). SPIONs 
can use active targeting by conjugating targeting ligands, and also be directed towards 
tumors by using a weak external magnetic field (152). Moreover, magnetic fluid 
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hyperthermia using magnetic liposomes has been shown to successfully reduce the volume 
of osteosarcoma tumor in animal models (153). 
The aim of this work is to develop a single-step microfluidic assisted route to reproducibly 
synthesize finely tuned multifunctional bone-seeking hybrid NPs (HNPs), with the 
potential for future applications in treatment and imaging of bone cancers (i.e., 
theragnosis). In recent years, microfluidics has emerged as a distinctive approach for the 
synthesis of a variety of well-defined nano-/microstructures, while using only small 
amounts of reagents (14, 15, 20, 23, 99, 154-156). 
Here, we demonstrate the microfluidic design of multifunctional targeting nanocarriers 
capable of concurrent diagnostic imaging, delivery of chemotherapy drugs, and 
hyperthermia treatment. HNPs consisting of poly(lactic-co-glycolic acid) (PLGA) chains 
were conjugated with bisphosphonate molecules as the bone-targeting moiety, and were 
subsequently loaded with Paclitaxel (PTX), as a model anti-cancer drug, and SPIONs as a 
magnetic resonance imaging (MRI) contrast agent. 
Special attention was placed on characterizing nanoprecipitation of the PLGA chains in 
terms of size, number of aggregated polymeric chains and compactness of the synthesized 
HNPs, as well as their drug loading efficiency. Size, polydispersity, and drug release 
patterns are governed through mixing time during particle formation, and was tightly 
controlled using the hydrodynamic flow focusing technique in a microfluidic platform. In 
order to assess behavior of PLGA chains in the vicinity of hydroxyapatite (HA) crystals, 
all-atom molecular dynamics (MD) simulations were conducted to explore the effects 
associated with the conjugated BP functional groups onto the polymer chains. 
4.2 Materials and Methods 
4.2.1 Materials 
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Acid terminated poly(D,L-lactide-co-glycolide) (PLGA; lactide:glycolide 50:50; Mn= 
31,500 g.mol-1; Mw= 48,000 g.mol
-1; Mw/Mn= 1.52 (GPC); inherent viscosity: 0.53 dL.g
-1) 
was acquired from Sigma-Aldrich (Resomer RG 504H). The refractive index increment 
(dn/dc) of the polymer solution was measured to be 0.05 mL.g-1 using asymmetric flow 
field-flow fractionation (AFFFF) method. 
Acid terminated PLGA (PLGA-COOH) chains were functionalized as reported elsewhere 
(157, 158). In brief, 65 mg of lyophilized bisphosphonate (sodium Alendronate, Sigma) 
was dissolved in 1 ml dimethylsulphoxide (DMSO, Sigma) and subsequently added to 7.8 
gr of acid terminated PLGA (PLGA-COOH), which was previously activated using 1-
Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC, Sigma)/ N-hydroxysuccinamide 
(NHS, Sigma); dissolved in 4 ml of equivalent mixture of DMSO and dichloromethane 
(DCM, Sigma) at 2°C and stirred for 2 h. The mixture was then gradually heated up to the 
room temperatures and stirred for 10 h. Afterwards, the reaction solution was dialyzed 
(Spectra/Por CE dialysis tubing, 500-1000 MWCO, Spectrum Labs) 3 times against 1 L of 
deionized water for 24 h. Finally, the dialyzed conjugated polymer was lyophilized and 
kept in freezer until use. 
Superparamagnetic iron oxide NPs (SPIONs) were synthesized by alkaline co-precipitation 
of ferric and ferrous chlorides in aqueous solution as reported before (159). Solutions of 
FeCl3.6H2O (0.086M) and FeCl2.4H2O (0.043M) were mixed and precipitated with 
concentrated ammonia while stirring vigorously. The immediately formed black precipitate 
was washed several times with ultra-pure water until the pH decreased from 10.0 to 7.0. 
The precipitate was collected and refluxed in a mixture of 0.8M nitric acid and 0.21M 
aqueous Fe(NO3)3.9H2O for 1 h. During this step, the initial black slurry turned brown and 
formation of nitric oxide was observed. The system was allowed to cool down to room 
temperature, the remaining liquid was discarded, and 100 ml of ultra-pure water was added 
to the slurry to re-disperse the precipitate. The brown suspension was dialyzed for 2 days 
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against 0.01M nitric acid, and stored at 4°C. During this final synthesis step, the Fe3O4 
mostly oxidized to Fe2O3. 
4.2.2 Device Fabrication 
Microfluidic devices were fabricated with poly(dimethylsiloxane) (PDMS, Sylgard 184, 
Dow Corning, Switzerland) via soft lithography technique. Silicon wafers spin-coated with 
SU-8 50 photocurable epoxy (Microchem, Inc.) to a thickness of 60 μm and baked. 
Lithography, development and annealing (at 150°C) procedures were performed at the 
EPFL Center for Micronanotechnology (CMi) to obtain negative master mold on the 
normal 4 inch silicon wafer. The surface of molds was modified using a self-assembled 
monolayer (SAM) of trimethylethoxy silane (Sigma) by vapor exposure for 40 min to 
prevent PDMS sticking. PDMS monomers and curing agent (10:1), poured over the mold, 
degassed in desiccators for 30 min, and cured in the oven (Memmert) at 80°C for 1 h. After 
curing, PDMS was removed from the mold and required holes were punched using a 150 
μm diameter punch. The PDMS was then bonded to a glass slide using O2 plasma (100 
mW, 1 min; Diener electronic GmbH). The PDMS-based microfluidic device consists of 
two inlets for water, one for the polymer/SPIONs/drug solution in THF, and one outlet. 
The water flow was split into two streams at the flow focusing cross-junction. The mixing 
channel was 120 μm wide, 50 μm high and 1 cm long. Aqueous solution of Fluorescein 
sodium (Sigma) and water were used to determine the range of stable flow rates (data not 
shown). 
4.2.3 Synthesizing of (hybrid) nanoparticles 
For the bulk synthesis of (hybrid) NPs (HNPs), PLGA/PLGA-BP solution in THF (5 
mg.mL-1) was prepared (with-/out SPIONs) under stirred condition. The nanoprecipitation 
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and formation of the HNPs was performed by drop-wise addition of this solution to 25 mL 
of water while stirring. 
For the drug-loaded HNPs, Paclitaxel (PTX, Sigma-Aldrich) was dissolved in THF and 
mixed with the polymeric (PLGA/PLGA-BP) solution. HNPs were then synthesized 
according the same procedure described above. 
For the microfluidic synthesis of NPs, PLGA/PLGA-BP solution in THF (5 mg.mL-1) was 
prepared under stirred conditions and then introduced into chip as the core flow using 
syringe pumps (Harvard Apparatus, PHD2000; HA200I model). The water streams, as the 
non-solvent, were introduced to the chip as lateral flows. To vary the degree of flow 
focusing, the flow ratios (FRs) of the polymer solution and water streams were adjusted 
using micropumps. 
For the drug-loaded HNPs, PTX was dissolved in THF at initial loading of 10 wt% (0.5 
mg.mL-1) and mixed with the polymer (PLGA/PLGA-BP) solution. Microfluidics-assisted 
synthesis of HNPs was performed according to the same procedure as described above.  
4.2.4 Characterization 
Transmission electron microscopy (TEM; CM200-FEG-Philips) were used to characterize 
the synthesized NPs. A dilute suspension of NPs was prepared and deposited onto the Cu 
grid with a carbon film. The morphology and size of the particles were characterized via 
diffraction (amplitude) contrast and (for crystalline materials) through high-resolution 
(phase contrast) imaging. The TEM was equipped with a LaB6 source operating at 100 kV 
accelerating voltage. The images were analyzed using ImageJ software (version 1.44p) 
with at least 20 different images. 
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Dynamic light scattering (DLS) and zeta potential measurements were performed using a 
Zetasizer (Zetasizer 3000HS, Malvern Instruments Ltd., Worcestershire, UK) in 
backscattering mode at 173° for the diluted suspensions in water. 
Transmittance of the prepared samples was measured at room temperature (20°C) with a 
Shimadzu UV mini 1240 UV/visible spectrophotometer at the wavelength of 550 nm. 







)⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡(Eq. 4 − 1) 
Where, L is the length of light path in the sample cell (1.0 cm quartz cuvette), It is the 
intensity of the light transmitted through the sample, and I0 is the intensity of the light 
transmitted through the solvent (i.e., deionized water). Measurements were repeated at least 
three times and mean values were reported. 
The magnetic properties of NPs were evaluated using a vibrating sample magnetometer 
(VSM, ADE 4HF) at room temperature. 
To determine the in vitro drug release profile, lyophilized PTX-loaded HNPs (1 mg) were 
dispersed in 1 mL of phosphate buffered saline (1X PBS, pH 7.4). The solutions were 
placed into a dialysis cartridge (3500 Da, Thermo Scientific, Rockford, IL) and immersed 
in 1 L PBS while gently shaken in a 37°C water bath. At predetermined time intervals, 
aliquots of the buffered solutions were collected for analysis, and an equivalent volume of 
fresh PBS was added to the water bath. 
The PTX concentration was measured with the high-performance liquid chromatography 
(HPLC) by mixing the 1 mL sample with 1 mL of acetonitrile. A reverse phase C18 column 
was used as the stationary phase and the mobile phase was consisted of acetonitrile/water 
(60:40 vol/vol). Separation was carried out at a flow rate of 1 mL.min-1 and PTX was 
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detected at the wavelength of 230 nm. This method was evaluated over a linear range of 
1–100 μg.mL-1. In this range, the percent deviation from theoretical value was found to be 
less than 5% and the coefficients of linearity remain greater than 0.96 using clean PTX 
standards. The PTX concentration in the solution was corrected to eliminate the sampling 
effects according to following equation (99): 
Cn
l = Cn[VT/(VT-VS)](Cn-1
l/Cn-1)                                                                               (Eq. 4-2)         
Where, Cn
l is the corrected concentration of the nth sample, Cn is the measured 
concentration of PTX in the nth sample, Cn-1 the measured concentration of the (n-1)
th 
sample, VT is the volume of receiver fluid, and VS represents the volume of sample drawn 
(1 mL). 
lyophilized PTX-loaded nanoparticles (1 mg) were dissolved in THF and the PTX 
concentrations were measured using a same HPLC protocol as mentioned before. The drug 
loading content and loading efficiency were determined by applying the following 
equations: 
PTX Loading content = (weight of the loaded PTX/weight of the NPs)×100        (Eq. 4-3) 
PTX Loading efficiency = (amount of PTX in the NPs /initial amount of the PTX)×100 
    (Eq. 4-4) 
Relative activities of PTX were evaluated by measuring the maximum rate of tubulin 
polymerization relative to the standard samples. The stability of PTX in the free and 
encapsulated states was investigated by measuring their activities using the tubulin protein 
assay after storage at temperatures of 25°C and 37°C over two weeks in 96-well plates 
according to previously reported protocols (161).  In brief, at defined time intervals of 1 
day, NPs were separated using centrifugation and re-dispersed in water at pH 4.5 to extract 
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the PTX from the NPs. The PTX was then separated using HPLC to perform a tubulin 
protein assay. PTX at defined concentrations in the 1-10 µM range was reacted with 50 µl 
of tubulin protein solution (general tubulin buffer, tubulin glycerol buffer, 1 mM GTP) and 
the reaction was followed by measuring the increase in apparent absorption at 350 nm over 
1 h at 37°C using an ELISA plate reader (Safire II, Tecan AG, Mannedorf, CH).  
10 ml of blood was acquired from mice and 2% w/v RBC solution was obtained. In brief, 
the blood was first centrifuged at 5000 rpm at 4°C for 10 min. The supernatant was then 
removed, and the erythrocytes were re-suspended with ice-cold PBS (pH = 7.4), followed 
by repeated centrifugation. This procedure was repeated four times to ensure removal of 
released hemoglobin. Finally, cells were resuspended in ice-cold PBS to provide RBC 
solution (2% w/v). The nanoparticles and Polyethylenimine (PEI) as reference polymer 
was also prepared at serial concentrations of 100, 200, 400, and 1000 μg.ml-1 with PBS 
(pH = 7.4). Then, 2 ml of the nanoparticle suspensions were added to centrifuge tubes 
containing 2 ml of the 2% w/v RBC solution and incubated at 37 °C for 1 h. Subsequently, 
the samples were centrifuged for 10 min at 2000 rpm, and 200 μl aliquots of the 
supernatants were transferred to 96-well plates. Absorbance of the released hemoglobin 
was measured at wavelength of 545 nm using a microplate reader.  
To evaluate the binding capacity of the synthesized bone-targeting and unconjugated NPs 
to bone, hydroxyapatite binding assay was carried out in vitro, using the PLGA-FITC as a 
fluorescence marker (162). Briefly, FITC-labeled NPs were dispersed in PBS (1X, pH 7.4) 
at concentration of 2.5 mg.ml-1 (pH 7.4) and incubated with 200 mg of hydroxyapatite 
powder (HA, Sigma-Aldrich) in a final volume of 10 ml. The incubated samples were 
centrifuged at 5000 rpm for 5 min and 2 ml of supernatant solution was collected at the 
times of 0, 5, 15, 30, 45, and 60 min. The fluorescence intensity of supernatant was assayed 
to detect unbind nanoparticles using spectrofluorophotometer (RF-5301PC, Shimadzu, 
Kyoto, Japan) at excitation wavelength of 496 nm. As positive controls, both PLGA-
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SPION-BP/ PLGA-SPION nanoparticles were incubated at the same condition without HA 
powder. The HA binding efficiency (in percent) was estimated as mean value of at least 
three independent experiments. One drop of the precipitated HA powders on a glass slide 
was imaged using fluorescent microscope to visually show the binding of FITC-labeled 
NPs. 
For pharmacokinetics (blood circulation) studies, nine female BALB/c mice (18–21 g) 
were randomly divided into three groups for the three different kinds of NPs. All mice were 
fed with commercial diet and water ad libitum and were on alternating 12 h light/dark 
cycles. All three groups were injected via tail vein at the same dose of 2 mg per kg of 
mice’s body weight. Blood samples were drawn from the retro-orbital sinus at different 
times of 0 min, 30 min, 1 h, 2 h, 5 h, 10 h, 18 h, 30 h, 48 h, 65 h, and 72 h into heparinized 
tube and then samples were centrifuged for 15 min. The plasma was separated and stored 
at −20 oC in dark before analysis. The plasma concentration of NPs defined based on 
fluorescence intensity of FITC groups using BioTek Microplate Reader (Winooski, VT). 
The normalized plasma concentrations of applied NPs are shown as a function of time. The 
data were fitted to a two-compartment model, from which the fast and slow half-lives 
characterizing the NPs formulations were extracted. 
Luciferase- positive MDA-MB-231 breast cancer cell line were plated at 40% confluency 
and cultured for 24 h. The cells were then trypsinized, washed, and resuspended in DMEM 
at 107 cells.ml-1 and kept on ice before injection. Female BALB/c mice were given an 
intratibial injection of the luciferase positive breast cancer cell line (0.1 ml). The mice were 
anesthetized with mixture of Xylazine and Ketamine before  injection. After a week of 
tumor inoculation, mice were randomized in four different groups (i) PBS only (control 
sample), (ii) non-targeted NPs (microfluidic NPs), (iii) targeted bulk-synthesized NPs 
(bulk NP-BP), and (iv) targeted microfluidic-synthesized NPs (microfluidic NP-BP). At 
the next day of tumor inoculation (day 1) and day 30, animals were injected with 0.1 ml of 
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D-luciferin (10 mg.ml-1) in PBS, and after 10 min, imaged under anesthesia with 2.5% 
isofluorane by bioluminescence imaging using the Xenogen bioluminescence imaging 
system (Xenogen Corp., Hopkinton, MA). At experimental endpoints, luciferin-injected 
animals were sacrificed based on institutional animal care and use guidelines. 
Luminescence is expressed as photons/sec/ROI (region of interest) minus background 
luminescence. The change in bioluminescence signal over time considered as an indicative 
of tumor size in this study. For biodistribution studies, after scarifying of mice (day 30 after 
treatment), selected organs were dissected and placed inside the imaging system. Mice 
autofluorescence and background signals were eliminated. 
Apoptosis cells were identified through a TUNEL assay (In Situ Cell Detection Assay kit; 
Roche) according to the manufacturer’s protocol. Images were captured by fluorescence 
microscope. 
The results are statistically analyzed using unpaired t-tests. For all tests the statistical 
significance is set at p < 0.05. p < 0.01 is considered as statistically very significant. 
 2.5. Computational Details 
Molecular Models of PLGA and PLGA-BP 
PLGA molecules are copolymers of poly lactic acid (PLA) and poly glycolic acid (PGA). 
For MD simulations, block PLGA copolymers consisting of PLA and PGA both with 
degree of polymerization of 30 was first constructed, as shown in Supplementary Figure 4-
1a. Subsequently, for the case of PLGA-BP copolymer, which are terminated by BP, the 
BP was covalently bonded from its amino group (-NH2) to one end of PLGA having free 
carboxylic acid group. After construction, molecular structure of both PLGA and PLGA-
BP polymers were optimized by means of Smart minimizer algorithm. Then, two three-
dimensional (3D) cubic amorphous cells, containing only one PLGA and PLGA-BP 
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polymeric materials, were created at a density of 1 g.cm-3 by making use of Amorphous 
Cell module implemented in Materials Studio software (114). These 3D simulation cells 
were initially optimized for 2000 energy minimization steps, and then equilibrated by MD 
simulations carried under NVT ensemble for 100 ps at 300 K. The resulting optimized 
PLGA and PLGA-BP molecules from MD simulations were placed on top of different HA 
surfaces for subsequent simulations. 
 
Figure 4-1 Chemical structure of (a) poly lactic-co-glycolic acid (PLGA), and (b) poly lactic-
co-glycolic acid covalently bonded with bisphosphonate (PLGA-BP) used for MD 
simulations. 
2.5.1. HA surfaces 
HA materials have crystallographic structure with chemical formula of (Ca10(PO4)6(OH)2), 
hexagonal P63/m space group, as well as unit cell parameters of a=b=9.424 Å, c=6.879 Å 
and ά=β=90°, γ=120° (163). In order to cover potential interfacial interactions of HA with 
PLGA (and PLGA-BP), three different HA crystallographic surfaces including (100), (110) 
as well as (001) were selected for current MD simulation analyses, as these are the most 
commonly studied HA surfaces in experiments (164, 165). These surfaces were built by 
cleaving HA unit cell along the corresponding HA surface with a surface thickness value 
of around 13 Å. Surface area of all HA surfaces were increased in both directions so as to 
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The constructed surfaces were then converted to 3D periodic cells by applying a vacuum 
space of thickness 150 Å above the surface. The use of this vacuum space above HA 
surface interacting with polymers together with certain surface thickness of 13 Å is to 
restrict PLGA and PLGA-BP intermolecular interactions to only one side of HA surfaces. 
Energy-minimized PLGA and PLGA-BP were then laid on top of as-built HA surfaces at 
a location more than at least 12 Å apart from the upper surface of HA, as studied for various 
HA surfaces. 
4.2.5 MD simulations 
MD simulations of PLGA and PLGA-BP equilibration phase, and simulation of PLGA and 
PLGA-BP positioned on top of different HA surfaces (i.e., HA-PLGA and HA-PLGA-BP) 
were performed by using COMPASS (condensed-phase optimized molecular potentials for 
atomistic simulation studies) force field (115, 116). Partial atomic charges for HA surfaces 
were assigned as follow: hydroxyl hydrogen atoms, +0.6; hydroxyl oxygen atoms, -1.6; 
oxygen atoms in PO4, -1.4; phosphorus atoms, +2.6; calcium atoms, +2, which were taken 
from reference (166). Similar to MD simulation of 3D cells for PLGA and PLGA-BP, all 
HA-PLGA and HA-PLGA-BP simulation systems were first optimized by running 2000-
step minimization. This was followed by a 1-ns MD simulation under NVT ensemble 
conditions at 300 K. 
All atomistic MD simulations were carried out using Discover module of Materials Studio 
software (114). Non-bonded van der Waals (vdW) and electrostatic interactions were taken 
into account using Ewald summation method. Velocity Verlet integration algorithm was 
used to solve Newton’s equation of motion with a time step of 1 fs (117). Andersen 
thermostat was used to control the temperature during NVT dynamics simulations. Periodic 
boundary conditions (PBC) were imposed in all three directions. In the case of HA-PLGA 
 89 
and HA-PLGA-BP, positions of all atoms in HA surface were kept fixed during MD 
simulations. 
The final structure attained at the end of 1-ns NVT MD simulation of all HA-PLGA as well 
as HA-PLGA-BP simulation systems were used to determine the interaction (binding) 
energy of PLGA and PLGA-BP with different HA surfaces. Interaction energy was 
calculated according to the following equation: 
ΔEbinding= EHA-PLGA-BP-(EHA+EPLGA/PLGA-BP)       (Eq. 4-5) 
Where, EPLGA/PLGA-BP represents potential energy of entire simulation system (that is, HA-
PLGA or HA-PLGA-BP) in which all atoms constituting HA surfaces have been kept 
constrained, EHA is potential energy of unconstrained HA surfaces without PLGA or 
PLGA-BP, and EPLGA/PLGA-BP indicates potential energy of PLGA or PLGA-BP without HA 
surfaces. 
The increased PLGA interaction energy with HA surfaces upon its BP-modification is as a 
result of stronger interfacial interactions, for instance, strong electrostatic interactions with 
uppermost calcium atoms, which is probably the strongest for HA (110) according to 
higher concentration of calcium atoms on its top surface shown, and hydrogen bonding 
interactions. Here, the intermolecular hydrogen bonding interactions between BP terminal 
groups in PLGA-BP with surface oxygen atoms in PO4 units as well as hydroxyl oxygen 
and hydrogen atoms in HA surfaces are investigated. To further analysis of intermolecular 
interactions between surfaces of HA and PLGA (and PLGA-BP) polymeric materials, 
which are crucial for enhanced interactions of HA-PLGA-BP as compared to HA-PLGA 
systems, radial distribution function (also called pair correlation function) were evaluated 
for different atomic pairs. For a pair of atoms consisting of A and B, RDF gA-B(r), which 





Where nB is the number of B atoms located around reference A atoms inside a spherical 
shell with thickness Δr, NB is the total number of B atoms and V is the cell volume. 
4.3 Results and Discussion 
Controlled nanoprecipitation of PLGA and PLGA-BP into NPs was achieved using a 
polydimethylsiloxane (PDMS)-based cross-junction microfluidic device consisting of 
perpendicular channels, which provides a hydrodynamically focused Tetrahydrofuran 
(THF) polymeric solution in in a stream of water, as shown in Figure 4-2a. The lateral 
streams of water act as a non-solvent for PLGA/PLGA-BP, and forms NPs during lateral 
diffusion of water molecules (molecular mixing). The microfluidic core flow was 
previously studied by using Fluorescein solution as the core flow, and monitoring flow 
stability with a fluorescent microscope to determine the range of flow rates that create a 
stable mixing interface. In microfluidic based synthesis, nanoparticle properties are greatly 
affected by the mixing time (τmix, residence time in the microreactor), which can be adjusted 
by varying the flow rate of polymer solution to water. Therefore, the flow ratios (FR) were 
adjusted from 0.03 to 0.2 (167), the fluidically stable  range previously determined by the 
fluorescent flow experiment.  This FR range resulted in τmix to vary from 2.5 to 75 ms 


























Figure 4-2 The physical characteristics of microfluidic synthesized nanoparticles. (a) 
Schematic representation of the cross-junction microfluidic device used for controlled 
formation of PLGA based (magnetic/targeted) NPs. (b) The hydrodynamic diameter of the 
microfluidic/bulk synthesized nanoparticles. The mixing time for each flow ratio (FR; the 
ratio of flow rate of polymer solution to water flow) was calculated and shown as open circles. 
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(c) Local polymer concentration (CNP) inside the PLGA/PLGA-BP nanoparticles as a function 
of the flow ratio. Aggregation numbers (Nagg) of the PLGA/PLGA-BP chains in the 
corresponding nanoparticles as a function of flow ratio. The lines are only as a guide. (d) The 
hydrodynamic diameter of the SPIONs-loaded synthesized hybrid nanoparticles based on 
PLGA and PLGA-BP using the microfluidic platform or the bulk synthesis method. (e-g) 
TEM images of the magnetic hybrid nanoparticles; PLGA-BP/SPIONs: FR=0.03 (e), PLGA-
BP/SPIONs: FR=0.1 (f), PLGA-BP/SPION: bulk (g). (h) The iron weight content of the loaded 
SPIONs into PLGA/PLGA-BP nanoparticles at four different flow ratios in comparison with 
those formed via the bulk mixing method. (k) Magnetic hysteresis for the microfluidic/bulk 
synthesized SPIONs-loaded PLGA/PLGA-BP nanoparticles in comparison with the bare 
SPIONs. 
In this article, we compared the formation of NPs composed of pure PLGA with those 
formed from co-precipitation of PLGA:PLGA-BP chains. NMR analysis showed the 
conjugation yield of PLGA-BP to be 41 mol%. We designed the final product to have 20 
mol% BP (i.e., PLGA-BP), thus 50:50 composition of PLGA: PLGA-BP was used in the 
NPs synthesis. 
Compared with bulk mixing methods, it has been shown that microfluidic synthesis locks 
NPs kinetically in a rapid mixing regimen that leads to the formation of smaller NPs with 
a higher degree of monodispersity (14, 168). Dynamic light scattering (DLS) results 
showed that longer mixing time leads to the larger NPs for both PLGA and PLGA/PLGA-
BP NPs (Figure 4-2b). The hydrodynamic size of bisphosphonate-PLGA NPs was found 
to be larger than unmodified PLGA NPs. This difference was more pronounced at lower 
FRs where an approximate size difference of 23% was observed between the compounds 
at a 0.03 FR. The Zeta potentials of the resultant NPs are shown in Figure 4-3. 
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Figure 4-3 Zeta potential values for PLGA and PLGA-BP nanoparticles that are formed at 
different flow ratios as well as bulk synthesized nanoparticles. 
Generally, the hydrodynamic size of colloidal polymeric NPs depends on the polymer 
contents and their swelling state, which are driven by the competing intra/intermolecular 
interactions during the mixing process. In order to quantify the polymer concentration of 
the NPs, we employed a recently developed method for estimating the local polymer 
concentration inside the spherical NPs (45, 160). Using this approach, valuable information 
on the PLGA NPs can be obtained based on their size (Figure 4-2b) and the turbidity of 
their suspension (Table 4-1). Local polymer concentration in NPs, CNP, was calculated 










[1 − 𝑐𝑜𝑠(𝑤𝑐𝑁𝑃)]})    (Eq. 4-7) 
where τ, Ct, and Rh are respectively turbidity of the NPs suspension, total polymer 




where λ, n0, and dn/dc are the wavelength for the turbidity measurements, the refractive 
index of the solvent, and the refractive index increment of the polymer in the measurement, 
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respectively. It is worth noting that this method was developed for spherical particles with 
low polydispersity index (PDI), and the narrow size distribution of our microfluidic 
synthesized NPs (PDI<0.13) meets this requirement.  
Table 4-1 The turbidity and calculated physical characteristics of the synthesized NPs at 
different FRs. 
            PLGA Nanoparticles 
F.R. turbidity Cnp (g/ml) Nagg N (particles/ml) 
0.031 0.903 0.7468 989 4.83E+14 
0.075 0.841 0.6399 1191 4.01E+14 
0.1 0.824 0.55 1430 3.34E+14 
0.2 0.513 0.2175 2037 2.35E+14 
Bulk Mixing 0.438 0.1562 2608 1.83E+14 
     
          PLGA-BP Nanoparticles 
F.R. turbidity Cnp (g/ml) Nagg N (particles/ml) 
0.031 0.989 0.5542 1370 3.49E+14 
0.075 0.9466 0.4743 1514 3.16E+14 
0.1 0.907 0.4316 1710 2.80E+14 
0.2 0.5512 0.189 2191 2.18E+14 
Bulk Mixing 0.4794 0.1377 2528 1.89E+14 
The CNP values calculated using Eq.5 at various flow ratios are reported in Figure 4-2c. 
The results show that smaller, but more compact; NPs are formed at lower flow ratios. The 
higher polymer concentration inside the unconjugated PLGA NPs can be attributed to the 
repulsive forces of the phosphonate groups of the PLGA-BP chains. However, the 
difference in the compactness (CNP) of these groups was found to be less pronounced at 
higher flow ratios. The compactness of the bulk-synthesized NPs, despite their much higher 
PDI, also estimated based on the Eq.5. The data in Figure 4-2 indicate that the 
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hydrodynamic flow focusing approach can tune the compactness of the polymeric NPs 
precisely, resulting in NPs with different properties customized for different applications. 
As shown in Figure 4-2 (b-c), the size of the NPs increased while their compactness (CNP) 
decreased with increasing the mixing time. This could be due to either swelling and/or 
increased number of aggregated chains to form PLGA NPs. To differentiate between the 
two, the aggregation number of polymer chains (Nagg) must be calculated. Having 





3𝐶𝑁𝑃𝑁𝐴 (Eq. 4-8) 
where NA is Avogadro’s number.  
Accordingly, the aggregation number of polymer chains forming NPs, Nagg, can be 




 (Eq. 4-9) 
where Mn is the average molecular weight of the participating polymers.  
Upon microfluidic mixing, rapid nanoprecipitation of polymer chains leads to the 
formation of the NPs. As shown in Figure 4-2c, Nagg rises with increasing flow ratio. At 
the lower flow ratios, mixing time is shorter than the time required for aggregation, τmix < 
τagg; hence, a lower number of polymeric chains are kinetically locked inside the NPs. 
Therefore, the increase in the hydrodynamic radius of NPs was as a result of increased 
number of aggregated chains that are loosely packed at the higher flow ratios. This 
phenomenon was more pronounced in the case of PLGA-BP chains. In this view, adjustable 
microfluidic mixing has enabled varying mixing times in order to optimize the precipitation 
 96 
of the PLGA chains. The volume number density of NPs (the number of particles per unit 
volume of the suspension) is one of the important properties of nanoparticulate systems, 
but is rarely reported due to experimental difficulties, despite its practical importance. 
Using the known CNP values already determined, the number density of the particles, N, 




3 (Eq. 4-10) 
It was found that the number density of synthesized NPs increases with decreasing the flow 
ratio (i.e., time of mixing) (Table 4-1). 
Many researchers are using microfluidic platforms to design finely tuned NPs (14, 15, 20, 
23, 99, 154-156).  For example, Valencia et al. developed a microfluidic rapid mixing 
system to produce lipid-polymer-quantum dot hybrid NPs (169).  In a recent study, 
complex nanocapsules composed of dendritic polyethylene NPs as anticancer drug 
nanocarriers was reported (156). Here we demonstrate the capability of a microfluidic 
approach to synthesize magnetic hybrid NPs (HNPs). By introducing superparamagnetic 
iron oxide NPs (SPIONs) into the microfluidic core flow, the SPIONs are entrapped inside 
the polymeric chains during polymeric nanoparticle formation. The average hydrodynamic 
diameter of the synthesized SPIONs by our co-precipitation method was 11±4 nm. The 
same flow ratios as the previous PLGA/PLGA-BP experiments were also used to 
synthesize SPIONs-loaded NPs. As shown in the Figure 4-2d, the size of loaded NPs was 
found to increase in the range of 4-25% for PLGA and 8-21% for the PLGA-BP-based 
HNPs. TEM images of the SPIONs-PLGA-BP HNPs at the flow ratios of 0.03 (48±5 nm), 
0.1 (67±16 nm), as well as the bulk synthesized (111±21 nm) HNPs are presented in the 
Figure 4-2 (e-g), respectively. All HNPs were spherical. The entrapped solid SPIONs are 
recognizable from their higher density on the TEM images. More rapid mixing regimens 
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resulted in a higher number of SPIONs being encapsulated inside the HNPs (Table 4-2) in 
both PLGA and PLGA/PLGA-BP systems. This phenomenon could be due to the narrower 
flow focusing region at the lower flow ratios (the rapid mixing regime) that more quickly 
facilitates the solvent exchange process and can result in faster precipitation of PLGA 
(PLGA-BP) chains in a more confined volume, which increases the probability of SPION 
entrapment. The iron content of the HNPs was measured by ICP-OES (Inductively Coupled 
Plasma – Optical Emission Spectrometry) after digestion with HCl (Figure 4-2h). As 
illustrated, the efficiency of SPION entrapment was highly affected by the mixing time. In 
the more rapid mixing regimens, the weight content of SPIONs was in the range of 55-60% 
for PLGA HNPs and 50-56% for the PLGA-BP HNPs. 
Table 4-2 Calculated numbers of SPION particles that can be trapped in the synthesized 






















0.031 25.48 6.93E-17 5.17E-17 3.12E-17 9 9.37 
0.075 28.54 9.74E-17 6.23E-17 3.53E-17 11 7.56 
0.1 31.9 1.36E-16 7.48E-17 4.14E-17 12 6.34 
0.2 48.9 4.9E-16 1.07E-16 4.50E-17 13 1.91 
Bulk 
Mixing 























0.031 31.37 1.29E-16 7.17E-17 4.03E-17 12 6.50 
0.075 34.16 1.67E-16 7.92E-17 4.17E-17 12 5.21 
0.1 36.71 2.07E-16 8.94E-17 4.49E-17 13 4.51 
0.2 52.51 6.06E-16 1.15E-16 4.07E-17 12 1.40 
Bulk 
Mixing 61.2 9.6E-16 1.32E-16 4.39E-17 13 0.95 
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The hysteresis loop for various HNPs at room temperature is shown in Figure 4-2k. The 
absence of remanence and coercivity confirmed the superparamagnetic properties of the 
SPION-loaded HNPs. The magnetic saturations for the microfluidic synthesized HNPs at 
FR 0.03 were approximately 66 and 60 emu.g-1 for the PLGA/SPIONs and PLGA-
BP/SPIONs, respectively. These values are 94% and 86% of the magnetic saturation of the 
pristine SPIONs (≈70 emu.g-1). The bulk synthesis resulted in lower saturation values of 
51 and 44 emu.g-1 for the PLGA/SPIONs and PLGA-BP/SPIONs, respectively. These 
results were expected since a larger number of SPIONs were encapsulated in the HNPs 
with microfluidics. Moreover, the more compact nature of the NPs assembled via 
microfluidics brings the magnetic particles closer to each other and subsequently alters the 
magnetic character of the HNPs. 
The colloidal stability of the hybrid NPs were also studied by measuring their 
hydrodynamic size as a function of time at 4 and 25ºC. No significant change was observed 
in the size of the HNPs over one month.The partial amphiphilic nature of PLGA chains 
allows for the encapsulation of both hydrophilic and hydrophobic compounds. In addition 
to encapsulation of magnetic NPs in the PLGA/PLGA-BP NPs, we further aimed to load 
Paclitaxel (PTX), a potent hydrophobic anticancer drug, inside the HNPs to further develop 
them as multifunctional HNPs. Surprisingly, after encapsulation of PTX into the HNPs, 
the size of NPs was decreased by approximately 10% (Figure 4-4a). This phenomenon 
could potentially be due to the overall increase in the hydrophobicity of the PLGA mixture 
in the presence of PTX molecules, which provides more effective PLGA chain association 
(14). Loading efficiency, with the initial drug content of 10 wt%, was evaluated and plotted 
as a function of flow ratio in Figure 4-4b. Simultaneous injection of drug/polymer mixtures 
is an effective route to encapsulate hydrophobic drugs with nanoprecipitation. As 
previously reported, using controlled nanoprecipitation with microfluidics enables 
remarkably higher drug loading compared to conventional bulk mixing methods (99). 
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Figure 4-4b shows the loading efficiency of PTX in PLGA-BP HNPs was in the range of 
73-80% in the rapid mixing regimen, and dropped to 50-58% with longer mixing. A similar 
trend was also observed for the non-conjugated PLGA NPs (Figure 4-4b). In should be 
noted that the presence of SPION does not (<5%) alter the encapsulation efficiency of PTX. 
 
Figure 4-4 Various features of paclitaxel (PTX) loaded microfluidic synthesized hybrid 
nanoparticles. (a) The hydrodynamic diameter of PTX-loaded microfluidic/bulk synthesized 
nanoparticles based on PLGA and its BP-conjugated equivalent. (b) PTX loading efficiency 
as a function of the flow ratio in comparison with the nanoparticles synthesized via the bulk 
mixing method at an initial drug content of 10 wt%. (Mean ± SD, n = 5 independent 
experiments). (c) Cumulative in vitro release profiles of PTX from PLGA-BP/SPIONs-PTX 
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HNPs synthesized from various methods at pH 7.4 and at 37°C. (Mean ± SD, n = 3 
independent experiments). (d) PTX diffusion coefficients from HNPs as a function of the 
mixing time. (e) Relative activity (%) of PTX at 25°C and 37°C for free drug and drug loaded 
microfluidic/bulk synthesized hybrid nanoparticles evaluated via the tubulin polymerization 
assay. (f) The PTX degradation rate constant (k) for the various drug loaded HNPs at 25°C 
and 37°C. 
The in vitro drug release profile of the synthesized PLGA-BP/SPION NPs in PBS 
(Phosphate Buffered Saline, pH= 7.4) at 37 °C is shown in Figure 4-4c. The patterns 
exhibited a relatively sustained release over 5 days. As shown, the microfluidically 
synthesized HNPs showed slower release patterns, which could be attributed to their more 
compact nanostructures (Figure 4-2c). The required time to release half of the loaded drug 
(t50%) from the bulk synthesized HNPs was about 15.5 h, whereas this time was 39, 53.4, 
32.7, and 20.1 h for HNPs formed at the flow ratios of 0.03, 0.075, 0.1 and 0.2, respectively. 
The slower release was associated with the higher compactness of the microfluidic 
synthesized HNPs. Furthermore, the diffusion coefficient of drug molecules from the HNPs 








                                                 (Eq. 4-11) 
Where Mt/M∞ represents the fraction of released PTX at time t, D is the diffusion coefficient 
of the drug molecules and R is the hydrodynamic radius of HNPs. The results imply that 
compactness of the HNPs is the key factor in defining the release behavior. As expected, 
more compact HNPs showed significantly lower diffusion coefficients of 1.8×10-22, 
1.5×10-22, and 3.1×10-22 m2.s-1, at the flow ratios of 0.03, 0.07, and 0.1, respectively. The 
NPs formed at the 0.2 flow ratio, as well as with bulk mixing (slow mixing regimen), 
showed larger diffusion coefficients of 8.9×10-22, and 16.6×10-22 m2.s-1, respectively. 
The efficiency of drug encapsulation and the drug release characteristics are important 
parameters in designing nanocarriers. However, it is equally important to assess the activity 
of the encapsulated drug. We used the tubulin polymerization assay at two different 
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temperatures, 25 and 37°C, for this purpose. Although the stability of PTX generally 
decreases at higher temperatures, this trend was less pronounced for drugs encapsulated in 
the microfluidic HNPs (Figure 4-4e). The time required for degradation of 50% of the 
initial PTX activity was found to be 413 and 144 h at 25 and 37°C for microfluidic HNPs 
at flow ratio of 0.03 (as an optimum sample due to its smaller size and sustained release 
properties), compared to 115 and 59 h for the bulk synthesized HNPs. The degradation 
half-life of the free PTX was also measured as 43 h at 25°C and 26 h and 37°C. As is 
depicted in Figure 4-4e, drug degradation is generally considered to be a first order process 
described by ln(a/a0) = kt, where a is the activity of drug at time t, a0 is the initial drug 
activity, and k is the degradation rate constant which can be calculated at the half-life of 
drug (t1/2). As exhibited in Figure 4-4f, the degradation rate constant (k) for the PTX-
encapsulated microfluidic synthesized HNPs is much smaller than the bulk synthesized 
HNPs and free PTX at both 25 and 37°C. Such improved PTX stability promises prolonged 
drug activity in vivo. Compact HNPs-PTX hampered diffusion of water molecules and 
protected the drug from epimerization and degradation (99). 
Surface functionalizations of NPs are often necessary to impart specific capabilities for in 
vivo applications. The ideal NPs should prevent immune system recognition and red blood 
cell (RBC) hemolysis. It has been shown that negatively charged surface groups can protect 
NPs against such unfavorable events (170). A study of RBC hemolysis by HNPs at 
concentrations of 50, 100, 200, and 500 μg.ml-1 compared to polyethylenimine (PEI), as a 
positive control, are shown in Figure 4-5. All HNPs showed low levels of RBC hemolysis 
even at higher concentrations, with no significant statistical difference among the samples. 
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Figure 4-5 Hemolysis assay of PLGA-BP/SPION nanoparticles that are formed at different 
flow ratios as well as bulk synthesized nanoparticles in comparision with PEI as an control 
sample. Data are presented as the average value ± standard deviation (n> 3). 
Due to their small size, NPs can reach their targets by passing through intercellular tight-
junctions and diffuse with enhanced permeation and retention (EPR) (171, 172). Therefore, 
particles in the size range of 50-200 nm can passively target their sites of action (168). 
Introducing a targeting moiety to NPs can further enhance their targeting efficiency. In 
primary or metastasized bone cancers, bone tissue is often exposed at lysis sites (157, 162). 
Here we have introduced bisphosphonate (BP) molecules to the hybrid NPs as a bone 
targeting moiety to foster active targeting of bone tumors. BPs exhibit strong affinity to the 
exposed bone surfaces (142, 157, 158, 162, 173, 174) mainly because their phosphonate 
groups act as ‘bone hooks,’ although hydroxyl and nitrogen groups can also contribute 
through hydrogen binding to the hydroxyapatite (HA) structure (175, 176).  The attachment 
of microfluidically synthesized BP-conjugated NPs at the surface of HA microcrystals was 
visually studied by using PLGA-FITC as a fluorescent marker. The molar ratio between 
PLGA/PLGA-FITC was calibrated for each sample independently, so that fluorescent 
intensity corresponds to nanoparticle concentration, not size. Figure 4-6a shows that NPs 
bind to HA surfaces after 30 min of incubation. The loosely bound particles were washed 
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away before fluorescence imaging. The fluorescence intensity of HNPs synthesized in the 
lower flow ratios (i.e., rapidly mixed regimen) was found to be higher compared to the 
other NPs.  
 
Figure 4-6 The binding affinity of HNPs to the bone minerals. (a) Fluorescent images of FITC-
labeled BP-conjugated HNPs, which are formed via a microfluidic platform at different flow 
ratios of 0.03 (i), 0.07 (ii), 0.1 (iii), 0.2 (iv), compared with the bulk synthesized particles (v) at 
the surface of HA after 30 min of incubations and washing. (b) Binding kinetics of various 
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types of BP-conjugated and (c) non-conjugated FITC-labeled HNPs to the HA. The HNPs 
were incubated with HA microcrystals for 5, 10, 30, 45, and 60 min. (Mean ± SD, n= 3 
independent experiments). (d) The structure of HA (100), (110), and (001) surfaces in the Ball 
& Stick style. The height (thickness) of all surfaces is approximately 13 Å. The color code is: 
oxygen atoms in red, hydrogen atoms in white, calcium atoms in green, and phosphorus atoms 
in purple. (e) Initial structures of (i) HA (100)-PLGA-BP, (ii) HA (110)-PLGA-BP, and (iii) 
HA (001)-PLGA-BP. All atoms are shown in line style. (f) Final equilibrated structures of (i) 
HA (100)-PLGA-BP, (ii) HA (110)-PLGA-BP, and (iii) HA (001)-PLGA-BP, obtained at the 
end of 1-ns NVT MD simulation. All atoms are shown in line style. (g) Binding energy 
(kcal.mol-1) of PLGA and PLGA-BP polymers to different HA surfaces. (h) RDFs of oxygen 
atom double bonded to carbon in PLGA or PLGA-BP with calcium ions in (i) HA (100), (ii) 
HA (110), and (iii) HA (001) surfaces; (iv) RDFs of oxygen atoms in PLGA-BP with calcium 
ions for different HA surfaces. (i) RDFs of hydroxyl hydrogen atoms in BP bonded to PLGA 
with (i) oxygen atoms in PO4 units and (ii) hydroxyl oxygen atoms in HA surfaces for different 
HA surfaces. 
To estimate the binding capacity of the PLGA-SPIONs-BP NPs to bone tissue, a HA 
binding assay was employed in vitro. The binding efficiency of the PLGA-SPIONs and 
PLGA-SPIONs-BP to HA is shown in Figure 4-6 (b,c). Non-targeting PLGA-SPIONs 
showed low binding efficiency, in the range of 5-11%, whereas the targeting NPs (PLGA-
SPIONs-BP) exhibited considerably higher binding to the HA (63-85%). Moreover, the 
microfluidics synthesized NPs showed higher binding to HA compared with the bulk 
synthesized particles. More than 73% of the targeting HNPs were bound to the HA after 
15 min. These results suggest successful targeting of bone tumors with the HNPs.  
In order to obtain an in-depth understanding of PLGA polymer behavior in the vicinity of 
the HA crystals, all-atom molecular dynamics (MD) simulations under two different 
simulation conditions, with and without BP, were performed. In order to explore the 
interfacial interactions between HA crystals and PLGA or PLGA-, the three most common 
HA crystallographic surfaces, (100), (110), and (001), were studied Figure 4-6d (164, 165).  
These surfaces were built by cleaving the HA unit cell along the corresponding HA surface 
with a surface thickness of 13 Å. The surface area of all HA surfaces was increased in both 
directions to ensure appropriate surface interactions with neighboring PLGA and PLGA-
BP molecules. The constructed surfaces were then converted to 3D periodic cells by 
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applying a vacuum space with a vertical distance of 150 Å above the surface. Energy-
minimized PLGA and PLGA-BP were then positioned on the top of as-built HA surfaces 
at a location at least 12 Å from the upper surface of HA (cf. Figure 4-6e) for PLGA-BP 
and Figure 4-7a for PLGA at various surfaces). 
 
Figure 4-7 Initial structures of (a) HA (100)-PLGA, (b) HA (110)-PLGA, and (c) HA (001)-
PLGA. All atoms were shown in Line style. 
Final equilibrated structures for MD simulations of PLGA and PLGA-BP above HA (100), 
HA (110), and HA (001) are shown in Figure 4-8 and Figure 4-6f, respectively. It was 
observed that PLGA/PLGA-BP molecules approached all three studied HA 
crystallographic surfaces. This type of strong localization of polymeric chains in the 
vicinity of different HA surfaces is indicative of strong intermolecular interactions. 
Consequently, it can be concluded that PLGA-BP has strong HA surface attachment 







a) b) c) 
 106 
 
Figure 4-8 Final equilibrated structures of (a) HA (100)-PLGA, (b) HA (110)-PLGA, and (c) 
HA (001)-PLGA, obtained at the end of 1-ns NVT MD simulation. All atoms were shown in 
Line style. 
In order to quantitatively assess the association of PLGA and PLGA-BP polymers to 
different HA surfaces, binding energies of simulated 3D cells were calculated, and 
presented in Figure 4-6g for all studied HA surfaces. Simulations show that for all HA 
surfaces interacting with PLGA or PLGA-BP, the binding energies were negative, which 
corroborate that both compounds tend to be close to HA surfaces. Moreover, the presence 
of BP end groups leads to a significant increase in the absolute value of interaction energy. 
The simulations show that HA (110) and HA (001) surfaces are most favored for PLGA-
BP interactions. 
The strong electrostatic interactions of bisphosphonate molecules with the uppermost 
calcium atoms is the main reason for the highest binding energy being at the HA (110) 
surface. Figure 4-9 displays that phosphonate terminal groups in PLGA-BP are able to form 
hydrogen bonds with surface oxygen atoms in -PO4 units as well as hydroxyl oxygen and 







a) b) c) 
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correlation function) were evaluated for different atomic pairs as a further analysis of the 
intermolecular interactions.  
 
 
Figure 4-9 Iintermolecular hydrogen bonding interactions between BP bonded to PLGA and 
(a) HA (100), (b) HA (110), and (c) HA (001). Hydrogen bonds were shown as dash line. All 











Figure 4-10 Reproduction of PLGA-BP/SPION nanoparticle at five different independent 
experiments with reproduced microfluidic microchannels. 
Figure 4-6h, presents the RDF results between oxygen atoms double bonded to carbon 
atoms in both PLGA and PLGA-BP NPs, with respect to calcium ions in HA surfaces. The 
appearance of the first intensified peak in these RDFs implies that both PLGA and PLGA-
BP polymers have strong interactions with HA surfaces. Moreover, except for the RDFs 
for the HA (100) surface, the peak height in RDFs corresponding to HA:PLGA-BP is 
greater than that of HA:PLGA, which further suggests that modifying PLGA polymers 
with BP molecules increases the interactions with HA surfaces. In the case of HA (100) 
surfaces, RDFs of oxygen atoms with calcium atoms in PLGA and PLGA-BP do not show 
significant difference, which is in agreement with the corresponding binding energies 
provided in Figure 4-6g. 
It is clear that all RDFs demonstrate a first sharp peak, especially for HA (110) surfaces, 
indicative of powerful BP interactions with HA surfaces. The BP hydrogen bonding 
interaction with HA surfaces is also examined by evaluating the RDFs for hydroxyl 
hydrogen atoms in BP with regards to oxygen atoms in PO4 and hydroxyl oxygen atoms in 
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various HA surfaces. As seen in Figure 4-6i, the appearance of the first sharp peak confirms 
the strong BP interaction with HA surfaces by the formation of intermolecular hydrogen 
bonds. The position of sharp peaks is observed at distances less than 2.5 Å, which is the 
required hydrogen acceptor atom-hydrogen atom distance for the formation of hydrogen 
bonds. These simulation results are in agreement with our experimental findings, and 
confirm that the conjugation of BPs onto PLGA chains significantly improves their affinity 
to HA surfaces. 
To evaluate the functionality of designed NPs in vivo, FITC-labeled nanoparticles were 
administered through the tail vein in BALB/c mice. Pharmacokinetics of the microfluidic- 
and bulk-synthesized NPs was first investigated in the absence of PTX drug. Figure 4-11a 
displays the blood circulation profile of NPs based on the fluorescence recovery of FITC-
labeled NPs following systemic administration of NPs. Based on a two-compartment 
model (fitted curves) the targeted microfluidic-synthesized nanocarriers are found to be a 
stable and long-circulating system that provide enhanced delivery of loaded therapeutics 
compared with either non-targeted NPs or targeted bulk-synthesized particles. 
The biodistribution studies were performed by monitoring and quantitative measurements 
of fluorescence-labeled NPs distributed in mice tissues. As shown in Figure 4-11b, 
synthesized NPs showed mostly localization in the liver, kidney, and tumor and relatively 
low accumulation in the lung, heart, and spleen. There was no significant difference 
between the targeted and non-targeted NPs was observed for their lung, heart, and spleen 
localization (Figure 4-11b).  
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Figure 4-11 In vivo efficacy evaluation of nanoparticles. (a) Pharmacokinetic data represent 
percentage of remaining NPs at several time points after intravenous injection of NPs to 
BALB/c mice. Data includes background subtraction of blood auto-fluorescence. Two-
compartment model is fitted to determine the NPs’ half-lives. (b) Quantification of 
fluorescence signal of FITC-labeled NPs (total fluorescence signal per tissue weight) in order 
to determine the effects of targeting on biodistribution profiles of NPs in liver, spleen, kidneys, 
lung, heart, and tumor and ratio of tissue accommodation for targeted microfluidic and bulk 
NPs in comparison with non-targeted microfluidic NPs (c). (d) Bioluminescence images of 
mice after injection of luciferase positive human breast cancer cells (MDA-MB-231) in tibia 
of BALB/c mice at day 1 and day 30. Color scale shows the bioluminescence intensity and the 
change in photon flux upon treatments with various types of PTX-loaded NPs. NPs are 
systematically administrated at the same dose of 0.5 mg per kg of mouse’s body weight, after 
seven days of tumor implantation. The PBS based treatment is used as a control. The color 
scale indicates luminescence intensity in radiance (photons/sec/cm2/steradian). (e) The fold 
change in bioluminescence intensity of tumor-bearing mice upon treatment with targeted and 
non-targeted PTX-loaded NPs at day 30 based on the quantification of bioluminescence 
images. (f) Histological sections of bone metastasis tumors at tibia sites are stained using the 
TUNEL kit and detected by immunofluorescence microscopy. The green fluorescence signals 
indicate induction of apoptosis upon different treatments which is quantified in (g). The 
presented data are expressed as average ± SD. The results are statistically analyzed using 
unpaired t-tests. For all tests the statistical significance was set at p < 0.05. p < 0.01 is 
considered as statistically very significant. *p < 0.05 and **p < 0.01 between targeted (either 
microfluidic or bulk synthesized) NPs and non-targeted microfluidic NPs. #p < 0.05 between 
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targeted microfluidic synthesized NPs and targeted bulk synthesized NPs. &p < 0.05 and &&p 
< 0.01 between all types of NP-based treatments and control (PBS treatment) samples. 
Although accumulation in liver is a common challenge for nanoparticulate delivery 
systems (177), but the obtained results here promises use of BP molecules at the surface of 
NPs can considerably lower their liver accumulation compared with non-conjugated NPs. 
The relative change in total fluorescent signal per tissue weight of targeted NPs over 
corresponding non-targeted particles in different tissues are shown in Figure 4-11c. The 
results showed 1.5- and 1.9-fold increase in normalized fluorescence signal of targeted NPs 
over non-targeted particles at the tumor site for bulk- and microfluidic-synthesized NPs, 
respectively (Figure 4-11c). The targeting-dependent biodistribution profile of FITC-
labeled NPs in the bone metastasis highlights the role of BP groups as targeting moieties, 
in agreement with reported data elsewhere (174, 177, 178). 
An intratibial model of bone metastasis was developed to evaluate the anti-tumor efficacy 
of prepared NPs. Bioluminescence images of mice after injection of luciferase positive 
human breast cancer cells (MDA-MB-231) in tibia of BALB/c mice at day 1 and day 30 
were monitored to estimate tumor volume after treatment with various NPs (Figure 4-11d). 
The targeted NPs (microfluidic NP-BP and Bulk NP-BP) containing equivalent amount of 
PTX drugs showed significant decrease in the rate of tumor growth implanted into the tibia 
of mice (p-value < 0.05) in comparison with PBS treated animals. The tumor growth 
suppression in the case of treatment with targeted microfluidic NPs was significantly (p-
value < 0.05) higher than non-targeted microfluidic NPs (Figure 4-11e). Mice treated with 
free PTX (1 mg.kg-1) showed a slight decrease in rate of tumor growth as compared with 
NPs-treated groups. Here also TUNEL apoptosis assay was performed on tumor sections 
to test whether the tumor suppression with NPs treatment is related to induce apoptosis in 
treated tumor. As shown in Figure 4-11f, the apoptosis level was enhanced after treatment 
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with targeted NPs, whereas the highest number of apoptotic cells can be found in tumor 
treatment with targeted microfluidic NPs (Figure 4-11g).  
The presented results suggest that the developed nanoparticle mediated drug delivery to 
bone by BP-conjugation significantly increase the therapeutic outcome, which could be 
further increased by applying magnetic fields to add the hyperthermia effects as well. 
4.4 Conclusion 
Bone-targeting anti-cancer hybrid nanoparticles (HNPs) were developed through an one-
step incorporation of active agents superparamagnetic iron oxide NPs (SPIONs) and 
paclitaxel (PTX) into nanoprecipitated poly(D,L-lactide-co-glycolide) (PLGA) chains. 
Using microfluidic chips we were able to precisely tune size, compactness, and 
polydispersity of HNPs. The demonstrated microfluidic method is distinctive as it provides 
control over nanoprecipitation of polymeric chains while encapsulating diagnostic and 
therapeutic compounds inside the HNPs in situ. PLGA chains were functionalized with 
bisphosphonate (BP) molecules as hydroxyapatite targeting moieties to impart bone-
seeking capacity to the designed HNPs. It was found that at lower flow ratios (i.e., shorter 
mixing times), less number of polymer chains contribute to form smaller and more compact 
NPs. Drug encapsulation and release profile studies revealed higher loading efficiency 
(>75%), a suppressed drug degradation rate, as well as more sustained release patterns for 
the microfluidic synthesized HNPs compared with those prepared with bulk mixing. The 
HNPs conjugated with BPs showed significantly higher bone binding affinity, which was 
confirmed by a HA binding assay. Furthermore, molecular interactions between PLGA-BP 
chains and three HA crystallographic surfaces, simulated with computational molecular 
dynamics, validated the significantly improved tendency of the conjugated polymer chains 
to bind to HA surfaces. Based on pharmacokinetic results, targeted microfluidic HNPs 
showed higher blood circulation half-life compared to other NPs. Owing to smaller size 
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and BP surface functional groups, the developed HNPs provide improved biodistribution 
through the body and higher accommodation in tumor tissue compared with either non-
targeting or bulk-synthesized particles.  In vivo studies verified the prolonged circulation 
of targeted microfluidic HNPs and non-invasive bioluminescence imaging showed higher 
level of tumor suppression in the case of bone metastatic tumor treatment with targeted 
microfluidic HNPs. The presented results converge to suggest the developed microfluidic 
fabrication method as a reproducible (Figure 4-10) and versatile approach to synthesize 
tailored multifunctional NPs for personalized theragnostics including chemotherapy, 




CHAPTER 5. MICROFLUIDIC-ASSISTED SELF-ASSEMBLY 
OF COMPLEX DENDRITIC POLYETHYLENE DRUG 
DELIVERY NANOCAPSULES4 
 Microfluidic platform for the synthesis of complex nanocapsules is presented via a 
controlled self-assembly. The monodisperse nanocapsules in the range of 50–200 nm 
consist of a dendritic polyethylene core and a Pluronic copolymer shell. The resultant 
nanocarriers encapsulate large amount of hydrophobic anticancer drug like paclitaxel while 
providing a low complement activation as well as sustained release profile with high 
tunability. 
5.1 Introduction 
 Particles with nanoscale dimensions have long been known to have properties 
distinct from their bulk counterparts. This opportunity to alter and tune material properties 
has made nanoparticles (NPs) a popular research area. Synthesizing polymer NPs is 
possible using either top-down or bottom-up processing. As bottom-up processing involves 
the self-assembly of particles via intermolecular  forces, it offers the greatest opportunities 
to tailor the particle structure and properties.(11) However, this technique is both powerful 
and unruly, as it comes with the price of being challenging to control. 
Nanomedicine has a wide range of possible applications, including disease prevention, 
diagnosis, monitoring, management, and treatment. Cancer diagnosis and therapy are 
perhaps the most promising areas for nanotechnology in medicine, and are expected to 
soon have applications in the market.(1-3) Although there are many diverse problems in 
                                                 
4This work has been published by M.M. Hasani‐Sadrabadi, V. Karimkhani, F.S. Majedi, J.J. Van Dersarl, E. 
Dashtimoghadam, F. Afshar-Taromi, H. Mirzadeh, A. Bertsch, K. I. Jacob, P. Renaud, F. J. Stadler, I. Kim, 
(2014) Advanced Materials 26 (19), 3118-3123. Reproduced by permission of Wiley- VCH. 
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treating cancer, a magic bullet that can simultaneously target cancer cells and avoid healthy 
cells, therefore, increasing treatment efficiency and reducing side effects,(4, 5) has long 
been the dream of cancer researchers. One of the most promising techniques is using 
engineered vehicles for drug transportation and targeting.(7, 8) Polymer NPs are promising 
candidates for the delivery vehicle, although using the correct polymer is of great 
importance.(7, 9, 10) 
Dendritic polymers have been widely used as vehicles for the prevention, diagnosis, and 
treatment of various types of cancer.(179) These polymers have increased the efficiency of 
drug delivery, but they come with concerns over nanotoxicity.(1) Due to their high 
functionality, dendrimers have a very high tendency to bind to amphiphilic lipids, heavy 
metal ions, bile acids, vitamins, proteins, and nucleic acids, which can cause serious side 
effects to the body. For example, dendritic polymers have been established to damage cell 
membranes through lipid binding, and affect oxygen delivery and peroxide metabolism by 
complexing with iron and zinc ions.(1) Due to their complex and costly syntheses,  
advancing dendritic polymers to human trials has been limited thus far.(1, 179) Recently, 
dendritic polyethylene (dPE) NPs have demonstrated their usefulness across various 
aspects of materials science(180-183) due to their unique and interesting properties. dPE 
consists of highly branched polyethylene (PE) that is completely hydrophobic, but unlike 
its linear counterparts, dPE is soluble in common organic solvents and, furthermore, can 
be easily synthesized using a one-pot recipe. 
We have chosen to focus on dPE as the polymer for NP drug delivery due to its 
biocompatibility, hyperbranched architecture, and size, which is on the order of 30 nm and 
allows us to make self-assembled NPs in the range of 50–200 nm, an  ideal size for drug 
delivery.(171) Moreover, many studies have shown that hyperbranched polymers have 
higher encapsulation efficiencies than their linear counterparts.(184) Most importantly, 
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dPE is completely hydrophobic, which makes it an excellent carrier for anticancer drugs, 
which are almost entirely hydrophobic. 
Current dPE synthesis methods typically utilize multistep cascade chemical reactions to 
create large, well defined, and monodisperse NPs.(185) To ensure the solubility of highly 
hydrophobic dPEs in the blood and other aqueous environments in the body, researchers 
have successfully applied cascade (homo- and co-) polymerization(186) reactions or 
“grafting-to” methods.(187) Although these techniques facilitate the creation of elegant 
and complex dPE structures for drug delivery and bioconjugation,(188, 189) the necessary 
process is very tedious, requires tremendous effort to make these systems, and is 
accompanied by sacrificing catalytic activity. To address these complications, we 
developed microfluidic chips that use guided self-assembly to produce monodisperse 
PEGylated hydrophobic-hydrophilic core-shell structures of dPEs with triblock 
copolymers. Consequently, through microfluidic assembly, we can avoid multistep and 
complex chemical reactions, and we have better control over the NP properties. 
5.2 Experimental Section: 
5.2.1 Materials 
All reactions were performed under a purified nitrogen atmosphere using standard glove 
box and Schlenk techniques. Polymerization grade ethylene (SK, Korea) was purified by 
passing it through columns containing Fisher RIDOXTM catalyst and 5 Å/13X molecular 
sieves. Organic solvents were purified by standard procedures and stored over molecular 
sieves (4 Å). All other reagents used in this study were purchased from Sigma-Aldrich and 
used without further purification. 
The Pd-diimine catalyst used in this study, [(ArN=C(Me)–(Me)C=NAr) Pd 
(CH3)(N≡CMe)] SbF6 (Ar=2,6-(iPr)2C6H3) (1), was synthesized following a procedure 
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reported in literature,S1 which is briefly described as follows. In a round-bottom flask, 30 
mmol of 2,6-diisopropyl-aniline, 15 mmol of butane-2,3-dione, and a catalytic amount of 
formic acid are added to 50 mL of methanol. After 24 h, the medium is filtered, and the 
yellow solid was washed 3 times with 25 mL of cold methanol and dried in vacuo.  Under 
an inert atmosphere, 1.5 mmol of (COD)PdClMe and 1.5 mmol of diimine ligand are 
dissolved in diethyl ether. The reaction is run for 24 h at room temperature. The formed 
air-stable orange precipitate is recovered by filtration, then washed 3 times with 25 mL of 
diethyl ether and dried in vacuo (yield 93.7%). To synthesize the final catalyst, 1 mmol of 
AgSbF6 was added to an acetonitrile solution of [(ArN=C(Me)–(Me)C=NAr)Pd(CH3)(Cl) 
(1 mmol in 50 mL of acetonitrile) at room temperature, resulting in the immediate 
precipitation of AgCl. This mixture was then stirred overnight. AgCl was removed via 
filtration, and the solvent was evaporated. The solid was dissolved in dichloromethane. 
Pentane was subsequently added to precipitate the product. The resulting solid was filtered, 
washed 3 times with 25 mL of pentane and dried in vacuo (yield>95%). Ethylene 
polymerization was performed in a 250 mL oven dried round-bottom flask equipped with 
a magnetic stirrer and an external thermometer. High dilution techniques were adopted to 
reduce the monomer mass transport effect. After adding the palladium(II) catalyst (100 
µmol, 80.3 mg), the reactor was charged with dried dichloromethane (80 mL) by using a 
syringe and immersed in a constant temperature bath previously set to the desired 
temperature. The most reproducible reaction temperature for multiple runs was 35 °C. 
When the reactor was equilibrated with the bath temperature, polymerization was initiated 
by introducing ethylene into the reactor after removing nitrogen gas under vacuum 
(polymerization carried out in atmospheric pressure). After 24 h, the flow of ethylene was 
stopped and the polymerization mixture was concentrated in vacuum. For the removal of 
residual catalysts, the remaining mixture was dissolved in petroleum ether and passed 
through a column of silica gel and neutral alumina to obtain a colorless solution. The 
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solvent was removed and the viscous oily PE was dried for 24 h under vacuum at 70 °C 
(8.7 gr).  
For checking ligand purity, analytical thin layer chromatography was conducted using 
Merck 0.25 mm silica gel 60F precoated aluminum plates with a fluorescent indicator, 
UV254.  1H-NMR and 13C-NMR spectra were recorded on a Varian Gemini-2000 (400 
MHz, 100 MHz) spectrometer. All chemical shifts were reported in parts per million (ppm) 
relative to residual CDCl3 (δ 7.24) for 
1H-NMR and CDCl3 (δ 77.00) for 
13C-NMR. The 
branching numbers for PE were determined by 1H-NMR and 13C-NMR spectroscopy 
(Figure 5-1). For 1H-NMR, branching was determined by using the ratio of methyl groups 
to the overall number of carbons and was reported as branches per thousand carbons. 
 
Figure 5-1 1H-NMR (left) and 13C-NMR (right) spectra for the determination of branching 
numbers for PE. 
For the SEC analysis, two mixed bed columns (Polymer Labs., PLgel Mixed-C, 300 mm × 
7.5 mm) were used at a column temperature of 40 °C. SEC chromatograms were produced 
using multi-angle laser light scattering (MALLS, Wyatt, TREOS) at a wavelength of 670 
nm, a refractive index detector (Shodex, RI-101), and a Viscotek differential viscometer 
using THF (Samchun, HPLC grade) at an eluent flow rate of 0.8 mL/min. Polymer samples 
for the SEC analysis were dissolved in THF at a concentration of ca. 5.0 mg/mL and an 
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injection volume of 100 μL. Average values of the refractive index increment (dn/dc) 0.073 
mL/g were used in determining molar mass. 
Thermal analysis of dPE was carried out with a differential scanning calorimeter (DSC 1, 
Mettler Toledo) at a 10 °C/min heating rate under nitrogen atmosphere. The results of the 
second scan were reported to eliminate the difference in sample history. Typically, the 
samples were heated to 50 °C (1st heating scan), kept at 50 °C for 5 minutes, cooled to -
100 °C at 10 °C/min, and then heated again to 25 °C at 10 °C/min (2nd heating scan). 
Maximal melting peak temperature and enthalpy of fusion of the melt-crystallized states 
were determined using the second heating scan. The inflection point for the heat flow as a 
function of temperature was taken as the glass transition temperature. The crystallinity, χ, 
was calculated from enthalpy of fusion by the following equation: 
   χ = (ΔHf/ ΔHf*) × 100                                                                                         (Eq. 5-1) 
using the value ΔHf* = 290 J/g for 100%-crystalline polyethylene. 
Rheological measurements were performed on a Malvern Kinexus Pro using a Peltier 
Temperature Controller and a 20 mm/2° cone/plate geometry. The rheological properties 
were determined by dynamic mechanical measurements in the frequency range of ω = 100 
…0.1 s-1 with a shear strain of 0 <10%, which is in the linear-viscoelastic range for 
polymer melts. The tests were conducted at temperatures T between -10 °C and 80 °C. dPE 
has an almost Newtonian behavior that is obvious from the independence of viscosity to 
frequency |*()|, which indicates the absence of sizable amounts of entanglements. 
5.2.2 Fabrication of microfluidic devices 
Microfluidic devices were fabricated with poly(dimethylsiloxane) (PDMS) using a 
standard micromolding process. To make the master molds, silicon wafers were spin-
coated with SU-8 50 photocurable epoxy (Microchem, Inc.) to a thickness of 60 μm. 
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Baking, lithography, and development procedures were performed at the EPFL Center for 
Micronanotechnology (CMi) to obtain negative microchannels on the wafer. The wafers 
were annealed at 150 °C to eliminate surface cracks in the SU-8. After performing the 
thermal annealing, the surfaces of the resultant molds were coated with a self-assembled 
monolayer (SAM) of trimethylethoxy silane (Sigma) by vapor exposure for 40 min. The 
SAM prevents sticking of the PDMS to the mold. PDMS (Sylgard 184, Dow Corning) 
monomer and curing agent were mixed with a weight ratio of 10:1, pored over the mold, 
degassed in desiccators, and cured in an oven (Memmert) at 80 °C for 1 h. After curing, 
PDMS was removed from the mold and in-/outlet holes were punched using a 150 μm 
diameter punch. The PDMS was then bonded to a glass slide using oxygen plasma (100 
mW, 1 min; Diener electronic GmbH). The PDMS-based microfluidic device had two 
inlets for neutral pH water, one for the Pluronic/dPE solution in THF, and one outlet. The 
water stream was split into two in order to achieve two water streams at the flow focusing 
cross-junction. The mixing channel was 150 μm wide, 60 μm high and 1 cm long. 
5.2.3 Fabrication of nanocapsules 
For the bulk synthesis of nanocapsules (NCs), dPE/Pluronic solution in THF was prepared 
under stirred conditions. The nanoprecipitation and formation of the NCs was performed 
by drop-wise addition of this solution to water under vigorous stirring. For the drug-loaded 
NCs, paclitaxel (PTX, Sigma-Aldrich) was dissolved in THF and mixed with the polymeric 
(dPE and Pluronic® F-127) solution. The preparation of the NCs used the same procedure 
detailed in the previous paragraph. 
For the microfluidic synthesis of nanocapsules (NCs), dPE/Pluronic solution in THF was 
prepared under stirred conditions and then introduced into microchip as a main flow. The 
water streams act as a nonsolvent, and drives self-assembly during lateral stream mixing. 
To vary the degree of focusing, and consequently the mixing time, the flow ratio between 
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the polymer and water streams can be easily adjusted using Syringe Pumps (Harvard 
Apparatus, PHD2000; HA200I model). 
For the drug-loaded NCs, paclitaxel (PTX, Sigma-Aldrich) was dissolved in THF at four 
different initial loading of 5, 10, 15, and 20 wt% mixed with the polymeric (dPE and 
Pluronic® F-127) solution. The preparation of the NCs used the same procedure detailed in 
the previous paragraph. As a control samples, mixture of Pluronic F127 and PTX (at initial 
loading weight of 10 wt%) was used without presence of dPE at constant flow ratio of 
0.076.  
5.2.4 Characterization of naocapsules 
Atomic force microscopy (AFM; Bruker’s Dimension FastScan) and transmission electron 
microscopy (TEM; CM200-FEG-Philips) were used to characterize the morphology of the 
NCs. A dilute suspension of NCs was prepared and deposited onto the Cu grid with a 
carbon film. The shape and size of the particles were characterized via diffraction 
(amplitude) contrast and (for crystalline materials) through high-resolution (phase contrast) 
imaging. The TEM used a LaB6 source operating at 100 kV accelerating voltage. The 
images were characterized using ImageJ software with at least 20 different measurements.  
Dynamic light scattering (DLS) and zeta potential measurements were performed using a 
Zetasizer (Zetasizer 3000HS, Malvern Instruments Ltd., Worcestershire, UK) in 
backscattering mode at 173° for water diluted systems. 
Transmittance of the prepared samples was measured at room temperature (20 °C) with a 
Shimadzu UV mini 1240 UV/visible spectrophotometer with a wavelength of 550 nm. 







)⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡(Eq. 5 − 2) 
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where L is the length of light path in the sample cell (1.0 cm quartz cuvette), It is the 
intensity of the light transmitted through the sample, and I0 is the intensity of the light 
transmitted through the solvent (deionized water). Measurements were performed at least 
three times with the mean values. 
As described elsewhere, measuring of C3 and C3b migration through crossed 
electrophoresis proved C3 cleavage as a consequent of complement activation. Human 
serum was obtained from healthy donors, and stored at -80°C before use. Then diluted NCs 
in human serum at 1/4 in VBS2+ (veronal-buffered saline containing 0.15mM calcium and 
0.5mM magnesium ions) were incubated for 1 h at 37°C with mild stirring. Afterward, 5 
μl of each sample was subjected to isoelectric focusing on agarose gel. Subsequently, 
second-dimension electrophoresis was done on Gelbond® films (Cambrex Bio Science, 
Rockland) in agarose gel containing a polyclonal antibody to human C3, to recognize both 
C3 and C3b (Complement C3 antiserum raised in goat; Sigma-Aldrich). Finally, the film 
was stained with Coomassie blue (Sigma). A semiquantitative estimation of the proportion 
of native and cleaved C3 was done through the relative sizes of immunoprecipitation peaks, 
and the ratio between the height of peaks of C3 and C3b was calculated (C3/C3b ratio). 
Poly(methyl methacrylate) (PMMA) (MW = 120 kDa; Sigma-Aldrich) nanoparticles, which 
were used as positive control,S7 were prepared using the same microfluidic technique. In 
brief, PMMA was first dissolved in THF and then the solution introduced to the designed 
PDMS microchannels as the core flow. It was then hydrodynamically focused between the 
lateral water streams. Afterward, PMMA nanoparticles were dialyzed against distilled 
water using Spectrpor® membrane 50 kDa for 48 h. 
To determine the in vitro drug release profile, lyophilized PTX-loaded NCs (1 mg) were 
dispersed in 1 mL of phosphate buffered saline (1X PBS, pH 7.4). The solutions were 
placed into a 3 kDa molecular weight cut-off dialysis cartridge (Thermo Scientific, 
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Rockford, IL). The cartridge was immersed in 1 L PBS and gently shaken in a 37 °C water 
bath. At predetermined intervals, buffered solutions were collected and replaced with an 
equivalent volume of fresh PBS.  
The PTX concentration was measured with high-performance liquid chromatography 
(HPLC) by mixing the 1 mL sample with 1 mL of acetonitrile. A reverse phase C18 column 
was used as the stationary phase and the mobile phase was consisted of acetonitrile/water 
(60:40 vol/vol). Separation was carried out at a flow rate of 1 mL·min-1 and PTX was 
detected at a wavelength of 230 nm. This method was evaluated over a linear range of 1–
100 μg·mL-1. In this range, the percent deviation from theoretical value was found to be 
less than 5% and the coefficients of linearity remain greater than 0.96 using clean PTX 
standards.  
The PTX concentration in the solution was corrected for sampling effects according to 
following equation: S8  
Cn
l = Cn[VT/(VT-VS)](Cn-1
l/Cn-1)                                                                               (Eq. 5-3) 
where Cn
l is the corrected concentration of the nth sample, Cn is the measured concentration 
of PTX in the nth sample, Cn-1 the measured concentration of the (n-1)th sample, VT is the 
volume of receiver fluid, and VS represents the volume of sample drawn (1 mL). 
Loading content and loading efficiencies were determined by applying the following 
equations: 
PTX Loading content = (weight of the loaded PTX/weight of the NC)×100                     (Eq. 5-4) 
PTX Loading efficiency = (amount of PTX in the NCs/initial amount of the PTX) ×100 (Eq. 5-5) 
Water-insoluble FITC was applied to form fluorescent NCs, which were traceable via 
FACS, in order to study distribution of the NCs in macrophages. Then these water-
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insoluble FITCs were encapsulated inside the NCs during their formation in the 
microfluidic platform.  The abovementioned water-insoluble FITC were synthesized as 
reported earlier.S11 In brief, FITC (53.5 mg, Sigma), oleylamine (115.5 mg, Sigma), and 
sodium hydroxide (1.34 mg, Sigma) were mixed in toluene (10mL, Sigma). Then the 
mixture was heated up to 120°C for 2 h. After that, toluene was removed under vacuum 
overnight. Finally, the solid remnants were washed three times with HCl (0.1N, Sigma) 
followed by distilled water and in a dark environment at 60°C the residues were dried for 
2 days. 
Macrophage Culture.S12 RAW264.7 murine macrophages were monolayer cultured in a 
humidifier incubator (5% CO2) at 37°C, then maintained in Dulbecco’s minimum essential 
medium (DMEM, Sigma-Aldrich) supplemented with 10% heat-inactivated fetal bovine 
serum albumin (FBS, Invitrogen), 1% L-glutamine, and 1% penicillin G/ streptomycin 
(Invitrogen). Phagocytosis experiments were done with the cell density of about 
5×105 cells.ml-1. The plates containing macrophages were put and stirred in a humidified 
incubator at 37°C, at the final concentration of 5 μM of FITC-conjugated NC for 3 h. 
Afterward, the cells were rapidly cooled down (4°C) and washed three times with iced 
PBS. Then, for FACS analysis, they were fixed with formalin/PBS 1% (v/v), scrapped, and 
resuspended in PBS and then analyzed using flow cytometry, on a CyAn ADP Analyzer 
(FACS, Beckman Coulter, Inc) in triplicate. Finally the results are expressed as the 
normalized mean phagocytic capacity. 
The human breast adenocarcinoma cell line (MCF-7) was used for the cytotoxicity 
experiments. In vitro cytotoxicity assay was performed using HMCS NPs against MCF-7 
cells. MCF-7 cells were cultured in DMEM (Sigma-Aldrich) without phenol red and 
supplemented with 10 % fetal bovine serum. The cell cultures were cultivated at 37 °C in 
an incubator maintained at 5% CO2. 
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The cytotoxicity tests were performed using MTT colorimetric assays.S13 Cytotoxicity of 
the NCs was determined after 72 h incubation with MCF-7 cells. To determine cell 
cytotoxicity/viability, the cells were plated at a density of 10,000 cells per well in 96 well 
plates and then incubated overnight at 37 °C in 5 % CO2 atmosphere. For PTX treatment, 
a stock solution of PTX (10 mg·mL-1 in DMSO) was diluted to the defined concentration 
in culture medium. After treating the samples for 72 h, the MTT solution (20 μL, 5 mg·mL-
1 in phosphate buffer, pH 7.4) was added. The incubation was continued for another 2 h at 
37 °C and 5 % CO2 for exponentially growing cells. The absorbance of the purple MTT 
formazan solubilized in DMSO was then measured using a plate reader (Safire II, Tecan 
Sales Switzerland AG, Mannedorf, CH) at 570 nm.  
The control experimental medium contained no NCs. The samples were maintained with 
uniform drug concentration. The spectrophotometer was calibrated to zero absorbance 
using culture medium without cells. The relative cell viability (%) related to the control 
wells, containing cell culture medium without NCs, was calculated by [A]test/[A]control × 
100, where [A]test is the absorbance of the test sample and [A]control is the absorbance of 
control sample. 
All the experiments were conducted in triplicate at the minimum. The statistical analyses 
of the experimental data were done using the Student’s t-test, and the results are presented 
as mean ± SD. Statistical significance was accepted at a level of p < 0.05. 
5.3 Results and Discussion: 
In this study, poly(ethylene glycol)106-b-poly(propylene glycol)70-b-poly(ethylene 
glycol)106 copolymer (Pluronic
® F-127; BASF) was self-assembled with dPE chains to 
make soluble nanocapsules (NCs). Hydroxyl-terminated dendrimers have been shown to 
be less toxic than those functionalized with other moieties, such as carboxyl or amine 
groups.(190) With this general microfluidic assembly method, which can be extended to 
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the other di- or multiblock copolymers, self-assembly of polymers occurs as a consequence 
of controlled changes in local water content, which results in monodisperse PEGylated 
dPEs with tunable sizes. The primary advantage of microfluidic mixing over bulk mixing 
is the additional control over final NC properties. Microfluidics can induce rapid mixing, 
has high flexibility for fine-tuning particle properties with high reproducibility, and is 
independent of user skill; all of these aspects are difficult to achieve using traditional 
techniques.(14-17, 20, 23, 191) Microfluidics has made fine control over NP features more 
accessible by introducing formation parameters, such as flow ratio, mixing time, and chip 
architecture.(192) Even small changes in these parameters can yield particles with 
completely different properties that are applicable in many fields.(102, 160, 193) Having 
control over many adjustable parameters enhances the precision and tunability of the 
resulting NPs.(168)  
The dPE used in this study was synthesized according to previously reported 
procedures.(194) Briefly, a α-diimine palladium(II) catalyst was used to polymerize high 
molecular weight (MW), hyperbranched PE with the chain-walking mechanism. The 
resulting dPE was characterized with a triple detector gel permeation chromatograph 
(GPC), 1H and 13C NMR spectroscopy, differential scanning calorimetry (DSC), dynamic 
light scattering (DLS), atomic force microscopy (AFM), and rheological measurements. 
The viscous dPE is completely amorphous at room temperature and has a MW of 155 
kg·mol-1 (~100 branches per 1000 carbon atoms), and is almost entirely free of 
entanglements. However, the MW is 170 times greater than the entanglement MW Me, and 
the radius of gyration, <Rg
2>0.5, is about 15 nm, which is considerably lower than linear 
analogues. 
The poly(dimethylsiloxane)-based microfluidic device consists of perpendicular channels 
(cross-junction), which creates a focused THF solution flow in a stream of water (Figure 
5-2a). The water streams act as a nonsolvent, and drives NP self-assembly during lateral 
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stream mixing. Since the mixing time is such an important parameter in determining NP 
properties, a stable flow is vital in order to guarantee that mixing is controlled exclusively 
by the interfacial diffusion between the polymer flow and the surrounding water. 
Fluorescein sodium (1 mg·mL-1 aqueous solution) and water were used to mimic the flows 
so that we were able to study the microfluidic device’s hydrodynamic flow focusing ability 
and determine the range of stable flow rates in the focused flow region. As shown in Figure 
5-2a (inset), the fluorescein stream (middle channel, 1 mL min-1) is hydrodynamically 
focused between the side water streams. To vary the degree of focusing, and consequently 





Figure 5-2 (a) Schematic representation of a t-shaped cross-junction microfluidic device, 
which is used to hydrodynamically focus the flow of Pluronic, dPE, and PTX in THF using a 
sheath flow of water. The inset is a fluorescence image of Fluorescein hydrodynamically 
focused with water streams (scale bar 100 μm). AFM (b, c) and TEM (d, e) images of 
Pluronic/dPE NCs synthesized at a flow ratio of 0.03 (b, d) in comparison with bulk 
synthesized NCs (c, e). 
Precipitation of the dPE and Pluronic molecules is initiated by the presence of water 
molecules, which is controlled by molecular diffusion at the interface of the polymer and 
water streams. As this is the first report of dPE-Pluronic NC self-assembly via a 
microfluidic platform, we describe the process in detail here: by changing the flow ratio 
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between the THF and water streams from 0.03 to 0.2, the mixing time, τmix, for self-
assembly was kept in the millisecond range. The mixing time varies from approximately 
2.5 to 75 ms (Eq. S2). For τmix < τagg (the aggregation time), NC formation is kinetically 
restricted, and the particles have smaller sizes and are more monodisperse than those 
prepared through bulk mixing.(14, 168) DLS (DLS; Zetasizer 3000HS, Malvern 
Instruments Ltd., Worcestershire, UK) results indicate that longer mixing times lead to 
larger NCs (Figure 5-3a). Furthermore, the polydispersity index (PDI) of the core-shell 
NCs is approximately 0.10, five times lower than those produced with bulk synthesis 
techniques (0.49). 
In vitro evaluation of complement activation in the presence of fabricated NCs can be 
considered as a prediction of their fate after intravenous injection in vivo.(195) In fact, most 
of the NCs which induce strong complement activation are rapidly taken up by 
macrophages of the mononuclear phagocyte systems, while NPs exhibiting low or non-
activators of the complement systems are not recognized by macrophages and could remain 
in the bloodstream.(196) In the current work, activation of the complement system induced 
by microfluidic/bulk synthesized NCs is studied in comparison with the control samples. 
It has been shown that molecules comprising PEG moieties such as Pluronic on the surface 
of mico-/nanoparticles, can strongly activate complement systems by three well-known 
pathways.(195, 197) Our results, as presented in Figure 5-3, show the effective inhibition 
of C3 cleavage and consequently, suppression toward complement activation. It seems that 
complement activation of the microfluidic synthesized NCs are proportional to their size, 




Figure 5-3 (i) Effects of flow ratio on diameter (based on DLS results) and turbidity of 
synthesized NCs with and without the drug paclitaxel (PTX). The theoretical mixing time is 
also shown. (ii) Crossed immunoelectrophoresis of C3 antigens in human serum diluted 1/4 
in VBS2+ after 60 min incubation with NC suspensions. (a) Serum/VBS2+ as positive control 
(C3/C3b = 4.79); (b) serum/EDTA 10mM 1:3 v/v; (no Ca2+  no C3 cleavage); (c) PMMA 
NCs as negative control (C3/C3b = 0.96); (d) PLdPE-FL0.03 (2.5 μs) (C3/C3b = 3.38); (e) 
PLdPE-FL0.05 (6.2 μs) (C3/C3b = 3.22); (f) PLdPE-FL0.076 (13.6 μs) (C3/C3b = 2.25); (g) 
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PLdPE-FL0.15 (47.0 μs) (C3/C3b = 1.54); (h) PLdPE-FL0.2 (76.0 μs) (C3/C3b = 1.32); (i) 
PLdPE-Bulk (C3/C3b = 1.25).  (iii) Plot of C3/C3b ratio as a function of mixing time. (iv) 
Phagocytosis of the different microfluidic and bulk NCs by RAW 264.7 murine macrophages 
at 37°C.  
It is understood that particle size and curvature affect the complement activation.(195, 198) 
The role of curvature becomes more significant for particles with sizes similar to the cross-
sectional diameter of complement proteins such as ~40 nm for IgM(198) and ~30 nm for 
C4b2a.(195) In view of this, assembly and deposition on to the surface of particles with 
high curvature is rather difficult. Despite the fact that C3 protein has the smaller size 
relative to the other complement proteins, and its surface-bound compartment (C3b) is 
assumed to occupy an area of 40 nm2,(199) but it has been shown here having smaller NCs 
(higher curvature value) has resulted in decreased activation of complement activation 
(Figure 5-3). The macrophage uptake of the NCs is also evaluated as an indicator of the 
immune system response. As shown in Figure 5-3 (iv), phagocytic uptake of NCs is size 
dependent and low for the microfluidically prepared NCs. These results are in agreement 
with the demonstrated complement activation results, which imply the considerable 
capability of the designed NCs to escape from the immune systems for various in vivo 
applications. 
The hydrophobic-core, hydrophilic-shell structure of the dPE/Pluronic NCs provides an 
ideal environment for encapsulating hydrophobic molecules. This ability is demonstrated 
with paclitaxel (PTX), a powerful hydrophobic anticancer drug. To encapsulate the drug, 
a 0.5 mg·mL-1 solution of PTX in THF was mixed with a solution of dPE and Pluronic and 
was then injected into the central channel of the microfluidic device. During NC formation, 
the hydrophobic PTX molecules associate with the hydrocarbon structure of dPE and 
become entrapped in the hydrophobic cores of the core-shell NCs. As shown in Figure 5-
2a, the incorporation of PTX leads to an increase in the size of the NCs. However, the PTX 
loaded NCs (57–171 nm) remain within the ideal size window for  increased NC 
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permeability and retention (50–200 nm).(171) The morphology of dPE/Pluronic NCs 
prepared at a flow ratio of 0.03 is shown in Figure 5-2c. All of the prepared NCs are 
spherical in shape (54 ± 7 nm based on TEM image) and do not aggregate in an aqueous 
environment. 
In order to quantify the ability of PEGylated dPE to encapsulate significant amounts of 
hydrophobic anticancer drugs, we loaded the dPE/Pluronic NCs with different 
concentrations of PTX (5, 10, 15, and 20 wt%). As expected, PTX loading was very 
efficient for microfluidic synthesized NCs. For example, at 10 wt% of initial drug loading 
efficiency increased from 69.1% ± 19.3 wt% (for bulk mixing) to 99.1% ± 4.5 wt% for 
NCs fabricated in the rapid mixing regime (0.03 flow ratio). This resulted in weight percent 
loading values that are among the highest reported in literature for PTX.(200, 201) As 
shown in Figure 5-4 and 5-5, the loading content of dPE/Pluronic NCs can be controlled 
through operational parameters in the microfluidic device. A relatively small increase in 
flow ratio, and therefore in mixing time, results in larger particles and decreased drug 
loading. Maximum PTX loading (9.906 wt%) occurred for NCs with the lowest flow ratio. 
Despite the high PTX loading efficiencies, no significant change of the size of NCs was 
observed, suggesting that the hyperbranched nature of dPE creates a high level of free 




Figure 5-4 The change in paclitaxel (PTX) loading contents/efficiency as a function of flow 
ratios in comparison with that of bulk mixing at 10 wt% of initial loading of the drug. (Mean 
± SD, n = 5 independent experiments). 
 
Figure 5-5 The change in size (a) and PTX loading contents (b) of prepared NCs as a function 
of flow ratios in comparison with that of bulk mixing at 5, 10, 15, and 20 wt% of initial loading 
of the drug. (Mean ± SD, n > 3 independent experiments). 
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Relative activities of PTX were estimated by calculating the maximum rate of tubulin 
protein polymerization relative to the standard samples (Figure 5-6). Stabilities of the free 
and encapsulated PTX inside different types of NCs were evaluated by measuring the 
variations of their activities using the tubulin assay after storage at 25 °C and 37 °C for 1–
14 d in 96-well microtiter plates according to previously established protocols. Briefly, at 
defined time intervals, NCs were separated using centrifugation and redispersed in water 
at pH 4.5 to extract PTX from NCs, and then PTX was separated using HPLC to perform 
a tubulin protein assay. Then, select concentrations of PTX were reacted with tubulin 
protein solution (general tubulin buffer, tubulin glycerol buffer, 1 mM GTP), and the 
reaction was followed by measuring the increase in apparent absorption at 350 nm over a 
1 h period at 37 °C using an ELISA plate reader (Safire II, Tecan Sales Switzerland AG, 
Mannedorf, CH).  
 
Figure 5-6 Relative activity of PTX drug using a tubulin protein polymerization assay for 
both free and encapsulated PTX at 25 °C and 37 °C. (Mean ± SD, n = 4 independent 
experiments). 
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As shown in Figure 5-6, drug degradation is generally considered as a first order process 
and can be described by the following equation: ln(a/a0) = kt, where a is the activity of 
drug at time t, a0 is the initial drug activity, k is the degradation rate constant. At half-life 
of drug (t1/2), we have a=a0/2 => t1/2= 0.693/k => k=0.693/t1/2. The results of PTX half-life 
(t1/2) and degradation rate constant (k) are shown in Figure 5-7 and Figure 5-8a, 
respectively. 
 
Figure 5-7 PTX half-life (t1/2) for the various drug formulations at two different temperatures 
of 25°C and 37°C. 
Figure 5-8 shows the in vitro release profiles of PTX in PBS (phosphate buffered solution, 
pH 7.4) at 37 °C from NCs formed using both microfluidic and bulk mixing. The profiles 
exhibit relatively fast releases during the early stages (day 1), then followed by slow 
asymptotic releases, which are typical for PTX-loaded, self-assembled NCs.(122, 201, 
202) Figure 5-8 also demonstrates that NCs formed through microfluidics have a slower 
and more sustained release rate than the bulk synthesized NCs. Within two weeks, almost 
100% of the PTX was released from bulk synthesized dPE/Pluronic NCs, whereas about 
86%, 76%, and 98% of the PTX was released from NCs formed at flow ratios of 0.03, 
0.075, and 0.2, respectively. 
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For dPE/Pluronic NCs formed in the rapid mixing regime (time of mixing 2.5 and 13 ms 
with NC sizes of 63 and 79 nm, respectively), larger NCs have slower release profiles. 
These results are in agreement with recent reports that smaller NCs, due to their greater 
surface area to volume ratio, have faster release rates.(203) Additionally, with the decrease 
in flow ratio comes a shorter mixing time (2.5 ms for R = 0.03), smaller NCs, and higher 
drug encapsulation efficiency (Figure 5-8b). 
 
Figure 5-8 (a) Paclitaxel (PTX) degradation rate constant (k) for the various drug 
formulations at two different temperatures of 25°C and 37°C. (b) The change in PTX loading 
efficiency as a function of flow ratios in comparison with that of bulk mixing at 5, 10, 15, and 
20 wt% of initial loadings of the drug. (Mean ± SD, n = 5 independent experiments). (c) 
Calculated diffusion coefficients of PTX within NCs as a function of mixing time at different 
initial loading weights of 5, 10, 15, and 20 wt%. (d) Cumulative in vitro release of PTX from 
designed NCs at 37 °C and pH 7.4 (Mean ± SD, n = 4 independent experiments.) Curves are 
fitted first-order release equations (R2> 0.98). The inset depicts calculated diffusion 
coefficients of PTX within NCs and relevant times for releasing 50% of the loaded drug. (e) 
MTT-based cell viability assay of MCF-7 cells after 72 h of exposure to free PTX, PTX loaded 
NCs, and unloaded NCs at 37°C. Unloaded NCs were used as a negative control to the PTX 
loaded NCs and are plotted on the abscissa so that the number of NCs in corresponding trials 
is the same. 
The diffusion coefficient of PTX molecules within the dPE NCs was determined through 
analysis of the drug release profiles. The calculated values for the diffusion coefficient and 
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the time needed for 50% drug release (t50) are shown in Figure 5-8. The NCs formed with 
microfluidics have considerably lower diffusion coefficients and an extended t50 release 
compared to NCs created with bulk mixing. This prolonged, controlled release is highly 
desirable for treatment applications. Although the diffusion coefficient was found to 
increase with mixing time, the longer t50 for NCs formed with a 13.6 ms mixing time may 
be ascribed to the higher number of hydrophobic carriers (dPE) in the corresponding NCs. 
These results confirm the important role of self-assembly time in determining drug loading 
density and release behavior of the polymeric NCs. 
Pluronic F127-PTX NPs were evaluated as control samples. These NPs were prepared 
using the same microfluidic platform at flow rate of 0.076 without incorporation of dPEs. 
As shown in Figure 5-9a, the size of resultant NPs is larger than dPE incorporated ones. 
These results confirm the efficient role of dPEs on formation of more compact 
nanostructures. As shown in Figure 5-9b, the presence of dPEs in the core of NCs have 
provided the sustained release of PTX. Diffusion coefficient of drug molecules from 
Pluronic F127-PTX complexes was calculated to be 2.45×10-21 m2.s-1, which is about 15 
times more than that of for Pluronic F127/dPE-PTX (1.61×10-22 m2.s-1). 
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Figure 5-9 (a) DLS results for Pluronic F127/dPE-PTX NCs and Pluronic F127-PTX NPs, 
which were synthesized using cross-junction microfluidic platforms at the same flow ratio of 
0.076. (b) Cumulative release profiles the corresponding nanocarriers.  
Although the PTX encapsulation efficiency inside the NCs can be tuned through the 
microfluidic assembly platform, it is equally important that the encapsulated PTX retains 
its functional activity during the storage. Measured by tubulin polymerization assays, PTX 
was found to degrade much slower, at both 25 and 37°C, when encapsulated in microfluidic 
NCs compared to both free PTX and PTX encapsulated via bulk mixing (Figure 5-9). As 
shown in Figure 5-8a, the degradation rate constant (k) value, which is calculated at 25 and 
37°C, is much lower for microfluidic synthesized NCs in comparison with the free and 
bulk encapsulated NCs. This prolonged stability can extend the effective circulation time 
of drug-loaded NCs in the human body. The relative activity of free PTX decreased 
considerably and reached half of its initial value after the second day of storage, whereas 
the encapsulation of PTX prevented degradation and prolonged its activity for weeks, 
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probably due to the hydrophobic dPE molecules protecting the PTX from direct contact 
with water molecules. 
One requirement for a good cancer-therapy delivery vehicle is to maximize the lethal 
effects of the drug in the proximity of tumor cells. As is seen in Figure 5-8, the toxicity of 
plain NCs, as defined by the half-maximum inhibiting concentration (IC50) for MCF-7 
cells, is on the order of 300–1000 nM. We found little difference between the toxicity of 
bulk and microfluidically generated NCs. The IC50 toxicity for free PTX is on the order of 
1 nM, but PTX toxicity is enhanced by almost two orders of magnitude through 
encapsulation into dPE-based microfluidic NCs. This dramatic effect may be due to 
increased cellular uptake of the microfluidic NCs. 
Our results demonstrate the feasibility and importance of rapid mixing for the facile 
fabrication of complex dPE/Pluronic-based NCs, as well as controlling their self-assembly, 
drug loading, and release characteristics. Due to the olefinic nature of the synthesized NC 
cores, they are highly capable of carrying hydrophobic drugs while prolonging their release 
behavior. Nevertheless, further research on their in vitro and in vivo behaviors is needed, 
especially in NC surface modification for targeting.  
5.4 Conclusion 
In summary, we have developed a microfluidic-assisted fabrication of complex 
dPE/Pluronic-based NCs showing highly efficient encapsulation capacity of hydrophobic 
drugs. The monodisperse NCs in the range of 50–200 nm, ideal sizes for drug delivery, 
consist of a dendritic polyethylene core and a Pluronic copolymer shell. The resultant 
nanocarriers encapsulating a large amount of anticancer drug (say hydrophobic PTX) 
provide a low complement activation as well as sustained release profile with high 
tunability. This approach can be extended for the syntheses of other types of tailored, drug-
loaded, dPE-based NCs with various shells for the emerging field of nanomedicine. 
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CHAPTER 6. NON-SPHERIVAL NANOMEDICNE: 
MICROFLUIDIC-ASSISTED SELF-ASSEMBLY OF ONE-
DIMENSIONAL DRUG DELIVERY NANOSTRUCTURES FOR 
COMBINATORIAL CANCER THERAPY5 
 Except traditional design criteria like high loading efficiency, the importance of 
nanocarriers shape on its blood circulation and cell internalization is one of the critical 
factors which attracted considerable attention of scientists and added more complexity to 
design an ideal drug cargo. Moreover, combinatorial cancer therapies offer big potentials 
to increase the treatment efficiency and decrease the side effects. In this study, we 
demonstrate a simple microfluidic-assisted approach for controlled self-assembly of 
carbon nanotube (CNT)-templated 1D hybrid nanostructures for combinatorial cancer 
therapy. The nanostructures have a narrow size distribution and consist of a CNT-templated 
dendritic polyethylene (dPE) core and polymeric shell. The designed nanocarriers were 
shown to be highly efficient for combinatorial cancer therapy. While CNTs can be used for 
hyperthermia therapy, the decorated dPE nanoparticulate layer provided efficient loading 
of hydrophobic anticancer drugs. The developed hybrid one-dimensional nanostructures 
showed high cellular uptake, a sustainable release profile, and high tunability.  
6.1 Introduction 
Despite great advances in the field of nanomedicine, cancer remains one of the deadliest 
and most feared diseases. A nanocarrier platform capable of targeting and curing a variety 
of cancers with marginal side effects has not been developed.(204) An ideal nanoscale 
                                                 
5 This work has been submitted for publication by M.M. Hasani‐Sadrabadi, V. Karimkhani, G. Bahlakeh, E. 
Dashtimoghadam, F.S. Majedi, F.J. Stadler, I. Kim, K.I. Jacob (2017) 
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nanocarrier should meet a number of critical criteria, including sufficiently long circulation 
time in the body, efficient targeting, accumulation in target cells, high capacity of drug 
loading, nontoxicity to normal cells, and high cellular uptake. Recent studies demonstrated 
that non-spherical nanostructures have numerous desirable properties and thus these 
particles have gained increasing attention. Non-spherical drug delivery vectors for cancer 
therapy increase cellular uptake and show long circulation times, large tumour 
accumulation, long tumour inhibition time, high drug-loading capacity, and high maximum 
tolerated dose.(204) In addition to size, nanoparticle geometry has a large impact on the 
margination dynamics of vascular walls.(205-207) Spherical nanoparticles show minimal 
lateral drift, decreasing their probability of entering the vicinity of vessel walls and creating 
contact/binding points with endothelial cells. This dramatically decreases the effectiveness 
of both passive-targeting mechanisms (i.e. enhanced permeability and retention) and active 
targeting strategies. In contrast, non-spherical particles are more susceptible to tumbling 
and oscillations in the vasculature. Such features significantly enhance the tendency of 
achieving nanoparticle/cell wall contact, offering a higher potential for extravasation 
through vasculature fenestrations.(206) 
Combinatorial cancer therapies exploit several therapeutic strategies that synergistically 
promote anti-cancer effects to overcome drug resistance. This can be accompanied by 
reducing the concentrations of active reagents to mitigate side effects.(208-212) Carbon 
nanotubes (CNTs) and their polymeric hybrid materials have attracted considerable 
attention in biomedical applications, particularly in the treatment and diagnosis of disease. 
The potential of CNTs originates from their one-dimensional nanoscale morphology with 
lengths ranging from the nano- to the microscale.(213, 214) Drug delivery arrays, 
photothermal therapy, and in vivo imaging have been extensively investigated based on 
CNT systems for cancer treatment.(214-218) However, the fabrication of combination 
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therapeutic nanostructures and hybrid CNT/polymer nanostructure systems requires 
complicated multistep procedures and reactions.(212-214, 219) 
Bottom-up processes involved in self-assembly of nanoparticles via intermolecular forces 
can be used to create complex structures and tailor and tune particle structure and 
properties.(11) Recently, dendritic polyethylene nanoparticles (dPEs) were shown to be 
effective for various materials science applications(52, 181, 182, 220-223) because of their 
unique and interesting properties. dPEs are composed of highly branched PE chains that 
can be synthesized in a simple one-pot protocol.(220) dPEs are very different from their 
linear equivalents, as they are soluble in common organic solvents such as tetrahydrofuran 
(THF) and chloroform. Because they are bulky hydrophobic molecules, dPEs show great 
potential as nanocarriers for hydrophobic molecules and drugs.(52, 223-225) To create 
monodisperse well-defined and large nanoparticles (NPs) with dPE, multistep cascade 
chemical reactions are needed.(225, 226) Moreover, to achieve dispersion of highly 
hydrophobic dPEs in aqueous environments such as the blood, (homo-
/co)polymerization(186, 227) reactions or “grafting-to” methods(223, 228) are required. 
Although these techniques simplify the design and tune the elegant and complex dPE 
structures for bioconjugation and drug delivery,(188, 189) the process is very tedious, 
labour-intensive, and commonly supplemented by reduction of catalytic activity. To 
overcome these limitations, we recently developed a microfluidic-assisted self-assembly 
approach for fabricating monodisperse PEGylated hydrophobic-hydrophilic core-shell 
structures of dPEs.(52)  
One of the unique characteristics of dPEs, first developed by Ye and co-workers, is their 
ability to solubilize CNTs and graphene nano-sheets in conventional low-polarity organic 
solvents with low-boiling points such as chloroform and THF.(229-232) This occurs 
through non-covalent and non-specific CH−π interactions of dPE molecules with CNT or 
graphene surfaces. Given the biocompatibility and encapsulation capacity of hydrophobic 
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anticancer drugs as well as their ability to assemble on CNTs, dPE/CNT hybrid 
nanostructures show the potential for flexible design of customized 1D nanocarriers. Such 
dPE/CNT designs broaden the loading capacity of the nanohybrid carrier, which are 
typically loaded into CNTs through π−π stacking.(216) 
The aim of present study was to conduct microfluidic-assisted synthesis and 
characterization of fine-tuned dPE/CNT hybrid nanocarriers loaded with paclitaxel (PTX) 
that is poorly soluble in water. To achieve these goals, CNT, dPEs, and poly(ethylene 
glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) copolymer (Pluronic F-
127) with an average molar mass of 13,000 were self-assembled on a microfluidic platform 
to develop water-dispersible 1D drug-delivery systems. It has been reported that neutral 
hydroxyl-terminated NPs show lower toxicity than other charged functional moieties such 
as amine or carboxyl groups.(190, 205)  Thus, the proposed microfluidic-directed assembly 
was used to prepare a PEGylated, non-spherical, dPE-decorated CNT nanostructure. This 
approach can be extended to other di- or multi-block hydrophilic-hydrophobic copolymers 
as well as brush-like copolymers. 
6.2 Materials and Methods 
Synthesis of dPE. Synthesis of dendritic polyethylene (dPE) nanoparticles and their 
characterization were reported in the previous chapter. In summary, dPE is a Newtonian 
fluid with zero shear viscosity η0 near 56 Pa·s at room temperature. The average molecular 
weight (MW) is 157 kg·mol−1 and mean radius of gyration is approximately 15 nm. The 
nanoparticles are highly branched (~ 100 branches/1000 carbons) and fairly spherical. 
Purification of single-walled carbon nanotubes (SWCNTs). We developed 200-nm long 
SWCNTS by controlled sonication and then separated them based on length using size-
exclusion chromatography and ultracentrifugation. Length separation of single-walled 
carbon nanotubes was performed as previously described.(233-235) For size-exclusion 
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chromatography 25 mg of HiPco Carbon SWCNT (NanoIntegris Technologies, Inc., 
Quebec, Canada) as raw material was suspended in 50 mL of sodium cholate (1 wt% in 
D2O) using a Q500 Sonicator (500 W; 3.2 mm probe; Qsonica, LLC., Newtown, CT, USA) 
at 7.5%. Size-exclusion chromatography was performed using Sephacryl High-Resolution 
gel filtration media (Sephacryl S-500 HR; GE Healthcare Life Sciences, Little Chalfont, 
UK) as reported previously.(234) The early fraction of nanotubes with known length 
distribution was diluted (10X) with sodium cholate solution and sonicated for 120 min. 
Glacial acetic acid (PharmaGrade, Sigma, St. Louis, MO, USA) was used to remove 
sodium cholate from the SWCNTs as previously described. This acid neutralizes the 
surfactant to form the corresponding acid, which is immediately immiscible with acetic 
acid, leading to breakdown of the stable sodium cholate helices. The carbon components 
then form networks under the influence of gravitational forces and van der Waals 
interactions and the sample was further solubilized in THF. The final solution was 
centrifuged at 17,000 ×g for 45 min. 
6.2.1 Microfluidic-assisted fabrication of CNT-based nanohybrids.  
Microfluidic devices were fabricated with poly(dimethylsiloxane) (PDMS; Sylgard 184 
Silicone Elastomer Kit, Dow Corning Co., Freeland, MI, USA) using a standard 
micromoulding process as reported previously.S1 To form the master moulds, silicon 
wafers were spin-coated with a Microchem (Westborough, MA, USA) negative epoxy 
resist (SU-8) to a thickness of 60 μm. Baking, lithography, and development procedures 
were performed at the EPFL Center for Micronanotechnology (Lausanne, Switzerland) to 
obtain negative microchannels on the wafer. The wafers were annealed at 150 °C to 
eliminate surface cracks in the SU-8. After thermal annealing, the surfaces of the resulting 
moulds were coated with a self-assembled monolayer of trimethylethoxy silane by vapor 
exposure for 40 min. The self-assembled monolayer prevents sticking of PDMS to the 
mould. Sylgard 184 monomer and curing agent were mixed in a weight ratio of 10:1, 
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poured over the mould, degassed in desiccators, and cured in an oven at 80 °C for 1 h. After 
curing, PDMS was removed from the mould and outlet holes were punched using a 150-
μm diameter punch. The PDMS was then bonded to a glass slide using an oxygen plasma 
cleaner (100 mW; 1 min) from Harrick Plasma Inc. (Ithaca, NY, USA) The PDMS-based 
microfluidic device had two inlets for neutral pH water, one for the CNT/Pluronic/dPE 
solution in THF and one outlet. The water stream was split into two to achieve two water 
streams at the flow focusing (T-) junction. The mixing channel was 150 μm wide, 60 μm 
high, and 1 cm long. For drug-loaded NCs, paclitaxel (PTX, Sigma-Aldrich) was dissolved 
in THF and mixed with the CNT, dPE, and Pluronic F-127 solution.  
6.2.2 Characterizations 
Microscopic morphology of nanostructures. Atomic force microscopy (Bruker’s 
Dimension FastScan, Billerica, MA, USA) and transmission electron microscopy (CM200-
FEG-Philips, Amsterdam, Netherlands) were used to characterize the morphology of the 
nanostructures. A dilute suspension of NCs was prepared and deposited onto the Cu grid 
with a carbon film. The shape and size of the nanohybrids were characterized by diffraction 
(amplitude) contrast and (for crystalline materials) through high-resolution (phase contrast) 
imaging. The transmission electron microscopy used an LaB6 source operating at 100 kV 
accelerating voltage. The images were characterised using ImageJ software (NIH, 
Bethesda, MD, USA) with at least 20 different measurements. Dynamic light scattering 
and zeta potential measurements were performed using a Zetasizer (Zetasizer 3000HS, 
Malvern Instruments Ltd., Malvern, UK) in backscattering mode at 173° for water-diluted 
systems. 
In vitro drug release measurement. To determine the in vitro drug release profile, 
lyophilized PTX-loaded CNT-based nanohybrids (1 mg) were dispersed in 1 mL of 
phosphate buffered saline (1X PBS, pH 7.4). The solutions were placed in a 3500 Da 
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MWCO dialysis cartridge (Thermo Scientific, Waltham, MA, USA). The cartridge was 
immersed in 1 L PBS and gently shaken in a 37 °C water bath. At predetermined intervals, 
buffered solutions were collected and replaced with an equivalent volume of fresh PBS. 
The PTX concentration was measured by high-performance liquid chromatography by 
mixing 1 mL sample with 1 mL of acetonitrile. A reverse-phase C18 column was used as 
the stationary phase and the mobile phase consisted of acetonitrile/water (60:40 vol/vol). 
Separation was carried out at a flow rate of 1 mL·min-1 and PTX was detected at a 
wavelength of 230 nm. This method was evaluated over a linear range of 1–100 μg·mL-1. 
In this range, the percent deviation from theoretical value was found to be less than 5% and 
coefficients of linearity remained greater than 0.96 using clean PTX standards. The PTX 
concentration in the solution was corrected for sampling effects according to following 




l is the corrected concentration of the nth sample, 
Cn is the measured concentration of PTX in the nth sample, Cn-1 the measured concentration 
of the (n-1)th sample, VT is the volume of receiver fluid, and VS represents the volume of 
sample drawn (1 mL). 
Encapsulation efficiency of the nanostructures and loading efficiencies were determined 
by applying the following equations: 
PTX Loading content = (weight of the loaded PTX/weight of the nanohybrids) × 100                
PTX Loading efficiency = (amount of PTX in the nanohybrids /initial amount of PTX) × 100 
6.2.3 Cytotoxicity and cellular assays 
Cytotoxicity of the nanohybrids. A standard MTT colorimetric assaying was carried out 
using HeLa cells to examine the cytotoxicity of the fabricated nanostructures. To determine 
cell cytotoxicity/viability, the cells were plated at a density of 10,000 cells per well in 96-
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well plates and then incubated overnight at 37 °C in an incubator maintained at 5% CO2. 
The cells were then incubated with NC-CNTs and PL-CNTs over a concentration range of 
0.5–50 μg·mL-1. The culture medium was discarded after 24 h and the cells were washed 
with PBS (pH 7.4) followed by incubation for 2 h with 100 μL of 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution in Dulbecco's Modified Eagle's 
medium (DMEM; 500 μg·mL-1 in phosphate buffer pH 7.4). The medium containing MTT 
was replaced with 150 μL of dimethyl sulphoxide in each well. After shaking the plates for 
10 min, the absorbance values of the wells were recorded with a microplate reader (Bio-
Tek Synergy HT, Winooski, VT, USA) at a wavelength of 570 nm. The control culture 
medium contained no nanoparticles. All measurements were performed at room 
temperature. The spectrophotometer was calibrated to zero absorbance using control 
culture medium containing no cells. The relative cell viability (%) related to the control 
wells, containing cell culture medium without nanoparticles, was calculated 
as [A]test/[A]control × 100, where [A]test was the absorbance of the test sample 
and [A]control was the absorbance of the control sample.  
Cellular uptake. For cellular uptake experiments, the HeLa cell line was used to 
investigate the uptake of FITC-labelled NC-CNTs and PL-CNTs. The particles were 
incubated with cells from 0 to 5 h (incubator 37 °C, 5% CO2) at a concentration range of 
0.5–50 μg.mL-1. After incubating the cells with the particles, the cells were rinsed three 
times with PBS and trypsinised to detach from the plates. The resulting cells were 
centrifuged and suspended in a 0.4% trypan blue solution in Dulbecco’s Phosphate Buffers 
Saline (DPBS) solution to quench extracellular FITC fluorescence. The cells were 
centrifuged again and the dye solution was withdrawn. Next, the cell pellets were 
resuspended in DPBS. All samples were kept on ice until fluorescence-activated cell 
sorting analysis. These samples were analysed by flow cytometry (CyAn ADP, Beckman 
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Coulter, Inc. Brea, CA, USA) to detect green and red fluorescence. The process was 
repeated for cells positioned in an inverted configuration as described previously. 
For microscopy, 1 × 105 cells per well were seeded on round glass cover-slips in 12-well 
plates. After reaching 80% confluency, the growth media was aspirated and 400 μL of 
FITC-labelled NC-CNTs and PL-CNTs in PBS were added to each well at a concentration 
of 10 μg·mL-1. Cells were then incubated for 4 h at 37°C and 5% CO2. The samples were 
washed five times with PBS and fixed with 3% paraformaldehyde solution. Cell nuclei 
were stained with propidium iodide and then fluorescent microscopy measurements were 
performed using a ZEISS LSM700 UP2 (Jena, Germany) confocal laser scanning 
microscope. 
A thermal imaging camera (FLIR Systems; Nashua, NH, USA) was used to record the NIR 
laser irradiation (808 nm; 1.5 W·cm-2)-induced increase in temperature. For photothermal 
ablation of cancer cells, HeLa cells were seeded in tissue culture dishes at a density of 
40,000 cells/cm2 and were cultured for 24 h at 37°C in an incubator maintained at 5% CO2 
until reaching 80% confluence. Next, the medium was replaced with nanohybrid-
containing medium (0.5, 1, 5, 10, 25, and 50 g·mL−1). After incubation for 4 h, the cells 
were rinsed three times with PBS to remove the free nanostructures. Fresh medium was 
added and then laser light at 808 nm; 1.5 W·cm-2 with a 250 m diameter spot-size was 
irradiated for 6 min. Cell viability was characterised by using the live/dead assay and MTT 
assay as described above after 24 h.  
RAW264.7 macrophage-like cells (ATCC, Manassas, VA, USA) were seeded 48 h prior 
to the experiment in 96-well culture plates at a density of 1 × 105 cells per well in culture 
medium supplemented with 5% foetal bovine serum. The cells were incubated in medium 
containing NC-CNTs and PL-CNTs (10 μg·mL-1) for 5 h. As a positive control, cytokine 
production was stimulated with LPS (50 ng·mL-1). Cytokine ELISA kits obtained from BD 
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Biosciences (Franklin Lakes, NJ, USA) were used to evaluate the expression levels of 
TNF-α and IL-10 in the medium according to the manufacturer’s protocols. For 
pharmacokinetics (blood circulation) studies, six female BALB/c mice (18–22 g) were 
randomly divided into two groups for the two different kinds of designed nanostructure 
NC-CNTs and PL-CNTs. All mice were fed a commercial diet and water ad libitum and 
were on alternating 12-h light/dark cycles. Both groups were injected via the tail vein at 
the same dose of 2 mg per kg of mice’s body weight. Blood samples were drawn from the 
retro-orbital sinus at different times, 0 and 30 min and 1, 1.5, 3, 5, 7, 9, and 12 h, into 
heparinized tubes and the samples were centrifuged for 15 min. The plasma was separated 
and stored at −20°C in the dark before analysis. The plasma concentration of NPs was 
defined based on the fluorescence intensity of the FITC groups using a Bio-Tek Microplate 
Reader. The normalized plasma concentrations of applied nanostructures are shown as a 
function of time.  
All experiments were conducted in at least triplicate. Statistical analyses of the 
experimental data were conducted using the t-test, and the results are presented as the mean 
± SD. Statistical significance was accepted at a level of p < 0.05. 
6.2.4 Simulation Methods 
Ab initio calculations. High-level electronic structure calculations based on ab initio 
quantum mechanics tools were employed to obtain dPE molecules with equilibrium 
structures for use in subsequent MD simulations. The chemical structure of dPE molecules 
was taken from work reported by Ittel et al.(236) Ab initio calculations of dPE molecules 
were carried out using Hartree-Fock (HF) theory with 6-31G** basis functions(237) 
without any constraints. The final geometry-optimized dPE molecule is shown in Figure 
6-1. Partial charges centred on dPE atoms were determined via electrostatic potential-based 
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method of CHELPG.(238) All ab initio electronic structure computations were performed 
using the Gaussian 09 suite of programs.(239)  
 
Figure 6-1 (a) HF/6-31G** optimized geometry of dPE, and (b) chemical structure of SWCNT 
(15,15) applied for MD simulations. All atoms are shown in ball and stick model (colour code: 
carbon, gray and hydrogen, white). 
Molecular dynamics (MD) simulations. To qualitatively and quantitatively evaluate the 
affinity between CNT and dPE, classical MD simulations were conducted for the CNT-
dPE complex. MD simulation approaches were conducted on a simulation box comprising 
dPE molecules and SWCNTs. An armchair SWCNT of chirality (15,15) with a diameter 
of 2.034 nm and length of 4.673 nm (shown in Figure 6-1b) was taken into consideration 
for simulation characterisation of the central CNT molecule, as CNTs of the same diameter 
were utilized in our experiments. The terminal carbon atoms in SWCNTs were saturated 
by hydrogen atoms. Next, the constructed SWCNT was placed at the centre of a simulation 
cell of dimensions 4.8 × 7.0 × 7.0 nm3, and then surrounded by 17 dPE molecules obtained 
from calculations at the HF/6-31G** level of theory. These dPE molecules were randomly 









The three-dimensional simulation box was energy-minimized using the Steepest Descent 
algorithm. Subsequently, the minimum energy SWCNT-dPE configuration was subjected 
to a 10-ns MD simulation performed in the constant volume and temperature (NVT) 
ensemble, where all SWCNT atoms were position-restrained and kept fixed at the centre 
of MD cell. The Berendsen thermostat was used to control the temperature at the desired 
value of 300 K. OPLS-AA force field parameters were adopted to describe the interactions 
between dPE and CNT.(240, 241) A leapfrog approach with a time step of 1 fs (10-15 s) 
was employed to integrate the Newton motion equation. The LINCS method was utilized 
to maintain all bonds fixed at their equilibrium values. Non-bonded interactions were 
truncated using a 1.2 nm cut-off distance. Periodic boundary conditions were imposed in 
all three directions of the simulation box. All atomistic MD simulations were executed 
using GROMACS simulation code (version 4.5.4).(242, 243) Dynamic trajectories from 
the last 5-ns NVT simulations were saved every 10 ps and used for later visual and 







Figure 6-2 Initial simulation cell of SWCNT-dPE: (a) front view, and (b) side view; final 
simulation cell of SWCNT-dPE obtained at the end of 10-ns MD simulations: (a′) front view, 
(b′) side view. CNT is in ball and stick model, and dPE molecules are shown in line model 
(colour code: carbon, gray; hydrogen, white).  
6.3 Results and Discussion 
dPEs were synthesized based on previously reported procedures.(52, 194, 222) A 
Brookhart type α-diimine palladium(II) catalyst was synthesized and used to polymerize 
high-molecular weight (MW), highly branched PE NPs via the so called chain-walking 
mechanism (see Supplementary Information). The synthesized dPEs were characterized by 
triple-detection size exclusion chromatography, 1H and 13C NMR spectroscopy, dynamic 
light scattering, atomic force microscopy, rheological measurements, and differential 
  
 











scanning calorimetry. The obtained dPE with honey-like viscosity was completely 
amorphous at 25 °C with MW of approximately 155 kg·mol−1 (approximately 100 branches 
per 1000 carbon atoms based on NMR characterization). Rheological measurements 
showed that dPEs are free of entanglements because of the large number of closely packed 
branches.(244, 245) although the MW is approximately 170-fold greater than the 
entanglement molecular weight (Me) for linear PE, while its radius of gyration, <rg
2>0.5 is 
approximately 15 nm, which is considerably smaller than linear analogues of the same 
MW.(246, 247) 
Short-length, single-walled CNTs were prepared by controlled sonication and subsequent 
separation based on length using size-exclusion chromatography and ultracentrifugation 
(see Supporting Information). To synthesize nanohybrids, CNT/dPE/Pluronic F-127 were 
pre-mixed with THF at room temperature and then introduced into the microchip as the 
core flow using a syringe micropump (Figure 6-3a). The water streams, used as the non-
solvent, were introduced onto the chip with lateral flow. To vary the degree of flow 
focusing, the flow ratios of the core dispersion and water streams were adjusted using 
micropumps for THF solutions and water. The generated nanostructures composed of self-
assembled dPE/Pluronic decorating CNTs were designated as nanocapsule-CNTs (NC-
CNTs). For drug-loaded nanostructures, PTX was dissolved in THF at an initial loading of 




Figure 6-3 Physical characteristics of microfluidic synthesized nanohybrids. (a) Schematic 
representation of cross-junction microfluidic device used for controlled formation of CNT-
based nanohybrids. Pre-mixed solution of dPE, CNT, Pluronic F127, and anticancer drug 
(PTX) in THF (main flow) was focused using two streams of water (lateral flow) at different 
flow rates. (b) Hypothetical arrangement of molecules around CNT. (c) Transmission 
electron micrograph (TEM) of the self-assembled nanohybrid nanoparticles; FR = 0.03, Scale 
bar: 50 nm. (d) Atomic force macroscopic image of single nanohybrid formed at FR = 0.03 
and deposited on mica (e) with its representative height distribution profile. (f) Length 
distribution of CNT-based nanohybrids (n = 300). (g) Coating thickness of microfluidic-
assisted synthesized nanohybrids at different flow rates with (filled spheres) and without 
(open spheres) anticancer drug (PTX). The loading efficiency of PTX is also plotted (filled 
square). (h) Initial simulation cell (left) and final simulation cell (right) of CNT-dPE after 10-
ns MD simulations. (i) Time evolution of van der Waals (vdW) interaction energy between 
CNT and dPE molecules during the final 5-ns of molecular dynamics (MD) simulations. 
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The main benefit of self-assembly by microfluidic mixing in comparison with that of 
conventional bulk methods is the precise control over time of mixing, and, consequently, 
tunability of the final assembled nanostructure properties. It has been proven that 
microfluidics gives great flexibility in adjusting and tuning shape, size and, therefore, 
properties of the nanostructures, ultimately leading to superior reproducibility and 
uniformity of the resultant particles.(14-17, 23, 52, 167, 248-251)  
To better understand the formation of the nanocarriers, we evaluated the intrinsic affinity 
of dPE to CNTs using molecular dynamics simulation. The final equilibrated configuration 
of the dPE-CNT complex attained from the canonical ensemble, constant-temperature; 
constant-volume ensemble (NVT), is shown in Figure 6-3h. Compared with the initial state, 
dPEs clearly moved towards the CNT surface and localized near their outer surface. 
Moreover, dPEs wrapped CNTs with neighbouring CH groups pointing towards their 
external surface, thus maximizing surface coverage. This enabled dPE molecules to form 
a layer around the CNTs via methyl (CH)-π interactions. The delocalized π electrons in 
aromatic benzene rings of CNT strongly interacted with numerous CH groups in dPE, 
enabling the dPEs to interact with the surface of CNTs. To quantify the extent of 
intermolecular interactions governing the behaviour of the CNT-dPE complexes, van der 
Waals interactions (vdW) were predicted within the last 5 ns of the simulations. Figure 6-
3i presents the calculated interaction energy versus simulation time. The CNT-dPE 
interaction energy showed negligible fluctuations, indicating that dPE adsorption and 
subsequent wrapping around the CNT stabilized the nanohybrids, likely by strengthening 
the vdW interactions. The increased binding energy was reflected by the negative sign, 
quantitatively confirming the affinity between CNT and dPE molecules, leading dPEs to 
localize near the CNT surface. CH−π interactions appeared between CNT and dPEs 
significantly contributed to the vdW interactions. 
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Drug-loading efficiency measurement revealed that NC-CNTs encapsulated more than 
80% of the drug. This high encapsulation efficiency, which is similar to that of our recently 
reported spherical dPE-based nanocapsules,(52) is among the highest value reported for 
micellar systems.(225) One of the main factors determining the efficiency of drug delivery 
nanocarriers is in vivo fate of the nanocarrier, which may be related to immune system 
activation. We evaluated the effect of nanostructures on stimulation of the immune system 
in vitro to predict the fate of NC-CNTs under physiological conditions. Tumour necrosis 
factor alpha (TNF-α) and interleukin-6 (IL-6) are two the most common cytokines 
produced by macrophages, which enter the bloodstream under abnormal conditions to 
provoke an immune system response. Lipopolysaccharides (LPS) are bulky 
organic molecules formed by covalent attachment of a lipid and polysaccharide, which can 
stimulate a strong immune response. Thus, LPS is useful as a negative control to evaluate 
the sensitivity of the immune system to the fabricated nanostructures. As shown in Figure 
6-4, the data confirmed that Pluronic-coated CNTs (PL-CNTs) and NC-CNTs stimulated 




Figure 6-4 Determination of immune response of nanohybrids after incubation with RAW 
264.7 macrophages by evaluating TNF-α (a) and IL-6 (b) cytokine expression using ELISA. 
(c) In vivo pharmacokinetic data represent percentage of remaining NPs at several time 
points after intravenous injection of NPs into BALB/c mice. Data include background 
subtraction of blood auto-fluorescence. Two-compartment model was used to determine 
nanohybrid half-lives.  
Previous studies showed that PEGylation (PEG, polyethylene glycol) of NPs, which 
increases circulation time in the bloodstream, is an efficient modification for avoiding 
activation of the immune system against NPs.(252) This strategy was used for make CNTs 
stealth for surveillance of the immune system, but Moghimi and co-workers showed that 
PEGylation of single-walled CNTs (SWCNTs) and multi-walled CNTs (e.g. different PEG 
chain length, PEG adsorption versus covalent linkage) do not completely stop complement 
activation against them.(253)  Complement activation occurs both in vitro and in vivo for 
PEGylated CNTs via the lectin pathway. Surprisingly, PEGylated SWCNTs with a 
branched PEG architecture activated the lectin pathway through only L-ficolin recognition, 
that did not generate anaphylatoxins or did not induce the complement system  affect or 
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arm triggering.(254) Very recently, Lee et al. showed that covalent conjugation of virus-
like NPs with branched polynorbornene increases their shielding efficiency from antibody 
recognition.(252) These results suggest that complement activation can be minimized.   
Figure 6-4c shows that the bioavailability of NC-CNTs was higher than for PL-CNTs. This 
may be associated with the higher softness of NC-CNTs. As described above, dPEs are 
rubbery and soft NPs; room temperature is significantly higher than their glass transition 
temperature. Thus, dPE-decorated CNTs form softer exterior compared with pristine 
CNTs. Numerous recent studies have evaluated the impact of elasticity on NP fate in the 
body.(255-258) By using soft and hard PEG-based hydrogel NPs, Anselmo et al. (255) 
showed that softer NPs have significantly reduced uptake in immune cells, endothelial 
cells, and cancer cells, but they showed enhanced circulation times and improved targeting. 
Key et al. (256) showed that soft discoidal polymeric NPs were more resistant to 
macrophage uptake compared with their hard counterparts. As a result, the NC-CNT 
system not only provides flexibility in anticancer drug selection, but also may enable tuning 
of the fate of NPs by changing the surface’s mechanical properties. As shown in Figure 6-
5, the internalization of fluorescein isothiocyanate (FITC)-labelled nanohybrids in HeLa 
cells was measured to determine the targeting capability of our proposed system. Figure 6-
5a shows receptor-mediated endocytosis measured by FITC-labelling. There was a 
significant increase in FITC intensity of treated samples with NC-CNT compared to PL-
CNTs. Moreover, internalization of NC-CNTs was higher than for PL-CNTs. Figure 6-5b 
shows the temperature dependency of NC-CNT endocytosis.  
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Figure 6-5 (a) Cellular uptake of FITC-labelled PL-CNT and NC-CNT nanohybrids after 2 
h incubation with nanohybrids at 25 g·mL-1 in a 10% foetal bovine serum (FBS) containing 
culture and measured by flow cytometry. b) Temperature-dependent cellular uptake based 
on median fluorescent intensity at 4 °C (black) and 37 °C (grey) (2 h; 25 µg·mL-1; 10% FBS). 
c) Uptake kinetics of nanohybrids incubated with the HeLa cancer cells (25 µg·mL-1; 10% 
FBS). d) Cellular uptake of nanohybrids as a function of nanohybrid concentration (2 h; 10% 
FBS). Values indicate mean ± one standard deviation from three independent measurements 
performed in triplicate. Confocal laser scanning microscopy images showing cellular uptake 
of FITC-labelled PL-CNT (e) and NC-CNT (f) nanohybrids, after 2 h incubation with HeLa 
cells in culture containing 10% FBS. The cell nuclei were stained with propidium iodide (red). 
The green dots represent internalized nanomaterials. The scale bar is 10 μm.  
Internalization tests were performed on samples incubated at 4 and 37 °C. It is well-known 
that endocytosis is strongly inhibited at 4 °C.(259) As endocytosis is an energy-activated 
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process, internalization is expected to be higher at elevated temperatures for both PL-CNT 
and NC-CNT nanohybrid systems. However, we found that the relative decrease in 
endocytosis for the developed nanohybrids at 4 °C was significantly lower than that for 
other nanoparticle drug-delivery systems.(260) Kostarelos et al.(261) showed that different 
functionalized SWCNT can be internalized by mammalian and prokaryotic cells via 
energy-independent mechanisms. Internalization was found to be higher for NC-CNTs 
than for PL-CNTs and, surprisingly, a more pronounced difference was observed at lower 
temperatures. Figure 6-5c shows the kinetics of internalization over 5 h. During the test, 
internalization of NC-CNTs was higher than for PL-CNTs. As shown in Figure 6-5d, the 
amount of internalized nanohybrid structures increased with increasing dosage for both 
PL-CNT and NC-CNT samples. In accordance with the above results, for all 
concentrations, internalization was higher for NC-CNTs than for PL-CNTs. Figure 3e and 
3f shows the confocal microscopy images of HeLa cells containing internalized PL-CNTs 
and NC-CNTs. Red and green areas represent the cell nucleus and CNTs, respectively. 
Figure 6-5e(iii) and 3f(iii) are the merged images of Figure 6-5e(i) with 6-5e (ii) and 6-
5f(i) with 6-5f(ii), respectively. These figures clearly show the higher internalization of 
NC-CNTs than that of PL-CNTs. 
One of the characteristics of CNTs is their photothermal effect in the near-infrared (NIR) 
region, while biological systems are transparent in this range.(262) Here, we attempted to 
exploit this potential for developing a 1D nanostructure platform for combinatorial cancer 
therapy. Figure 6-6a shows the temperature change of the media over time after laser 
irradiation. While the maximum temperature increase for PBS was less than 5 °C, both the 
PL-CNT and NC-CNT systems showed more than 20 °C increases after irradiation. 
Throughout the experiment, the temperature increase was higher for PL-CNTs than for 
NC-CNTs. This may be because of the thermal insulating effect of dPE. Figure 6-6b shows 
the in vitro release profile of PTX-loaded NC-CNTs in PBS (pH 7.4) at different 
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temperatures. The release profiles at 37 and 45°C revealed reasonably fast releases during 
early stages, followed by sustained asymptotic release, which was previously observed for 
PTX-loaded self-assembled NCs.(52, 263-265)  As expected, the release rate was higher 
at elevated temperatures. To examine the effect of laser radiation on PTX release, two 
pulses of irradiation (808 nm; 1.5 W.cm-2) were applied to the sample maintained at 37 °C 
(indicated by arrows in Figure 6-6b). Laser exposure caused increased release compared to 
the corresponding samples without laser exposure. Thus, fine-tunable drug release in 
combination with photothermal therapy is expected using NC-CNT nanohybrid structures. 
One of the main prerequisites for an ideal anti-cancer nanomedicine is its ability to 
maximize toxic effects near tumour cells. Here, we examined the toxicity of unloaded and 
PTX-loaded NC-CNTs with and without laser irradiation. As expected, Pluronic F127-
assembled nanostructures did not show cytotoxic effects. Both PL-CNTs and NC-CNTs 
without laser exposure showed similar toxicities in a concentration-dependent manner and 
more than 75% cell viability at all examined CNT concentrations. After applying the laser, 
the death rate of cancer cells significantly increased. This effect was more pronounced at 
higher CNT concentrations and more notable for NC-CNTs, which showed more than 90% 
cytotoxicity at 50 μg.mL-1 of CNT. This can be ascribed to the higher cellular uptake of 
NC-CNTs compared to that of PL-CNTs. Figure 6-6b shows the effect of PTX on the 
toxicity of nanohybrids. Interestingly, NC-CNTs without a drug were not toxic up to very 
high concentrations. Moreover, the efficiency of laser irradiation in the system without 
PTX was significant at higher CNT concentrations. However, the toxicity of PTX-loaded 
NC-CNTs was very high, which was associated with the higher PTX concentration inside 
the cells after high internalization of NC-CNTs. The results revealed a synergistic cytotoxic 
effect for PTX-loaded NC-CNTs after laser exposure. In fact, one order of magnitude less 
PTX is required to achieve equivalent toxicity when nanohybrid structures are exposed to 
laser light.  
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Figure 6-6 (a) In vial heat generation in PBS suspensions containing 10 μg·mL-1 of various 
types of designed CNT-based nanohybrids after NIR-irradiation (808-nm laser; 1.5 W·cm-2; 
6 min). (b) Cumulative in vitro release profiles of PTX from designed nanohybrids at pH 7.4 
PBS solution and at different temperatures. Arrows indicate the time of laser exposure (mean 
± SD, n = 3 independent experiments). MTT-based cell viability assay of HeLa cells after 72 
h of exposure to PTX-loaded (d) and unloaded (c) NPs as a function of concentration at 37 
°C. The effect of laser exposure on cellular viability of HeLa cells. (e) Visualized evaluation 
of cellular viability of HeLa cancer cells after various treatments via live-dead assay (scale 
bar 200 μm). Photothermal destruction of HeLa cells (i) without and (ii) with presence of 10 
μg.mL-1 NC-CNTs (without PTX) after 6 min NIR irradiation (808 nm; 1.5 W·cm-2), solid 
marked circle indicates laser irradiation spot. 10 μg·mL-1 of PTX-loaded NC-CNTs cultured 
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with cells for 4 h (iii) and 72 h (iv) and then removed by changing the media. All images were 
taken 24 h post (photothermal/PTX) treatment. Dead cells are red while viable cells are green. 
The photothermal cytotoxicity was consistent with the results of the intracellular uptake of 
nanohybrids (Figure 6-5). The importance of localized and precise photodestruction of 
cancer cells or cancerous tissue has been emphasized in numerous previous studies. In 
CNT-treated cells, significant cell death was observed after 6 min of irradiation due to heat 
accumulation inside cells and sufficient temperature increase to initiate DNA damage. 
Comparison of the laser-irradiated area versus that of the non-irradiated region showed 
increased localized cell death. 
6.4 Conclusion 
In conclusion, we demonstrated the potential of using a microfluidic-assisted approach for 
synthesizing complex hybrid nanostructures based on carbon nanotubes. Through non-
covalent non-specific CH−π interaction, hydrophobic dPE molecules decorated on the 
CNT surface and later block copolymers used to hydrophilic functionalized nano-kit. The 
designed dPE-CNT hybrid nanostructures with a narrow size distribution were shown to 
have a high capacity for loading anticancer drugs, which can be precisely tuned to provide 
a sustainable release pattern. Moreover, this simply fabricated but complex nanostructure 
showed high cellular uptake. The resultant nanocarriers showed remarkable efficiency for 
delivery of combinatorial cancer therapeutics based on photodynamics and chemotherapy. 
Regarding the employed interactions, the accessible nanostructures are not limited to 1D 
and with choosing other carbon-based materials like graphene and/or other simple or 
complex copolymer (e.g. containing targeting moieties), broader library of nanostructures 
with higher accuracy and efficiency can be synthesized. 
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CHAPTER 7. VIRUS-INSPIRED MECHANOBIOLOGICAL 
DESIGN OF CANCER NANOMEDICINES 
 Here we have tried to address the importance of mechanobiological properties of 
polymeric nanoparticles as they engage with biological systems. A microfluidic system 
was used to generate monodisperse nanoparticles with broad ranges of mechanical 
stiffness. A 3D tumor-on-chip device was then developed to mimic the dynamic and 3D 
microenvironment near the tumor spheroids in vitro which is further used to screen the 
targeting properties of engineered nanoparticles, too. We tried to optimize the mechanical 
properties and accordingly design a nanotherapeutics agent with prolonged blood 
circulation, enhanced tumor penetration and apoptosis promoting capability. Finally, we 
designed virus-mimicking NPs that can switch their mechanical stiffness to maximize their 
therapeutic efficacy. 
7.1 Introduction 
 Mimicking features of a natural material is not a trivial undertaking. Natural 
particles such as pathogens (esp. viruses) are highly optimized for their specific 
functions in vivo. Such systems possess features desired in designing drug delivery 
vehicles. This approach enables us to satisfy the central dogma of drug delivery, which is 
to design bio-inspired vehicles that target tissues and cells with maximal therapeutic 
efficacy. Human immunodeficiency virus (HIV) is one of the most professional biological 
hijackers (266). These nanomaterials can circulate long enough through the blood to find 
their potential targets. It has been reported that immature HIV particles are more than four 
to 14-folds stiffer than mature ones (266, 267). Moreover, there is a striking correlation 
between the softness of HIV viruses during maturation and their ability to enter 
cells. Reported results show that HIV regulates its mechanical properties and turns stiff 
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when entering or leaving the cells, whereas being soft during blood circulation and 
undergoes maturation-induced stiffness switch during the infection process (267). Based 
on these findings, it is logical to consider mechanical properties as one of the cornerstones 
of nanoparticles’ (NPs) pharmacokinetics, tumoral distribution pattern, cellular uptake rate 
and their mechanism of internalization. There are few reports that confirm the effects of 
micro-/nanoparticles’ elasticity on pharmacokinetics and their cellular internalization in 
various cell lines (255, 268, 269). However, there is no systematic study to investigate the 
mechanobiological properties of NPs by keeping all the other physical variants such as 
size, surface charge, and ligand density constant. Therefore, this calls for the studies aimed 
at evaluating the effect of elastic deformation of NPs on their biological behavior. Here we 
proposed engineering strategies for enhancing the efficacy of cancer nanotherapeutics by 
controlling their physico-mechanical properties. As a robust synthesis tool that provides a 
controlled mixing regime, we used microfluidics platforms to synthesize monodisperse 
NPs with adjustable physicochemical properties. The central hypothesis is that mechanical 
properties of NPs, which is often ignored in nano-bio interface, significantly affect their 
therapeutic efficacies. Therefore, we systematically investigated the effects of mechanical 
characteristics of NPs on their biological functionalities both in vitro and in vivo, and then 
inspired by viruses, we offered a way to remotely switch the mechanical properties of NPs 
from soft to hard.  
7.2 Materials and Methods 
7.2.1 Chemicals and Biologicals 
Unless noted otherwise, all chemicals were purchased from Sigma-Aldrich, Inc. (St. Louis, 
MO). All glassware was cleaned overnight using concentrated sulfuric acid and then 
thoroughly rinsed with Milli-Q water. human umbilical vein endothelial cells (HUVEC), 
U87MG human glioblastoma, human embryonic kidney cells 293 (HEK-293), human 
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breast adenocarcinoma (MCF-7) were purchased from American Type Culture Collection 
(ATCC). All other cell culture reagents, solutions, and dishes were obtained from Thermo 
Fisher Scientific (Waltham, MA) except as indicated otherwise. 
7.2.2 Experimental 
Hydrophobic modification of chitosan was performed according to our previous reports 
(44, 248). In brief, 1 gr chitosan (CS; medium molecular weight, 280,000 g/mol, degree of 
deacetylation 83%, Fluka) was stirred for 12 h in aqueous acetic acid (50 mL, 1% w/v). 
Once dissolved, the solution was filtered with a 0.2 µm Nylon syringe filter. The pH was 
then adjusted to 5.5 by addition of sodium hydroxide. An ethanolic solution of 300 mg 
palmitic acid N-hydroxysuccinimide ester was added drop-wise to the chitosan solution at 
98 °C under reflux and reacted for 48 h. The solution was then cooled down to room 
temperature and, after adding acetone, was precipitated by adjusting the solution pH to 9.0. 
The precipitated polymer was then filtered twice, washed with an excess of acetone, and 
lyophilized. The prepared hydrophobically modified chitosan (HMCS) was analyzed by 1H 
NMR (Bruker 400 MHz). 
The degree of substitution (DS) of palmitoyl groups on chitosan was determined using the 
ninhydrin assay (44). HMCS was dissolved in an aqueous acetic acid and then 0.5 mL of 
4 M acetic acid in acetate buffer (pH= 5.5) was added into 0.5 mL of the prepared solution. 
1 ml of ninhydrin reagent was then added and test tubes were placed in a boiling water bath 
for 20 min. The solutions were then cooled and absorbance at 570 nm was measured. The 
unmodified chitosan solution was used as control and the acetic acid/acetate buffer was 
used as the blank solution. 
Fluorescein-modified hydrophobically modified chitosan (FITC-HMCS) were synthesized 
based on the reaction between fluorescein isothiocyanate (FITC) and the chitosan as 
described elsewhere (270). In brief, FITC was dissolved in methanol (2 mg.ml-1) and then 
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added drop-wise to the solution of HMCS in 1% w/v acetic acid. After 5 h reaction in 
darkness, at ambient temperature, the FITC-labeled chitosan was precipitated in 0.2 M 
NaOH and separated from unreacted FITC in a Sephadex G-50 column with 1/15 M 
phosphate buffer/0.2 M NaCl as an elution solvent. Fractions containing the labeled 
polymer were collected and dialyzed using a 3500 Da molecular weight cut-off dialysis 
cartridge (Thermo Scientific, Rockford, IL) against deionized water for four days until no 
fluorescence was detected in the supernatant before freeze drying. The resultant FITC-
HMCS was used to prepare the fluorescent labeled NPs as described above. 
Microfluidic devices were fabricated with poly(dimethylsiloxane) (PDMS) using a 
standard soft-lithography process (271). To make the master molds, silicon wafers were 
spin-coated with SU-8 photocurable epoxy to a thickness of 60 μm. Baking, lithography, 
and development procedures were performed at the clean room facilities to obtain negative 
channels on the wafer. The wafers were then annealed at 150 ºC to eliminate surface cracks 
in the SU-8. After annealing, the surface of molds was coated with a self-assembled 
monolayer of trimethylethoxy silane by vapor exposure for 40 min. The SAM prevents 
PDMS from sticking to the mold. PDMS (Sylgrad 184) monomer and curing agent were 
mixed in a weight ratio of 10:1, poured into the mold, degassed in desiccators and cured in 
an oven at 80 ºC for 1 h. After curing, the PDMS was removed from the mold and in-/outlet 
holes were punched using a 150 μm diameter punch. The PDMS was then bonded to a glass 
slide using oxygen plasma (100 mW, 1 min). The PDMS microfluidic device had two inlets 
for alkaline water (pH 9), one for the aqueous solution of HMCS with the pH of 5.5 at four 
different initial concentrations of 0.5, 1.0, 2.0, and 5.0 mg.ml-1), and one outlet. Water 
stream is split into two, in order to achieve two water streams at the flow focusing cross-
junction. The mixing channel was 150 μm wide, 60 μm high and 1 cm long. The flow rates 
were adjusted for each concentration individually as shown in Table 7-1. 
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Table 7-1 Microfluidic processing conditions for making HMCS-based nanoparticles at 

















0.5 0.5 15 0.03 2.8 
1 0.5 16 0.03 2.5 
2 0.4 14 0.03 2.1 
5 0.7 20 0.04 3.1 
FR-2 
0.5 0.5 7 0.07 12.2 
1 0.5 6.5 0.08 14.0 
2 0.5 7.1 0.07 11.9 
5 0.4 5.5 0.07 12.6 
FR-3 
0.5 0.5 5 0.10 22.6 
1 0.5 5 0.10 22.6 
2 0.4 4.3 0.09 19.8 
5 0.6 5.5 0.11 26.5 
FR-4 
0.5 0.5 2.5 0.20 76.1 
1 0.5 2.5 0.20 76.1 
2 0.4 1.9 0.21 82.8 
5 0.6 2.9 0.21 80.5 
For bulk synthesis of HMCS nanoparticles, polymeric solutions were prepared by 
dissolving 2.5 mg.ml-1 polymer in 1% w/v acetic acid solution under constant stirring. 
HMCS nanoparticles were synthesized through nanoprecipitation by drop-wise addition of 
1M sodium hydroxide to adjust the pH to 7.4. 
To make photocrosslinkable nanoparticles, chitosan (1 mg/ml) chains first modified with 
poly (ethylene glycol) diacid (PEG-(COOH)2; 600 Da) (5 mg/ml) after activation with 
EDC/Sulfo-NHS for 5 min. The reaction was performed at pH 5 for 3 h. After purification 
of the product via dialysis and subsequent lyophilization, the carboxylic acid groups were 
reacted with diamine again using EDC/Sulfo-NHS chemistry for 5 h. These hydrazine 
groups are necessary for photocontrollable reaction with functionalized multi-arm PEGs. 
Functionalization of 4-arm PEG amine (5,000 Da; Creative PEGWorks, Chapel Hill, NC) 
was performed as previously reported by Anseth and coworkers (272). Incorporation of 
 169 
photoreactive 2-nitrobenzyl-alcohol groups on PEG molecules form 2-
nitrosobenzaldehyde (272) upon UV exposure using a laser diode at the wavelength of 405 
nm with the intensity of 20 mW/cm2 that can react with hydrazine groups of slightly 
modified chitosan chains (Figure 7-1).  
  
Figure 7-1 Schematic of proposed reaction between 2-nitrobenzyl-alcohol groups on 4-arm 
PEG with hydrazine groups of modified chitosan after UV exposure. 
For drug loading into nanoparticles, Paclitaxel was dissolved in acidic water (pH 4.5) and 
mixed with the polymeric solution. Then, the nanoparticles synthesis was followed as 
detailed above. 
Transmission electron microscopy (TEM; CM200-FEG-Philips) was used to characterize 
size and morphology of the nanoparticles. To this end, a dilute suspension of nanoparticles 
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was prepared and deposited onto a Cu TEM grid with a carbon film. The shape and size of 
the particles was characterized via diffraction (amplitude) contrast and, for crystalline 
materials, through high resolution (phase contrast) imaging. The TEM used a LaB6 source 
operating at 100 kV. The images were characterized using ImageJ software with at least 
20 different measurements.  
Dynamic light scattering (DLS) as well as zeta potential measurements were performed 
using a Zetasizer (Zetasizer 3000HS, Malvern Instruments Ltd., Worcestershire, UK) in 
backscattering mode at 173˚ for water diluted systems. 
Transmittance of the prepared samples was measured at room temperature (20 °C) with a 
Shimadzu UV mini 1240 UV/visible spectrophotometer with a wavelength of 550 nm. 







)⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡⁡(𝐸𝑞. 7 − 1) 
where L is the length of light path in the sample cell (1.0 cm quartz cuvette), It is the 
intensity of the light transmitted through the sample, and I0 is the intensity of the light 
transmitted through the solvent (deionized water). Each measurement was performed at 
least three times. 
A PTR 46 refractometer (Index Instruments, UK) was used to measure the refractive index 
of 1% v/v aqueous acetic acid solution which was obtained as n0 =1.332. The values of the 
refractive index increment (dn/dc) of the polymer solutions were determined through the 
asymmetric flow field-flow fractionation (AFFFF) method using AF2000 FOCUS system 
(Postnova Analytics, Landsberg, Germany). The dn/dc was measured at the wavelength of 
635 nm. 
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For mechanical characterization of nanoparticles, standard V-shaped gold-coated silicon 
nitride tipless AFM cantilevers (Bruker/Veeco, Veeco Metrology Inc., now BrukerNano, 
Camarillo, CA) were used in this study. The cantilever spring constant was measured using 
the thermal fluctuations method. The spring constant of the cantilevers was found to be 
0.105 N/m. Measurements were performed using a Veeco AFM II Dimension 3100 (Veeco 
Metrology Inc., now BrukerNano) instrument in liquid mode (ultrapure water) after drying 
the nanoparticles on poly (acrylic acid)-treated mica surface and re-hydrated with ultrapure 
water before test. To minimize viscoelastic effects, force-indentation curves were recorded 
at the frequency of 1 Hz. 
To functionalized HMCS nanoparticles with cyclic RGD (Arg-Gly-Asp-d-Phe-Lys), 
carboxylic acid terminated cRGD-PEG reacted with amine-containing chitosan 
nanoparticles via 1-Ethyl-3-[3-dimethylaminopropyl] carbodiimide (EDC)/ N-
hydroxysuccinimide (NHS) chemistry. After 5 h of reaction nanoparticles were dialyzed 
(Float-A-Lyzer, MWCO: 20kDa; Spectrum Laboratories, Inc., Rancho Dominguez, CA) 
for two days against PBS to remove unreacted cRGD-PEG molecules. The nanoparticles 
suspension was lyophilized and kept refrigerated before further use. 
Quantification of RGD groups on the nanoparticles’ surface wasw assessed using the 
LavaPep Peptide Quantification Kit (Gel Company Inc, San Francisco, CA, USA) as 
reported elesewhere (273). In brief, 100 μl of cRGD-PEG-HMCS nanoparticles (1 mg/ml) 
was mixed with 100 μl of the LavaPep working reagent and incubated for 1 h under dark 
condition and the fluorescence intensity was measured using a plate reader (Safire II, Tecan 
Sales Switzerland AG, Mannedorf, CH). The number of cRGD groups was estimated using 
a calibration curve of free peptides. 
To determine the in vitro drug release profile, lyophilized PTX-loaded nanoparticles (1 
mg) were dispersed in 1 ml of phosphate buffered saline (1X PBS, pH 7.4). The solutions 
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were placed into a 3.5 kDa molecular weight cut-off dialysis cartridge (Float-A-Lyzer). 
The cartridge was immersed in 1 L PBS and gently shaken in a 37°C water bath. At 
predetermined intervals, buffer solution samples were collected and replaced with an 
equivalent volume of fresh PBS. A Sequential pH change (from 7.4 to 6.5 or 5.5) in PBS 
medium was applied to study the effect of pH on release profiles. The PTX concentration 
was measured with reversed-phase high-performance liquid chromatography (HPLC) by 
mixing 1 ml of sample with 1 ml of acetonitrile as follows: A C18 column was used as the 
stationary phase, while the mobile phase consisted of acetonitrile:water (60:40 vol/vol). 
Separation was carried out at a flow rate of 1 mL.min-1. PTX was detected at a wavelength 
of 230 nm. This method was evaluated over a linear range of 1-100 μg.ml-1. In this range, 
the deviation from theoretical values was less than 5% and the R-square values remained 
less than 4% using clean PTX standards.  




l / Cn-1), where Cn
l is the corrected concentration of the nth sample, 
Cn is the measured concentration of PTX in the n
th sample, Cn-1 the measured concentration 
of the (n-1)th sample, VT is the volume of the receiver fluid and VS represents the volume 
of the drawn sample (1 ml). 
Encapsulation efficiency of the nanoparticles and loading contents were determined by 
applying the following equations: 
PTX Loading content = (Weight of the loaded PTX / Weight of the NPs)×100 
PTX Loading efficiency = (The amount of PTX in the NPs/ Initial amount of the PTX in 
NPs) × 100 
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Relative activities of PTX were estimated by calculating the maximum rate of tubulin 
polymerization relative to the standard samples as reported before (44, 274). Stability of 
the free and encapsulated PTX inside different types of nanoparticles was evaluated by 
measuring the variations of their activities using the tubulin protein assay after storage at 
25°C and 37°C for 1-14 days in a 96-well microtiter plates according to previously 
established protocols. Briefly, at defined time intervals nanoparticles were separated using 
centrifugation and redispersed in water at pH 4.5 to extract the PTX from the nanoparticles. 
The PTX was then separated using HPLC to perform a tubulin protein assay. PTX at 
defined concentrations was reacted with tubulin protein solution (general tubulin buffer, 
tubulin glycerol buffer, 1 mM GTP) and the reaction was followed by measuring the 
increase in apparent absorption at 350 nm over 1 h at 37°C using a Safire II plate reader. 
To analyze expression of integrin receptor using Western blot, HUVEC, U87 MG, HEK-
293, and MCF-7 cells were lysed using protein extraction buffer (Bio-Rad, Irvine, CA). 
The extracted proteins were fractionated in 10% sodium dodecyl sulfate-polyacrylamide 
gels (PAGE) and electrophoretically transferred to a nitrocellulose membrane (Bio-Rad). 
The membranes were then incubated with antibodies against avb3 as well 
as GAPDH which was used as the housekeeping protein. For flow cytometry analysis, 
antibodies to integrin vβ3 were purchased from Abcam.  Cells were analyzed on 
FACSVerse using FlowJo software (Treestar). 
The cellular uptake of different types of FITC-labeled HMCS nanoparticles were measured 
using flow cytometry, FACSVerse Analyzer (BD Biosciences). For the FACS analysis1 
106cells (each type) were dispersed into Eppendorf tubes. Then nanoparticles were added 
at different concentrations of 100 μg.ml-1, except for the unstained negative control, and 
the cells were incubated for 2 h in normal medium in a tissue culture incubator. The cells 
were then washed using ice-cold PBS containing 10% FBS, and transferred into FACS 
tubes. All samples were kept on ice until FACS analysis. 
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The cells were seeded in a T-25 flask and treated with 0.1% NaN3 and 80 μM Dynasore in 
a serum-free MEM for 1 h before incubation of the nanoparticles at 37°C/5% CO2. For the 
action of chlorpromazine, the cells were pre-incubated in a serum-free MEM containing 
10 μg/ml chlorpromazine (ChemBridge) for 15 min at 37°C and 5% CO2. The medium was 
then replaced with a fresh media containing the inhibitors and particles. These cells were 
further incubated for 30 min at 37°C and 5% CO2. The cells were washed with D-PBS and 
trypsinized and processed for the flow cytometry test. Further, to examine the contribution 
of macropinocytosis in the uptake cascade, the cells were incubated with a 
macropinocytosis inhibitor, 5-(N-ethyl-N-isopropyl) amirolide (EIPA), at the 
concentration of 100 μM for 30 min. Then, the cells were incubated with a fresh medium 
containing the nanoparticles. Then, the cells were washed after 1 h (50). The resulting cells 
were analyzed via FACS. To further explore the mechanism through which these 
nanoparticles entered the cells, we performed an internalization experiment at 4°C to block 
the active endocytosis cascade. 
Effect of different formulations of nanoparticles on proliferation of cancer cell lines was 
evaluated by MTT assay. In brief, cells were cultured on standard 96-well plate at a density 
of 10,000 cells per well. The cells were cultured at 37 °C in a 5% CO2 incubator. After 
incubating for 24 h, the culture medium was replaced by fresh medium containing specific 
concentrations of nanoparticles representing PTX concentrations of 0.001-1000 nM and 
incubated for 72 h. For paclitaxel treatment, a stock solution of paclitaxel (10 mg.ml-1 in 
DMSO) was diluted to the defined concentration in culture medium. Then, tetrazolium salt 
(M2128) was added for an additional 4 h. Thereafter, formazan crystals were dissolved in 
dimethyl sulfoxide while shaking for 20 min. Absorbance at 570 nm was measured by 
utilizing a microplate reader at 570 nm. The control medium contained no nanoparticles. 
The samples were maintained with uniform drug concentration. The spectrophotometer 
was calibrated to zero absorbance using culture medium without cells. The relative cell 
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viability (%) related to the control wells, containing cell culture medium without 
nanoparticles, was calculated by [A]test/[A]control × 100, where [A]test is the absorbance of 
the test sample and [A]control is the absorbance of the control sample. To evaluate the 
viability of the encapsulated U87 MG cells in 3D collagen-based matrix, a live-dead assay 
(Calcein AM/ethidium bromide homodimer-1) was utilized after treating the encapsulated 
cells with different formulation of nanoparticles at different concentrations. NIH ImageJ 
software (NIH, Bethesda, MD) was used to quantify the percentage of live cells. 
The role of PTX-loaded nanoparticles’ treatment on migration of HUVECs toward VEGF 
gradient was performed using Transwell migration assay as reported elsewhere (275, 276). 
The migrated cells were stained on the bottom sides of the membrane and counted to assess 
the migration of HUVEC cells.  
Matrigel-based angiogenesis assay was done according to the manufacturer’s protocol 
(Corning; Santa Barbara, CA) (277, 278). In brief, Matrigel (10 μl) was added to 96-well 
plates and kept in cell culture incubator for 1 h. GFP Expressing HUVECs were seeded at 
a density of 2.5 × 105 cells per well. All HUVEC experiments were conducted in EBM2 
medium (Lonza) supplemented with 25 ng/ml VEGF (Abcam) and 2.5 ng/ml epidermal 
growth factor (Abcam). A formulation array of PTX-loaded and unloaded nanoparticles 
containing PTX were added to media and co-cultured with cells for 72 h. Afterward, wells 
were washed twice with DPBS and the formation of tube-like structures in 3D matrix was 
evaluated using a confocal laser scanning microscope (Confocal Leica SP5 Blue). 
Cell aggregates were made using a force aggregation method as reported elsewhere (279). 
Micropatterned wells were kindly provided by Mark Ungrin group at University of 
Calgary. Square pyramidal microwells with 400 μm side-wall dimension of each square 
pyramidal well  (AggreWell, Stem Cell Technologies; 400 μm side-wall dimension of each 
square pyramidal micro-well) were used as described previously (279, 280). U87 MG cells 
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trypsinized and seeded on micropatterned wells at a concentration of 1.2×106 cells per 
well.  
 Well plates were centrifuged at 200×g for 5 min. Plates were visualized under the 
microscope to confirm cells have spun to the bottom of each microwell. The plate was 
incubated for 24 h at 37 °C in an incubator, aggregates were then harvested from each well, 
and finally the aggregate suspension was collected in a 15 mL conical tube before injection 
into the on-a-chip platform. At this seeding density, aggregates containing 800-
1200 cells were formed. 
Soft lithography procedures were used to fabricate the aggregate trap microfluidic device. 
The same procedure was used as described above to make PDMS-based microfluidic chip. 
Before use, the device was flushed with Pluronic F-127 copolymer solution (0.2 mg/ml) to 
prevent unspecific protein/cell interactions with PDMS walls. The capture efficiency of the 
chip was first optimized with 150 µm fluorescent polystyrene beads. In brief, aggregates 
suspension was introduced to the device at concentration of 1000 aggregates per ml via a 
syringe pump. The number of captured aggregates was visualized via fluorescence 
microscopy after immunostaining of cells with anti-integrin β3-FITC antibody. To evaluate 
association of nanoparticles with cancer cell aggregates, the device placed in microscope 
incubation chamber and the flow of nanoparticles was controlled with a precision micro 
peristaltic pump (Cole-Parmer). Accumulation of nanoparticles was visualized over time 
using a confocal laser scanning microscope. Distribution of FITC-labeled nanoparticles 
through the cell aggregates was evaluated using ImageJ software after normalizing the 
fluorescence signal to the surrounding media.  
Soft lithography method was conducted to develop a multilayer microfluidics device to 
represent the main features of tumor microenvironment in vitro. The upper and lower layers 
were fabricated by casting PDMS resin (10 resin: 1 curing agent) on master molds contains 
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positive patterns. The height of the channels was 300 μm. Thin nanoporous glass 
membranes with 500 nm pores (SiMPore’s G-FLAT™ Microporous Glass Membranes; 
West Henrietta, NY) were used between the upper and lower channels.  
The membrane surface was treated with oxygen plasma and irreversibly bond to upper and 
lower PDMS substrates sequentially after manual alignment. Aggregates suspension was 
introduced to the device at concentration of 1000 aggregates per ml via a syringe pump 
(green channels) and then collagen solution was injected. Collagen hydrogels were 
prepared by mixing the rat tail collagen I, sodium hydroxide and EDTA on ice as reported 
elsewhere (281). The final concentration of collagen was 2.5 and 5.0 mg/ml. After vortex 
mixing for 30 s, the gel solution was injected to the lower chamber of 3DToC device via a 
syringe pump while providing the flow of ice-cold PBS in the other channels, then 
incubated overnight at 37 °C.  
Different hydraulic pressure conditions have been applied at capillary, interstitial and 
tumor microchannels as proposed before (282). Here, 10, 5, and 20 mmHg pressures were 
applied at both ends of interstitial, tumor, and capillary channels, respectively. These 
pressures were selected to represent physiologically relevant conditions. Penetration of 
FITC-labeled nanoparticles in collagen hydrogel monitored using a confocal laser scanning 
microscope at different time points (30 min-12 h). Daily investigation of aggregate size 
was performed over the time course of 7 days. 
Flow cytometry analysis (FACSVerse, BD Bioscience) was performed to evaluate 
apoptosis of U87 MG cell after treatment with different nanoparticle formulations inside 
the 3D tumor-on-chip device. Cell aggregates were extracted from device after digestion 
of collagen hydrogel. Relative number of apoptotic cells was evaluated using Annexin V-
PE Apoptosis Detection Kit (BD Bioscience).  
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Protein corona experiment performed as reported elsewhere (283, 284). In brief, blood was 
taken from ten healthy donors in accordance with institutional policy. Plasma was 
separated and the protein aggregates further removed by ultracentrifugation. Soft (sample 
A) and hard (sample B) nanoparticles were incubated with human plasma under gentle 
shaking for 3 h, separated using ultracentrifugation at 20,000×g for 1 h, and then washed 
thee times. The ratio of particles to plasma was calculated to represent approximately 
constant surface area. Proteins then eluted after dissolving HMCS nanoparticles by 
reducing the pH to 3.0 and shaking the solution for 30 min. proteins concentration was 
assessed by micro BCA protein assay after correcting the values for chitosan chains. Then, 
proteins were digested following the reported protocols (285). Quantitative analysis of 
protein samples was performed by liquid-chromatography mass-spectrometry (LC-MS) 
technique. LTQ Orbitrap XL Mass Spectrometer (Thermo Fisher Scientific) coupled with 
Eksigent NanoLC-2D HPLC and Autosampler was used after 10-fold dilution of digested 
protein samples in 0.1% formic acid. The experimental details were followed as reported 
by Schöttler et al. (283). MS spectra were collected over an m/z range of 300-2000 Da. All 
samples were analyzed in triplicate and quantitative data were made to estimate the amount 
of each protein in fmol. 
All experiments on mice were performed in accordance with institutional policy on human 
and ethical treatment of animals. For in vivo, female BALB/c mice (18–21 g) were used. 
For all the experiment, U87 MG human glioblastoma tumor model were generated by 
subcutaneous injection of 5×106 cells in 50 ml PBS into the front left legs of the mice. 
When the tumor diameter reached 5 mm (after about three weeks), the mice randomly 
assigned for the experiments. All mice were fed with a commercial diet and water ad 
libitum and were on alternating 12 h light/dark cycles.  
For in vivo pharmacokinetic (blood circulation) studies, six tumor-bearing BALB/c mice 
were randomly divided into two groups for the two different types of nanoparticles (n=3) 
 179 
and free drug. Both groups received injections via the tail vein at a dose of 2 mg 
nanoparticles per kg of body weight. Blood samples were drawn into heparinized tubes 
from the retro-orbital sinus at different time points and then centrifuged for 15 min. The 
plasma was separated and stored at −20 °C in the dark before analysis. The plasma 
concentration of blood containing particles was defined based on the fluorescence intensity 
using microplate Reader. The normalized plasma concentrations of the applied particles 
were plotted as a function of time. The data were fit to a two-compartment model, from 
which the half-lives characterizing the nanoparticle formulations can be extracted.  
Tissue accumulation of nanoparticles in tumor and other organs including bone, heart, 
kidney, liver, muscle, and spleen also evaluated by measuring the tissue’s fluorescence 
signal 48 h after tail vein injection of FITC-labeled nanoparticles to determine the 
percentage of injected dose per gram (%ID/g) for each sample (n=4). 
In order to assess tumor suppression and survival rates, mice were randomly assigned to 
experimental groups (n=5) to receive physiological Saline (PBS), free PTX, and PTX-
loaded nanoparticles with different formulations via tail vein injection on the first and 
seventh days of the experiments. The paclitaxel dose kept constant to 10 mg/kg body 
weight across all the formulations. Tumor volume was monitored using a digital caliper at 
different timepoints and the volume was mounted as length×(width)2/2. The serial 
measurements of tumor volume were followed for two weeks on which the animals were 
sacrificed. The survival times of tumor-bearing mice were also investigated by the same 
procedure as described above but after treatment of animals at 0, 7, 14, and 21 days with 
free PTX, and PTX-loaded nanoparticles with different formulations. The survival time 
was assessed (n=5) over period of two months. 
To evaluate angiogenesis in the presence of different types of nanoparticles in vivo, the 
Matrigel assay was performed according to procedure reported elsewhere (286, 287). In 
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brief, mice (n=5) were injected subcutaneously on the flank of mice with 400 μl of VEGF-
containing Matrigel encapsulating 4×106 HUVECs. After 48 hours, mice were received 
injections of PTX-loaded nanoparticles (10 mg of equivalent PTX mass per kg of body 
weight) via the tail vein. After 48 h, 100 μl of tetramethylrhodamine isothiocyanate–
Dextran (TRITC-Dextran; 155 kDa) was injected intravenously (50mg/ml) via the tail 
veins (288). After 10 minutes, animals were sacrificed and the Matrigel plugs were 
removed, fixed and imaged by confocal fluorescence microscope. The relative 
fluorescence intensities were quantified using ImageJ software. After identifying the 
vessels’ borders the extravascular TRITC content was quantified. Vascular leakage was 
defined as extravascular TRITC/total TRITC (288).  
The retrieved tumor tissue samples were prepared (fixed, paraffin embedded, and 
sectioned). For immunofluorescence staining, the prepared specimens were treated with 
TUNEL kit (Click-iT® TUNEL Alexa Fluor® Imaging Assay) to detect the apoptosis 
according to manufacturer’s instruction. The images were taken using a fluorescent 
microscope (Leica Microsystems). 
All experiments were conducted at least in triplicate. The statistical analysis of the 
experimental data was done using the Student’s t-test or ANOVA, and the results were 
presented as mean ±S.D. For all the tests, the threshold was set to p < 0.05 for “statistically 
significant”, p < 0.01 for “statistically very significant” and p < 0.001 for “statistically 
extremely significant”. 
7.3 Results and Discussion 
 Polymeric NPs can be synthesized either by top-down or bottom-up approaches. 
Since the bottom-up process involves self-assembly of particles via intermolecular forces, 
it offers great opportunities for tailoring structure and properties of particles. However, 
having control over the synthesis procedure can be really challenging in this approach. 
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Thanks to the microfluidic techniques (Figure 7-2a), we can reproducibly create small 
monodisperse NPs through the well-controlled mixing regimes that form via hydrodynamic 
flow focusing. Our previous results confirm the possibility of controlling the main physical 
and biological characteristics of NPs such as size (50-250 nm), Zeta potential (1-14 mV), 
drug loading efficiency (>95%), and drug release profiles (≈3×10-22 m2.s-1) (44, 248, 270, 
274, 289, 290) simply by playing with flow rates. However, in order to keep all the NPs’ 
features constant and play with just a single physical property (e.g., mechanical stiffness) 
we cannot rely just on flow ratio as the tuning factor. Here, by introducing the second 
controlling factor, polymer initial concentration, we have provided two degrees of control 
over the physical properties of NPs. We have used hydrophobically-modified chitosan 
(HMCS) with N-palmitoyl groups in the current work. We have shown HMCS can form 
nanoparticle through self-assembly and encapsulate hydrophobic anticancer drugs (44, 
248). As demonstrated in Figure 7-2 b-c, we synthesized an array of HMCS NPs with 




Figure 7-2 Schematic representation of cross junction microfluidic used for hydrodynamic 
flow focusing of hydrophobically-modified chitosan (HMCS) stream using sheath flow of 
water at basic pH. The effect of flow ratio and initial polymer concentration on (b) 
morphology and (c) hydrodynamic diameter (based on the DLS measurements) for 
synthesized NPs. (d) The calculated compactness of NPs (local polymer concentration; cNP 
inside the NPs). (e) The diffusion1 and (f) sedimentation2 velocities of the synthesized NPs. (g) 
AFM-nanoindentation images and (h) calculated Young’s modulus (E) of prepared NPs at 
different conditions. (i) Having an array of NPs enabled us to select series of NPs with same 
sizes, but different mechanical properties.  
 1Diffusion velocity: VD=2D/x; x: certain distance of travel (culture medium height); 2sedimentation 
velocity: Vs=2gr2cNP(ρP-ρ0)/9ηρP; g: gravitational acceleration, cNP: NPs compactness. 
In addition to the initial polymer concentration, degree of substitution (i.e., palmitoyl 
group) affects the overall physical properties of HMCS NPs. Based on transmission 
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electron microscopy (TEM) images and turbidity results (Table 7-2), it is evident that 
prepared NPs have different levels of compactness.  
Table 7-2 Turbidity values for HMCS nanoparticles prepared with microfluidics technique. 
Turbidity 
(cm-1) 
Initial Polymer Concentration; 
Ct (mg.ml-1) 
 0.5 1.0 2.0 5.0 
FR-1 0.231 0.272 0.311 0.361 
FR-2 0.188 0.220 0.276 0.319 
FR-3 0.141 0.171 0.212 0.253 
FR-4 0.084 0.150 0.170 0.203 
The local polymer concentration inside the NPs, cNP, was calculated (see Chapter 2 for 
details) as an indicator of compactness. As seen, compactness of NPs was found to increase 
as flow ratio decreased. In fact, in shorter mixing times, higher probability of hydrophobic 
segments to form intermolecular association leads to formation of more compact NPs 
(Figure 7-2d). By having the cNP, molecular weight of NPs, MNP, number of the polymer 
chains aggregated to form NPs, Nagg, number density of NPs, N, as well as the average 
mass of individual NPs were calculated and presented in Table 7-3 (see Chapter 2 for 
calculation details). The obtained results revealed that number of the aggregated chains 
rises with increase in the time of mixing. Such observation suggests that at lower flow 
ratios and on account of rapid mixing regime, chains have limited time to aggregate, which 
results in lower number of kinetically assembled chains forming NPs, which is also 
affected by the initial polymer concentration. The obtained results for compactness and 
aggregation number converge to indicate that at lower flow ratios (fast mixing regimes; 
FR-1 and FR-2) smaller and more compact NPs form that are composed of relatively higher 
number of aggregated chains. In view of this, formation of NPs at higher flow ratios (slow 
mixing regimes) results in bigger hydrodynamic sizes and lower compactness values due 
to the arrangement of HMCS chains at longer time of mixing.  
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Table 7-3 The calculated NPs’ molecular weight (MNP) (a), the concentration of NPs (NNP) (b), 
and aggregation number (Nagg) of the polymer chains in the corresponding NPs (b). 
 
Diffusive and sedimentation behavior of NPs evaluated based on the calculated parameters 
and the results of sedimentation and diffusion velocities are plotted in Figure 7-2 e,f. 
Diffusive properties, velocity (Figure 7-2e) and coefficient (Table 7-3a) are scaled with the 
size of NPs but the sedimentation characteristics, velocity (Figure 7-2f) and coefficient 
(Table 7-4b), are much more depending on the compactness and weight (Table 7-4d) of 
NPs. 
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Table 7-4 The nanoparticles’ diffusion (a), sedimentation (b), and drag coefficients as well as 
calculated mass of NPs. 
 
These parameters have been adjusted to enable us to have NPs with similar sizes but 
different compactness; and as a result, they possess different mechanical properties as 
measured by atomic force microscopy (AFM) nanoindentation (Figure 7-2 g-h). 
Interestingly, by moving diagonally along these graphs, we have NPs with quite the same 
hydrodynamic radiuses (89-91 nm), but as they are formed in different regimes, the 
mechanical properties are different by about 7 folds (Figure 7-2 h,i). From now on, we call 
these NPs as A-D from softest (CHMCS =0.5 and FR-4) to stiffest one (CHMCS =5.0 and FR-
1) (Figure 7-2 i). The selected sizes are in the acceptable range for passive targeted drug 
delivery, which helps to achieve enhanced penetration and accumulation of particles in 
tumor sites. 2,4-5 However, as these particles possessed variable surface charges (zeta 
potential: 5-19 mV) poly (ethylene glycol) (PEG) modification was implemented to 
eliminate the effect of surface charge on biological behaviors of these particles. Since 
modification with pristine PEG significantly reduces the potential of NPs to associate with 
cells, we used cyclic-RGD (cRGD) modified PEG (cRGD-PEG) for decorating our 
particles at optimized surface densities (Figure 7-3 a-c). The optimized ligand density is 
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measured to be 20,000 cRGD.µm-2 which equals to about 500 ligands per NPs. This level 
is shown to have low phagocytosis by macrophages (RAW264.7) as well as high cellular 
uptake by integrin expressing cells (e.g. HUVEC) (Figure 7-3 d-e). 
 
Figure 7-3 (a) Schematic representation of bioconjugation of chitosan-based NPs with cyclic-
RGD-based poly (ethylene glycol) (cRGD-PEG). (b) Quantification of cRGD surface density 
and (c) the number of conjugated cRGD per NPs as a function of initial cRGD-PEG in 
reaction. Association of NPs in RAW 264.7 (d) macrophages and (e) endothelial cells 
(HUVEC) which examined to select the optimized number of ligand per NPs. The presented 
data are expressed as average ± SD. The results were statistically analyzed using unpaired t 
tests. Statistical significance is indicated by * (p < 0.05). 
As seen in Figure 7-4a, PEGylation process is optimized to provide nanoparticles with the 
same level of cRGD ligand. Surface charge (Figure 7-4b) of NPs are studied and the values 
of Zeta potentials are reported in Figure 7-4b. NPs with lower surface charges needed more 
cRGD-PEG to present the same level of ligand. Although functionalization of NPs with 
PEG was used to eliminate the effect of surface charge of NPs, is may not be able to react 
with all the primary amines due to the steric hindrance. To confirm that the remaining free 
amines will not interfere with the biological properties of NPs, we further treated them with 
citraconic anhydride to covalently block the remaining amine groups. As shown in Figure 
7-4c, chemical blockade of amine groups did not affect the surface charge and 
internalization of nanoparticles so further blocking was not required. 
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Figure 7-4 (a) Optimizing of the formulation by changing the ratio of reactive cRGD-PEG to 
NPs to have nanoparticles with same density of ligands. Zeta potential measurements (b) and 
HUVEC internalization experiments (c) confirmed sufficient coverage of primary amine 
groups on HMCS surface and further blockade of amine groups with Citraconic Anhydride 
did not affect surface charge and internalization of nanoparticles. 
Due to amphiphilic nature of HMCSs, we can encapsulate both hydrophobic and 
hydrophilic agents (44, 270, 290). Here, we have tried to encapsulate paclitaxel (PTX), as 
a hydrophobic anticancer drug, during the formation of NPs [Note 1: An acidic condition 
during the injection of HMCS/PTX prevents PTX epimerization and prolongs its activity]. 
PTX loading content (Figure 7-5a) and efficiencies were evaluated at different initial drug 
contents of 5-20 wt%/wtPolymer. It seems that in the case of more compact NPs (D and C), 
more hydrophobic moieties were involved and interacted with PTX molecules during the 
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formation of NPs, resulting in higher encapsulation efficiencies. This high level of 
interactions can also protect the drug molecules from degradation (i.e., epimerization) both 
at shelf temperatures and inside the body as confirmed by evaluating the functionality of 
encapsulated PTX molecules to inhibit tubulin polymerization (Figure 7-6). The in vitro 
release profiles of NPs containing same content of drug were compared in phosphate buffer 
saline (PBS) at different pH range of 7.4, 6.5, and 5.5 over two weeks (Figure 7-5). As 
shown in Figure 7-5, more compact NPs showed slower releases compared to the softer 
ones with less sensitivity to pH reduction (pH 6.5 mimicking the tumor microenvironment 
and pH 5.5 as an indication of intracellular (lysosomal) pH). Estimation of the required 
time to release half of the loaded PTX (t50) from the NPs and calculation of diffusion 
coefficients (Figure 7-b inset) confirmed the idea. 
 
Figure 7-5 (a) The change in paclitaxel (PTX) loading content as a function of initial PTX 
loading concentration for NPs with different compactness. (b) Cumulative in vitro release of 
PTX from different formulations of microfluidic synthesized NPs at 37 °C and pH 7.4. 
Calculated diffusion coefficients are illustrated in subset. (c-f) Controlled release of PTX from 
microfluidic-synthesized NPs after changes in pH of the media from 7.4 to 6.5 and 5.5 at 37 
°C (Mean ± SD, n = 4 independent experiments.). 
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Figure 7-6 Relative activity of PTX at (a,b) 25°C and (c,b) 37 °C for free drug and PTX loaded 
NPs A-D with different compactness compared to PTX loaded bulk synthesized NPs. 
To evaluate whether cRGD-PEG functionalized NPs could recognize αvβ3 integrins on 
endothelial cells, the association of these NPs were examined on HUVECs using flow 
cytometry. HUVECs were chosen as a model cell line with overexpression of integrin (e.g., 
αvβ3) receptors as confirmed by flow cytometry and Western Blot assays (Figure 7-7a). 
Presented cRGD molecules on the NP surface are assumed to induce multivalent 
associations with the integrin receptors resulting in increased NPs binding and uptake 
(Figure 7-3 d,e). Designed NPs with different mechanical stiffness were incubated with 
HUVECs and the internalization levels were assessed (Figure 7-7 b-d). NPs without 
modification with PEG-cRGD also presented high levels of internalization compared to the 
PEGylated counterparts in the absence of cRGD (Figure 7-7b, p<0.001) due to the presence 
of primary amines on the surface of NPs that can be protonated and internalized as reported 
before (44, 291). Specificity of binding was evaluated via competition assay by adding free 
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cRGD and monoclonal antibody against αvβ3 integrin as well as via NPs functionalized 
with a scrambled ligand (RDG). The quantitative endothelial cell uptake assay confirmed 
the importance of the active targeting achieved by cRGD. The uptake level of cRGD-
functionalized NPs was enhanced with increase in the mechanical stiffness of NPs (Figure 
7-7c, p<0.01), indicating the importance of mechanical properties in cell internalization. 
All four groups of tested NPs internalized the HUVECs, but their internalization kinetics 
was different. Indeed, less internalization took place for softer NPs (Figure 7-7d). Blank 
synthesized NPs, particles without PTX loading were not toxic even at high concentrations 
(Figure 7-7e). However, free PTX is toxic, and the half-maximal inhibitory concentration 
(IC50) for HUVECs is about 3 nM. PTX toxicity was significantly enhanced through 
encapsulation in engineered NPs. This phenomenon is likely due to protecting drug from 
degradation that particle encapsulation provides and also high-levels of cellular 
internalizations. Consequently, drug release mainly occurs inside the cells which 
effectively enhances therapeutic efficacy.  
In addition to the capability of PTX-loaded NPs to internalize and kill HUVECs, they can 
also inhibit cellular functions. We tested HUVECs migration inhibition due to the VEGF 
gradient in the presence of various nanoparticle-treatment strategies using transwell assay 
after 48 h of incubation (Figure 7-7 g-i). With increasing PTX concentration, all PTX-
based treatments exhibited HUVEC migration inhibition. However, the highest inhibitory 
behavior was observed in the case of hard NPs functionalized with cRGD ligands 
especially at lower drug concentrations. At high drug concentrations, the difference 
between the inhibition rates was not significant. Compared to the free drug, drug-loaded 
NPs exhibited much higher migration inhibition at lower PTX concentrations (< 1nM). The 
same trend was observed in the test of HUVECs tube formation in 3D matrigel in the 
presence of VEGF (Figure 7-7 h-j). PTX carrying NPs effectively targeted and inhibited 
the angiogenesis ability of endothelial cells. The blank NPs, nontoxic to HUVECs, 
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displayed very low inhibitory effects on migration and tube formation of endothelial cells. 
Stiff cRGD-functionalized NPs exhibited significant inhibitory activity even at very low 
drug concentrations, which is related to the higher internalization potential of stiffer NPs 
as well as the positive effect of presented cRGD on the particle surface.  
 
Figure 7-7 (a) Flow cytometry and Western Blot analysis that confirms overexpression of 
integrin αvβ3 by HUVECs. (b) Cellular uptake of the FITC-labeled NPs for different 
formulations after 2 h incubation with the HUVECs. (c) HUVEC uptake for cRGD-
functionalized NPs with different stiffness. (d) The uptake kinetics of NPs incubated with the 
HUVECs. MTT cell viability assay of HUVECs after 72 h of exposure to (e) unloaded NPs, 
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(f) free PTX, and PTX loaded NPs at 37 °C. Unloaded NPs are plotted on the abscissa so that 
the number of NPs in the corresponding trials was the same. (g) Representative photographs 
of stained (blue) migrated HUVECs and Transwell assay results of endothelial cell migration 
after 12 h of treatment with different concentrations of NPs with/without PTX. (h) In vitro 
angiogenesis results of endothelial cell’s (GFP-positive HUVECs) tube formation in a 3D 
Matrigel after 12 h of treatment with different NPs formulation. 
In order to study the effects of mechanical properties of designed targeting NPs on cancer 
cell lines, we chose three different cell lines with different level of integrin expressions. 
Human glioblastoma (U-87 MG), kidney cancer (HEK-293), and breast cancer (MCF-7) 
cell lines with high, moderate, and very low expressions of αvβ3 integrin, respectively were 
tested (Figure 7-8a). Here, only two sets of NPs, softest (sample A) and stiffest (sample 
D), were evaluated. As shown in Figure 7-8b, stiffer targeted NPs showed greater tendency 
for internalizing the cells with high level of integrin receptor expression. Difference in 
uptake quantities was also seen for non-PEGylated NPs; since both stiffness and surface 
charges of particles varies, the changes in uptake cannot be related solely to their 
mechanical properties.  
Combination of mechanical stiffness and active targeting attributes to offer a synergetic 
effect in potential cancer treatment. Another feature that is expected from an efficient 
cancer nanomedicine is to offer maximum lethal effects at the lowest possible dosage of 
the drug. Here toxicity of PTX-loaded NPs was studied against three cell lines of interest 
and the half-maximal inhibitory concentrations (IC50) were estimated (Figure 7-8 e-h). In 
the case of cells with high levels of integrin expression, as the particles can effectively 
engage with cell surface and internalize, stiffer NPs (C and D formulations) had the lowest 
IC50 (highest toxicity). However, when internalization is not probable (MCF-7 cells), soft 
NPs (A and B formulations) showed higher efficiency as they released drug faster and 
affected the cellular viability in shorter periods of time while the PTX loaded in stiffer NPs 
remained unleashed (Figure 7-8h). 
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Figure 7-8 (a) Flow cytometry and western Blot analysis of integrin αvβ3 expression. U87 
MG, HEK-293, and MCF-7 cells were confirmed to have strong, moderate, and extremely 
weak expression of integrin αvβ3. GAPDH was used as a control. Cellular uptake of the 
FITC-labeled NPs for different formulations after 2 h incubation with the U87 MG (b), HEK-
293 (c), and MCF-7 (d) cells. MTT based cell viability assay of U87 MG (e), HEK-293 (f), and 
MCF-7 (g) cells after 72 h of exposure to unloaded NPs in 2D culture at 37 °C. (h)  Plot of 
estimated half-maximal inhibitory concentration (IC50) of different PTX-loaded 
nanoparticle-based treatment for U87 MG, HEK-293, and MCF-7 cells. 
As tumor tissues are 3D microenvironments, and the results of nanoparticle-cell 
interactions in cell monolayers (Figure 7-8) may not be predictive enough to evaluate the 
clinical outcomes of nanomedicines, inspired by the pioneer work by Warren Chan group 
(292); hence, we tried to address this challenge by testing 3D cell aggregates and dynamic 
flow conditions inside a microfluidic chip (Figure 7-9a). We used forced aggregation 
technique (279) to form monodisperse aggregates, with sizes around 100-150 um, from 
U87 MG cells inside the microfabricated microwells (Figure 7-9b). The aggregates were 
then loaded into the microfluidic chips which were designed to have “traps” for holding 
aggregates in place (Figure 7-9c). Aggregates can be easily studied using inverted optical 
or fluorescence microscopy to evaluate their size and shapes in real time (Figure 7-9d). The 
developed tumor aggregates-on-chip platform was then subjected to a flow of NPs with 
different mechanical properties or active cellular targeting. As shown in Figure 7-9 e,f, 
average fluorescent intensity in the aggregates confirm higher accumulation levels of stiff 
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NPs (Sample D) compared with soft NPs (Sample A), while integrin receptor targeting 
enhanced accumulation and retention of NPs. PEGylated but not cRGD-conjugated 
particles were found to show minimal interactions with cell aggregates.  
 
Figure 7-9 (a) Schematic of the PDMS-based microfluidic chip (aggregate-on-chip) to trap 
the cell aggregates. (b) Bright-field microscopy of formed aggregates on the designed 400 um 
microwells. (c) U87 MG cell aggregates were formed using force aggregation and were then 
injected in aggregate-on-chip device. (d) Fluorescent image of physically trapped cell 
aggregates after staining by anti-integrin β3. (e) Confocal fluorescent image and intensity 
profile of penetration of fluorescently-labeled stiff (upper panels) and soft (lower panels) NPs 
to a cell aggregate after 30 min, 2 h, 4 h, and 12 h of flow at 30 μl /h. (f) Average fluorescent 
intensity calculated from aggregate accumulation of targeted and non-targeted NPs as a 
function of time (left graph) and after flushing with PBS. 
Although, targeted NPs accommodated higher than non-targeted ones, but even in the case 
of targeted NPs, stiffer particles penetrated more into the central regions of cell aggregates 
in comparison with softer counterparts (Figure 7-10). Flushing the chip with media caused 
a minor decrease in fluorescence level, which was more pronounced in the case of non-
targeted NPs as they could not properly integrate with cells and can simply be washed away 
compared with cRGD-functionalized NPs (Figure 7-9f). 
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Figure 7-10 Average fluorescent intensity of targeted NPs at central (a) and peripheral (b) 
regions of aggregates as a function of time. 
The proposed simple microfluidic platform (Figure 7-9) can mimic the 3D organization of 
tumor cells while enabling the cell-nanoparticle interaction under flow conditions. On the 
other hand, the in vitro results showed significant difference in cytotoxicity of particles in 
2D cultures and encapsulated in 3D collagen gel (Figure 7-11 a,b). Further, NPs need to 
pass through the nanoscale tight junctions between the endothelial cells to reach tumor 
tissues; so, we designed a physiologically relevant tumor-on-chip (3DToC) platform to 
address these criteria and also engulf cancer cell aggregates. Schematic of the multilayer 
microfluidic device designed to systematically characterize the effects of tumors 
pathophysiological conditions on NP penetration is presented in Figure 7-11c. This 
platform has been designed based on the previous works reported elsewhere (282, 293-
295) with some modifications to trap cell aggregates in the designated places. To mimic 
the transportation around the tumor tissue, the platform was designed to have a capillary 
channel for delivering NPs (blue; upper channel), two interstitial side channels to provide 
negative pressure (red; lower channel) and a tumor chamber in between where the tumor 
tissue, consisting of cell aggregates in a 3D collagen, (green; lower channel) is placed 
(Figure 7-11c). There is also a porous membrane with 400 nm pores sandwiched between 
the upper and lower fluidic channels. 
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Figure 7-11 (a) MTT cell viability assay (b) and estimated half-maximal inhibitory 
concentration (IC50) of U87 MG cells after 72 h exposure to unloaded NPs in 2D vs. 3D 
cultures at 37 °C. (c) Schematic representation of designed 3D tumor-on-chip (3DToC) device 
used to mimic tissue microenvironment in vitro. 3DToC is designed to have capillary channel 
for delivering NPs (blue; upper channel), lymphatic channels (red; lower channel) where 
tumor tissue, cell aggregates in 3D collagen matrix, (green; lower channel) is placed between 
them. There is a porous membrane (400 nm) sandwiched between upper and lower PDMS 
layers. (d) Fluorescent signal shows the microstructure of collagen matrix formed with 
different initial concentrations of 2.5 and 5 mg/ml. (e) Penetration of FITC-labeled soft (upper 
panels) and hard (lower panels) NPs in a collagen gel (2.5 mg/ml) as a function of time under 
the flow. (f) Flow cytometry assessment of U87 MG cells apoptosis after digestion of collagen 
matrix and extracting cells from 3DToC device after 7 days. (g) Time-related evaluating 
average volume of tumor aggregate after treatment with different formulations of NPs at 
similar dose (1 nM). 
Due to the high affinity of targeted NPs to endothelial cells (Figure 7-7), we could not 
culture HUVECs cells on top of membrane to simulate of the endothelium layer, so the 
porous membrane was used to control the cut-off size. The 3DToC platform was connected 
to pressure controllers to independently control the capillary, interstitial, and lymphatic 
fluid pressures. We also made a collagen gel inside the tumor channel at two different 
concentrations of 2.5 and 5.0 mg/ml as proposed before (281) to simulate the tumor’s ECM 
at different tortuosity which affect  penetration of NPs to the tumor cells (Figure 7-11d).  
To evaluate the functionality of proposed NPs in vitro, we first designed a tumor on chip 
(ToC) model to mimic the main characteristics of tumor microenvironments. The ToC was 
designed to let the NPs accumulate in tumor regions under the flow and at physiologically 
 197 
relevant velocity and pressure through the capillary channels and pass the porous 
membrane layer which simulate the gap junctions between the endothelial cells in leaky 
tumor vasculatures. 
This 3DToC also provide an optical window for real time study of NP’s penetration into a 
3D tumor microenvironment as well as analyzing the tumor size in a way which has not 
been possible in vitro so far. As shown in Figure 7-11e, stiffer NPs can penetrate faster and 
distribute better through the collagen matrix after passing the 400 nm pores.  
Moreover, after the experiments we restored the cells from aggregates by digesting the 
collagen matrix and detected substantial amount of hard targeted NPs inside the U87 cells. 
The flow cytometry (Annexin V apoptosis assay) evaluation of restored cells confirmed 
successful killing of cancer cells with drug loaded NPs, which highlights the importance 
of mechanical properties of a therapeutic nanomedicine. A real-time optical non-invasive 
evaluation of aggregate size over time revealed the capabilities of the targeted NPs in 
suppressing tumor growth in vitro.  
Further, the effects of mechanical properties of NPs on their biodistribution and 
pharmacokinetics (PK) were studied. To this end, mice bearing subcutaneous integrin 
αvβ3-positive U87MG tumors were intravenously injected with different formulations of 
NPs. At selected time points after intravenous injection into healthy and tumor bearing 
mice, animals were sacrificed and organs were retrieved to estimate biodistribution of NPs 
with different stiffness (Figure 7-12a). As anticipated, NPs mainly accumulated in the well-
perfused liver and spleen tissues due to their discontinuity in endothelium gaps. Stiffer NPs 
(targeted and non-targeted) exhibited higher liver affinity while softer particles showed 
higher tumor accommodation. The latter finding is attributed to higher blood circulation 
times of softer particles, which is defined as the ability of NPs to remain in the blood 
circulation for extended intervals and avoid clearance by the immune system. Additionally, 
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for both hard and soft NPs, tumor accommodation was significantly higher where cRGD 
targeting moieties were present. It could be inferred that softness plays a pivotal role in 
controlling biodistribution of NPs, and this effect can be boosted by active targeting. 
 
Figure 7-12 (a) Quantitative tissue accumulation of NPs in tumor and other organs in 48 h 
after tail vein injection of fluorescently-labeled NPs. (b) Pharmacokinetic data on blood 
clearance of free PTX drug PTX loaded in soft and hard NPs (n = 5). (c) Schematic 
representation of presumptive interactions with plasma proteins and NPs. (d) Heat map of 
the adsorbed proteins on PEGylated stiff and soft NPs, evaluated by proteomic mass 
spectrometry and ordered based on their abundances. The average amounts are illustrated 
in fmol. Percentage of identified proteins is grouped according to their biological class. (e) In 
vivo Anti-tumor effect of free and nanoparticle-loaded PTX based formulations (PTX 
concentration: 1 mg/kg) on U87MG tumor-bearing mice. (f) Suppression of tumor growth by 
assessing the mean volume of tumor (n=6). (g) Survival rates of tumor-bearing mice. 
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A two-compartment PK model was fitted on the circulation data to estimate blood 
circulation time of NPs (Figure 7-12b). PK analysis demonstrated that stiff NPs rapidly 
cleared from blood while softer NPs sowed longer circulations. Further, it was found that 
free PTX formulation was quickly removed from the circulating system in about 2 h after 
injection. This finding is in agreement with the presented macrophages uptake results 
(Figure 7-3) which showed lower cellular association than their unmodified (amine) 
counterparts.  
In this study, the main goal of PEGylation was to eliminate the effects related to NPs’ 
surface charge; however, PEGylation concurrently act as a stealth agent to improve blood 
circulation half-life as mentioned before. Our previous results (see Chapter 2 for details) 
revealed the effects of protein adsorption on cellular uptake of chitosan-based NPs. Here, 
we found higher uptake of NPs in the protein-free medium. To further assess this 
observation and to check whether mechanical properties of NPs plays any role in protein 
adsorption (Figure 7-12c), we analyzed the adsorption of over 100 proteins using liquid 
chromatography–mass spectrometry (LC-MS). Figure 7-12d, demonstrates the most 
adsorbed proteins identified (hard corona). Clusterin and other apolipoproteins were found 
to be the major proteins in hard corona for both NPs. High levels of clusterin adsorption 
were previously reported for other PEG- and poly(phosphoester)- (283) functionalized, 
silica(285)- and lipid-based (296) NPs. High adsorption levels of lipoproteins have been 
reported previously for NPs with hydrophobic nature (297, 298). Similarly, high adsorption 
levels of several lipoproteins have been reported for more hydrophilic NPs like amine-
modified quantum dots (297), PEGylated and poly(phosphoester)-functionalized gold NPs 
(283, 298). The amphiphilic nature of HMCS NPs can be the reason for high levels of 
apolipoproteins adsorption. In the case of soft, less compact structures this phenomenon 
may be due to the more exposed hydrophobic groups that cause more adsorption of 
lipoproteins. The lower level of complement proteins adsorption on the surface of soft NPs 
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can elucidate their higher blood circulation times (39). In this case, complement activation 
can be attributed to the opsonization and cleavage of NPs from the blood (52). It is reported 
that in 2D surfaces proteins have less tendency to be adsorbed on substrates with lower 
mechanical stiffness (299), which is consistent with our observations for spherical NPs.  
After intravenous injection of NPs in U87MG (integrin αvβ3-positive) tumor bearing mice, 
tumor size was analyzed at different time points (Figure 7-12 e,f). As shown in Figure 7-
12f, all PTX-based formulations exhibited significant inhibitory effects on glioblastoma 
growth compared to the control groups (PBS; physiological saline). In vitro results in 2D 
and 3D cultures (Figure 7-11), confirmed the lethal effects of PTX on tumor cells while 
this drug was less effective in vivo due to the short blood circulation and fast degradation 
of PTX. 
Nontheless, targeted NPs showed the strongest inhibitory effects amongst all the other 
groups which was in agreement with our in vitro results (Figure 7-11 f,g). These NPs not 
only are capable of targeting tumor cells and their neovasculatures (endothelial cells), but 
also they highly accumulated in tumor tissues by taking the advantage of enhanced 
permeability and retention (EPR) effect. This was also confirmed using our tumor-on-chip 
platform. However, the difference between hard and soft NPs was not statically significant 
in this case. 
Compared to PBS and free PTX formulations, nanotherapeutics significantly prolonged the 
survival time, which was further enhanced in the presence of the targeting moiety. Such an 
in vivo enhancement may be due to the protection of drug from degradation while 
prolonging its blood circulation and providing a sustained release of the drug near the 
integrin over-expressed tumor/neovascular cells. However, in contrast to what was seen in 
vitro, the soft NPs showed better in vivo outputs. This highlights the importance of PK and 
biodistribution in defining the therapeutic efficacy of nanomedicines. 
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Overall, it seems that soft NPs are ideal for blood circulation and offer improved tissue 
distributions while stiffer NPs show greater tendency to penetrate tumor microenvironment 
and expressed higher levels of cellular engagement. Stiffer NPs also provided superior 
protection of their loaded drug. To solve the controversy between the requirements, we 
tried to use a biomimetic approach. Viruses are highly optimized for in vivo targeting of 
their agents and this ability can be mimicked to some extend and help us design the next-
generation of nanoscale therapeutics. For example, human immunodeficiency virus (HIV) 
can circulate in its soft form and as soon as reaching the target tissue/cell it irreversibly 
switch to a stiffer form to achieve more efficient penetration/internalization. Here, we 
aimed to develop NPs with switchable (dynamic) mechanical properties with prolonged 
circulation half-lives due to their extreme softness and enhance their targeting efficiency 
by remotely increasing their hardness when reach to the tumor site. Applying the synthesis 
strategy described in Figure 7-13a, we selected UV-activated nitrobenzene-amine reaction 
that could increase the crosslinking density inside the NPs and harden them in less than a 
minute. To do so, NPs were loaded with nitrobenzene-functionalized 4-arm PEG molecules 
during their synthesis to enable us to remotely trigger the crosslinking of NPs upon UV 
exposure at 365 nm (Figure 7-13a).  
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Figure 7-13 Schematic of the proposed approach to make NPs with switchable mechanical 
properties. Upon UV exposure (20 mW/cm2) the pre-loaded 4-arm PEGs react with hydrazine 
groups of chitosans. (b) Change in the elastic modulus (E) of NPs as a function of UV 
irradiation time at 20 mW/cm2. (b) Cellular uptake of the FITC-labeled NPs after 2 h 
incubation with the HUVEC, U87 MG, HEK-293, and MCF-7 cells. (d) Over time evaluation 
of the average volume of tumor aggregate after treatment with different formulations of NPs 
with and without UV exposure performed on a 3D tumor-on-chip platform. (e) Flow 
cytometry assessment of U87 MG cells apoptosis after digestion of the collagen matrix and 
extraction of cells from the 3DToC device after 7 days.  
While there are other novel approaches like thiol–ene photoinitiated reactions (300) to 
spatiotemporally tune mechanical characteristics of polymer based structures, most of them 
require radical photoinitiators, which may not be favorable for in vivo applications. Here 
we are implemented the elegant approach proposed by Anseth and coworkers (272) to 
develop a photoinitiated method for tuning mechanical properties of our NPs. This way 
upon UV exposure the incorporated photoreactive 2-nitrobenzyl-alcohol groups on the 
PEG molecules form 2-nitrosobenzaldehyde (272) that react with hydrazine groups of 
slightly modified chitosan chains. The chains of chitosan were modified with PEG-diacid 
(600 Da) and then diamined via EDC/Sulfo-NHS chemistry to provide sufficient hydrazine 
groups for photocontrollable reaction with functionalized multi-arm PEGs. The kinetics of 
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hardening of NPs in the presence of UV-irradiation (20 mW/cm2) were studied with AFM 
nanoindentation as shown in Figure 7-13b. Upon UV exposure, an instant increase in the 
elastic modulus (E) was observed, confirming the formation of hydrazone bonds between 
PEG and chitosan. Elastic modulus of our NPs were also in the same range as natural 
viruses (301).  
The in vitro experiments were done on the newly synthesized soft NPs that incorporated 
photoreactive PEG molecules before (Soft*) and after UV-initiated hardening process 
(Soft*+ Laser). As shown in Figure 7-13c, the cRGD modified version of these switchable 
NPs provided the same levels of internalization as hard NPs. The same trend for 
internalization, as a function of integrin receptor expression, was observed for these newly 
formed NPs. Although, presence of the 4-arm PEG decreased the encapsulation efficiency 
of NPs at high PTX concentrations (data not shown). However, it loaded enough PTX to 
provide the desired therapeutic effects. Upon UV activation, these NPs illustrated same 
levels of 3D tumor penetration and cytotoxicity as their hard counterparts which was also 
confirmed by our 3D tumor-on-chip platform (Figure 7-13 d,e).  
In vivo proof-of-concept experiments were also performed on U87 MG tumor bearing mice 
by having local UV exposure just on the tumor side (Figure 7-14a) to check the possibility 
of switch in the mechanical properties of NPs while they are inside the body. 
Pharmacokinetics results confirmed the same blood circulation profile for the switchable 
NPs (Figure 7-14b). Although harder NPs were better cases for of drug protection but since 
circulation period was short and upon reaching to the tumor site hardening took place, we 
had a good drug protection in the whole procedure. The biodistribution of NPs were also 
quite the same for the soft* NPs with and without local UV irradiation except for the tumor 
tissue. As shown in Figure 7-14c, local irradiation, in vivo, helped the NPs that were 
trapped near the tumor tissue switch to the stiff state and accommodate better with the 
tumor cells. Analysis of the survival rate of tumor bearing animals also confirmed the 
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enhancement in therapeutic efficacy of cancer nanomedicine by this virus-inspired 
approach. The problem associated with UV-penetration through the body will be overcome 
in the future works by replacing this photoinitiated reaction with near-infrared sensitive 
ones. 
 
Figure 7-14 (a) In vivo Anti-tumor effect of mechanically switchable PTX-loaded nanoparticle 
on U87MG tumor-bearing mice. (b) Pharmacokinetic data on blood clearance of the free PTX 
and when loaded in soft* and hard NPs with and without UV irradiation (n = 5). (c) 
Quantitative tissue accumulation of NPs in tumor and other organs 48 h after tail vein 
injection of fluorescently-labeled NPs with and without UV irradiation. (d) Survival rates of 
tumor-bearing mice treated with different modularity of NPs. (e) In vivo vascular disruption 
in the subcutaneous matrigel model after treatment with targeted NPs with different 
formulations. The plugs were removed after the treatment and imaged by fluorescent 
microscopy. (f) Alteration in vessel morphology evaluated by measuring the RITC-Dextran 
leakage from the vasculatures. (g) Tumor tissue cross-section immunostained for TUNEL-
positive cells. (h) Quantification of apoptosis by assessing the number of TUNE-positive cells. 
The presented data are expressed as average ± SD. The results were statistically analyzed 
using unpaired t-tests.  For all the tests, the threshold was set to p < 0.05 for “statistically 
significant”, p < 0.01 for “statistically very significant” and p < 0.001 for “statistically 
extremely significant”.  Statistical significance is indicated by * (significant), ** (very 
significant), and *** (extremely significant) for differences between each experimental group 
and the soft nanoparticles.  Statistical significance is indicated by # (significant), ## (very 
significant), and ### (extremely significant) for differences between different treatments and 
the hard nanoparticles.  
We also evaluated the antiangiogenic effects of the designed targeted NPs in the mice 
carrying subcutaneous Matrigel plugs (287). The Matrigel also incorporated basic 
fibroblast growth factor (bFGF) and VEGF to promote angiogenesis. It is also important 
to mention that this model was designed to represent the normal angiogenesis induced by 
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proangiogenic factors (VEGF and bFGF) and may be different from the tumor 
angiogenesis process (287). After three days of subcutaneous transplantation, the mice 
were tail vein injected with PTX containing NPs in the presence and absence of UV-
exposure on tumor side.  Antiangiogenic effects were assessed after 7 days by studying the 
alteration in vessel morphology through measuring the increase in RITC-Dextran leakage 
(288) Figure 7-14 e,f).  
TdT-mediated dUTP nick end labelling (TUNEL) staining, was used to stain the apoptotic 
cells in in the tumor tissue (Figure 7-14g). Nanoparticle-mediated delivery of PTX caused 
significant increase in the tumor cell apoptosis compared to the free PTX treatment. These 
results were in agreement with the improved survival rates of animals after treatment with 
targeted NPs. Interestingly, local triggering of mechanical switching significantly 
enhanced the number of TUNEL-positive cells in the tumor tissue (p<0.05) (Figure 7-14h). 
Our control experiments also indicated that UV-exposure itself in the absence of NPs or in 
the case of non-switchable hard or soft NPs had no effect on the apoptosis rate. The 
observed improvement in the case of virus-inspired NPs in comparison with other anti-
tumor-treated groups, was probably as a consequence of local piling-up of PTX inside the 
tumor tissue as well as possible enhancement in the cellular internalizations, leading to the 
increased apoptosis. 
7.4 Conclusion 
Our results proved the importance of mechanical properties of the nanomedicine which can 
affects a broad range of biological behaviors from drug-carrier or particle-cell interactions 
to the protein adsorption pattern of these NPs in blood plasma, their circulation through the 
body and in different tissues, and tumor treatment efficiency. We tried to optimize the 
required mechanical properties and accordingly design a nanotherapeutics agent with 
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CHAPTER 8. CONCLUSION 
8.1 Concluding Remarks 
 As a robust synthesis tool that provides a controlled mixing regime, we used 
microfluidic platforms to synthesize monodisperse nanoparticles (NPs) with adjustable 
physicochemical properties. Size and surface charge of these nanoparticulate systems 
strongly tune their nanobio interactions. Here, we first assessed the effects of 
hydrodynamic size and surface charge of NPs on their cellular internalization (Chapter 2). 
The role of the biomolecular corona that surrounds NPs upon entering biological fluids was 
also investigated in the modified 2D cultures and by considering sedimentation and 
diffusion properties of microfluidics-assisted synthesized NPs. Also, it should be 
considered that NPs face substantial changes in their environment before reaching their 
targets. Specifically, in the case of oral administration of cancer therapeutics, drug 
molecules should be protected during their passage from the gastrointestinal tract. In 
Chapter 3, for the first time, we presented a dual microfluidic system that enabled 
fabrication of core-shell drug nanocarriers with high tunability. Self-assembled 
biopolymer-based NPs were produced in a cross-junction microfluidic device followed by 
a fine coating with a pH- sensitive copolymer through a Tesla micromixer. We confirmed 
the molecular interactions between the layers using molecular dynamic simulation. Coating 
NPs with a pH-sensitive layer gave them the ability to bypass the acidic gastric fluid while 
protecting their cargo. Such a tunable drug delivery system that allows physiological-
responsive release can be a potential carrier for colon cancer chemotherapeutics. Even with 
a cross-junction microfluidic device we can make complex nanoparticles. In Chapter 4, 
monodisperse and highly reproducible hybrid NPs were developed through a one-step 
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incorporation of magnetic NPs and an anticancer drug into nanoprecipitated poly(D,L-
lactide-co-glycolide) (PLGA) chains. We also incorporated bisphosphonate-functionliazed 
PLGA in order to activly target bone-like tissues. NPs conjugated with bisphosphonate 
showed significantly higher bone binding affinity both in vitro and in vivo. Furthermore, 
molecular interactions between functionalized PLGA and hydroxyapatite surfaces were 
approved via computational molecular dynamics. In vivo results verified the prolonged 
circulation of engineered NPs and higher levels of tumor suppression in the case of a bone 
metastatic tumor. The versatile synthesis approach that is proposed here to tailor 
multifunctional NPs can be used for personalized theranostics including chemotherapy, 
magnetic resonance imaging and hyperthermia treatment, aswell. We also used the same 
platform to make nanocapsules with ultra-high capacity for anti-cancer drug loading. In 
Chapter 5, dendritic polyethylene (dPE) was encapsulated by a tri-block amphiphilic 
copolymer. Microfluidic-assisted nanocapsules that formed showed highly efficient 
encapsulation capacities for encapsulating hydrophobic drugs while providing sustained 
release profiles with great tunability. This approach can be extended for the syntheses of 
other types of tailored, drug-loaded, dendritic polymer-based nanocapsules for the 
emerging field of nanomedicine. Using the same components and by adding a hydrophobic 
template we were able to control formation of one-dimensional nanostructures. In Chapter 
6, carbon nanotubes were used to provide non-covalent CH−π interaction sites with 
hydrophobic dPE molecules. These simply fabricated but complex nanostructures showed 
high cellular uptake in cancer cells. These nanostructures showed remarkable efficiency 
when used as combinatorial cancer therapeutics based on the photodynamics and 
chemotherapy. Considering the applied interactions, accessible nanostructures may not be 
limited to 1D and by choosing other carbon-based materials like graphene and/or other 
simple or complex copolymers (e.g. containing targeting moieties), broader library of 
nanostructures with higher accuracy and efficiency can be synthesized. The central 
hypothesis in Chapter 7 was that mechanical properties of NPs, which is often ignored in 
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nano-bio interface, can significantly affect their therapeutic efficacies. Therefore, we 
systematically investigated the effects of mechanical characteristics of NPs on their 
biological functionalities both in vitro and in vivo. We also developed a 3D tumor-on-chip 
(3DToC) device in order to mimic transport phenomena near the tumor tissue. This 3DToC 
platform was designed to provide dynamic and 3D cultures for tumor cells in order to 
evaluate NPs-cells and NPs-matrix interactions in real-time. Our results demonstrated the 
importance of mechanical properties of the nanomedicine which can affects a broad range 
of biological behaviors from drug-carrier or particle-cell interactions to the protein 
adsorption pattern of these NPs in blood plasma, their circulation through the body and in 
different tissues, and their tumor treatment efficiency. We tried to optimize the required 
mechanical properties and accordingly design a nanotherapeutics agent with prolonged 
blood circulation, enhanced tumor penetration tendency and apoptosis promoting 
capability. In the end, we designed virus-mimicking NPs that can switch their mechanical 
stiffness. The working hypothesis was that by designing dynamic NPs, capable of 
switching their stiffness in response to an external stimulus, we can create a trade-off 
between low elasticity, which is mainly needed during the blood circulation, and high 
elasticity, which is most desirable for tumor penetration and cellular uptake. The switching 
can be triggered remotely by laser irradiation in the site of action. All in all, our findings 
point to the high potential of microfluidic systems on designing complex multifunctional 
nanoparticles with precise bottom-up approach for various biomedical applications. The 
presented results are expected to attract scientists in the fields of chemistry, soft matter, 
cell biology, pharmacy, and medicine. 
8.2 Future perspectives 
The major contribution of this thesis has been to develop a microfluidics-based approach 
for developing next-generation of nanoparticles as cancer therapeutics. While many new 
understandings have been gained during this research and it declared a promising outlook 
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toward this technology, many aspects remained untouched. The translation of these 
functional nanoparticles from academic labs to industrial scale needs mass production of 
these nanoparticles. This issue may be addressed by designing microfluidic devices with 
parallel channels rather than just increasing the characteristic dimension of the channels. 
In this sense, the fluidic system needs to be modified with industrial-scale fluid control 
systems.  
Purification of these NPs also needs to be adapted for industrial use. New microfluidic 
platforms can be developed to purify fabricated particles effectively right after their 
production. However, since these purifications are required for high volumes of 
nanoparticles, currently available designs still need improvement for industrial 
applications. 
The proposed (organic) solvent-free approach of making biopolymer-based nanoparticles  
can be really desirable for pharmacological companies, considering the growing interest in 
developing green chemistry methods for therapeutics. The user independent process and 
minor batch-to-batch variation make microfluidics-based approaches highly appropriate 
for creating a library of nanoparticles suitable for screening potential new therapeutics. 
This microfluidics approach can be used for making various types of soft (polymeric) 
nanoparticles. However, this system has limited effectiveness in producing monodisperse 
metallic and ceramic nanoparticles. Further adjustment of the microfluidic design for 
producing non-polymeric nanostructures can lead to great advances in photothermal 
therapy as well as in vivo imaging. 
As traditional 2D in vitro systems have limited success in predicting the efficacy of cancer 
nanomedicine. Here we developed a 3D tumor-on-chip platform to better real-time study 
of the in vitro performance of designed nanoparticles in in vivo mimicking conditions. This 
library of nanoparticles can also be used for high-throughput screening of the efficacy of 
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candidate drugs on various primary cancer cells or cancer cell lines. Our chip consists of 
tumor cell aggregates as well as their extracellular matrix to consider the effect of cell-
matrix interactions. However, addition of other microenvironment components like 
fibroblasts and endothelial cells, as well as immune cells is critical to make the model more 
physiologically relevant. These chips can also be developed to use patient-derived tumor 
cells and make personalized nanomedicine possible.  
Similarly, the use of microfluidic platform technologies to reproducibly synthesize and 
screen libraries of nanoparticles with different chemical compositions and/or physical and 
chemical properties can potentially advance nanoparticle discovery similar to what 
happened in medicinal chemistry that high-throughput screening of small molecules led to 
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